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ABSTRACT  
 
High risk human papillomavirus (HPV) is the etiological agent of cervical cancer, which 
is the third most important cancer mortality in women worldwide. The incidence of cervical 
cancer in Pakistan and its relevance to HPV is very little documented and exact figures are 
not known. Timely detection of HPV plays significant role to decrease the disease 
progression, therefore in this study the incidence of high risk HPV is investigated. 80 
cervical lesion specimens were screened for HPV 16 and 18 infection and 92 % samples 
were found positive for HPV 16 and 18 along with high rate of co-infection. Based on these 
findings, genome analysis of HPV 16 from Pakistan was first time carried out using 
cervical cancer specimen. Sequence analysis has shown 11 changes both at amino acid and 
nucleotide level. Out of this, 7 novel and 2 sequence conflicts were observed. Such changes 
indicate the genetic basis of viral evolution. Moreover, the L1 protein based phylogenetic 
study suggests that HPV 16 strain from Pakistan groups with European taxa. The PV’s E2 
and L1 protein are known to play key role in virus life cycle by interacting with different 
cellular and viral proteins. The association of E2 with L1 has been characterised for the 
first time in this study. The C terminus region from amino acid 335-365 of E2 binds with 
L1. Interestingly, this association modulates E2 dependent transcription and replication in 
a dose dependent manner. However, L1 was not forming the replication foci along with E1 
and E2, when fixed with formaldehyde. Cellular localisation studies shows that both E2 
and L1 co-localised in nucleus. E2 alone is expressed in nucleolus however, presence of 
L1 excludes nucleolar E2 and redistributes it into nucleus. It is hypothesised that re-
localisation of E2 by L1 protein is responsible for E2 dependent functions. The co-
localisation of both proteins was also observed in intermediate epithelium layer of HPV 16 
positive organotypic raft sections, where the vegetative virus replication takes place. The 
functional interaction of HPV 16 E2-L1 shown in this study provides novel insight towards 
virus life cycle.     
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CHAPTER 1 
 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Papillomaviruses  
Papillomaviruses (PVs) are small, icosahedral, non-enveloped, double-stranded DNA 
viruses belonging to the family Papillomaviridae and are known to infect mammals, birds 
and non-avian reptiles (Doorbar, 2005; Zheng and Baker, 2006). It is species specific and 
shows tissue tropism as well, replicates in nucleus of squamous epithelial cells. The virus 
particles are 52-55 nm in diameter and have a density of 1.34 g/ml in cesium chloride 
density gradient (Knipe et al., 2007).  
1.1.1 Virus classification and disease association 
PV types are classified on the basis of sequence homology of L1 gene in virus genome, 
host species (birds=3, reptiles=1 Mammals=64, and Humans= 120) and the disease with 
which they are associated (Chan et al., 1992a; van Ranst et al., 1992; Chan et al., 1995). 
L1 gene is highly conserved and can be aligned for all PVs. To be considered as a separate 
‘type’, the L1 nucleotide sequence should be at least 10 % different from other PVs 
(Bernard et al., 2010; De Villiers et al., 2004).  
To date, more than 170 HPV types have been identified. HPV types are further 
characterised in groups including high risk (type 16, 18, 31, 33, 35, 45) and low risk types 
(6, 11, 54, 61, 70, 72, 81; Muñoz et al., 2003). High risk types are involved in causing 
different malignancies like cervical cancer, vulvar cancer, anal cancer and oral cancer (Zur 
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Hausen, 1996; Parkin, 2006) whereas low risk types are involved in causing warts 
(Doorbar, 2006).   
The HPV types are further divided into genera and species based on L1 sequence 
homology. The 60 %-70 % nucleotide identity defines ‘genera’ and 71 %-89 % nucleotide 
identity defines ‘specie’ (de Villiers et al., 2004). There are five HPV genera namely alpha 
(α), Beta (β), gamma (γ), Mu (µ) and Nu (ν; Doorbar, 2012). The most widespread genera 
are α and β comprising about 90 % of HPV types (Figure 1.1). The α PV are associated 
with cutaneous as well as mucosal infections from both the high and low risk types. The 
HPV 16 and 18 belong to α PV. The β PV causes benign cutaneous infections (de Villiers 
et al., 2004; Doorbar, 2012). However, the immunocompromised individuals have a 
tendency to develop non-melanoma skin cancer, once infected with β PV (Harwood and 
Proby, 2002). The rest of HPVs are known for causing benign cutaneous warts and comes 
under genera γ, µ and ν (de Villiers et al., 2004; Doorbar, 2012). 
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Figure 1.1: The phylogenetic tree of HPV genera (obtained from Doorbar, 2006). The 
alpha PV is the largest group contains more than 60 types and associated with cutaneous 
and mucosal infections. HPV 16 and 18 comes under this group. The Beta, Gamma, Mu 
and Nu genera are associated with benign cutaneous infections. 
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1.1.2 Cervical cancer  
Cervical cancer is the second most common cancer in women worldwide (Parkin, 2006). 
Despite of its worldwide prevalence, the occurrence of cancer varies from 10 times more 
in one country than in other (Wright et al., 1994). Presence of HPV has been identified in 
more than 90 % of cervical cancer cases (Walboomers et al., 1999; Zur Hausen, 1996).  
The cancer occurs in the transformation zone of cervix, where the cells of exocervicx and 
endocervix make a junction (Krebs, 2000, Wright et al., 1994). Nearly 85 % cases are 
squamous cell carcinomas while rest are adenocarcinomas. During malignant 
transformation, the cervical lesions undergo dysplastic changes over a period of time 
(Krebs, 2000; Richart et al., 1969; Wright et al., 1994). According to histological 
classification of cervical interepithelial lesions (CIN) grade I, II and III refers to mild, 
moderate and severe dysplasia. However, in Bethesda system (Kurman and Solomon, 
1994) the abnormal cell morphologies are classified as low grade and high grade squamous 
intraepithelial lesions (LSIL, HSIL). Low grade lesions are associated with mild 
cytological changes, whereas high grade lesions corresponds to severe abnormalities 
(Knipe et al., 2007). Mostly the mild dysplastic changes do not progress and resolve 
spontaneously. However, if they will not regress, they give rise to severe dysplatic lesions 
over a period of time. The interval between development of cervical dysplasia and 
development of cervical cancer is long and screening of Papanicolaou (pap) smears has a 
potential to identify premalignant lesions (Knipe et al., 2007). In this test, cells are 
collected from transformation zone of cervix and observed under a microscope for 
abnormal cellular changes. In March 2009, FDA has approved HPV DNA detection test 
named as Cervista™ HPV HR (for type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 
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68) for women younger than age 30 (www.fda.gov) who have unclear Pap screening results 
Use of Pap smear test along with HPV DNA detection increase the chances of catching 
viral infection in time.  Currently the vaccine Cervarix (against type 16 and 18) by 
GlaxoSmithKline (GSK) and Gardasil (against type 6, 11, 16 and 18) by Merck are 
available for young women. Viral protein L1 is the major component of these vaccines and 
induces wide range of antibodies (Cohen, 2005). However, these vaccines do not raise the 
immunity against all HPV types, neither can they be of help for people who already have 
developed the infection (Sánchez et al., 2008). Consequently, it is required to understand 
molecular role of HPV in order to gain therapeutic insights against carcinomas.  
1.1.2.1 Cervical cancer in Pakistan 
Due to lack of proper cancer registry process in most of the hospitals, there is a paucity of 
data on prevalence and mortality of cervical cancer in Pakistan. WHO (2007) and SOGP 
2009 (www.sogp.org) ranks cervical cancer as the 4th most frequent cancer in women in 
Pakistan. It is the 12th most frequent cancer among women between 15 and 44 years of 
age. 47.27 million (45 %) female population, ages 15 or above, are at risk of developing 
cervical cancer. It is estimated that 2962 women are diagnosed with cervical cancer and 
1605 women die due to this cancer per year. 
1.2 The HPV genome  
HPV genome is approximately 8.0 Kbp in size and encodes 8 open reading frames (ORF; 
Knipe et al., 2007). Depending on their genome location, these ORFs are classified as 
either early (E) or late (L). Early region encodes important viral regulatory proteins (E1, 
E2, E5, E6, and E7) which plays a key role in virus life cycle. In productively infected cells 
the late region is responsible to encode E4, L1 and L2 proteins (Baker and Cowsert, 1990). 
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PV genome comprises of   ~ 1.0 Kbp region referred to as long control region (LCR) which 
contains viral regulatory elements including  origin of DNA replication, transcriptional 
regulatory factors and enhancers (Knipe et al., 2007).   
The HPV genome contains two major promoters that are used in order to regulate 
expression of the viral proteins throughout the HPV life cycle. The early promoter (P97 for 
HPV 16, P105 for HPV 18, and P90 for HPV 6) is located within the LCR and is 
responsible for initiation of transcription upstream of the E6 ORF (Chow et al., 1987; 
Smotkin and Wettstein, 1986). The late promoter p742 (P670 for HPV 16) is positioned 
within the E7 ORF and it is activated upon differentiation of the keratinocytes in the upper 
layers of the epithelium (Grassmann et al., 1996). In case of HPV 16 and 6, an additional 
promoter has been found in the E5 ORF and it could be associated with the expression of 
L2 (Graham and Gaston, 2012). Schematic genome representation is shown in Figure 1.2.   
The high risk and low risk HPV types are differentiated on the basis E6/E7 mRNA 
expression. The early promoter (P97 for HPV 16 and HPV 31, P105 for HPV 18) 
synthesizes intact E6/E7 mRNA or mRNA with splices in E6 gene, whereas the same genes 
of low risk HPV are trasncribed from two independent promoters (Chow and Broker, 
1997). The late genes are regulated by promoter that is activated only in terminally 
differentiated keratinocytes. This promoter controls the expression for both of the L1 and 
L2 genes.   
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Figure 1.2: Genome organisation of HPV 16 (modified from Doorbar, 2006; Graham and 
Gaston, 2012). The 8 Kb double-stranded HPV 16 genome is shown in circular and linear 
representation. The early and late genes along with LCR are indicated. All the genes are 
expressed from early promoter p97 and late promoter p670 located in the upstream and 
downstream of E6-E7 gene respectively. The PAE and PAL are the early and late 
polyadenylation sites and indicated with a filled triangle (▲). 
1.2.1 Long control region (LCR) 
Long control region (LCR) is precisely 850 bp, located between the end of L1 and start of 
E6 gene; divided into three regions namely 5' segment, central segment and 3' segment 
(Figure 1.3). LCR is not conserved among different PV types however, it contains highly 
conserved short motifs. These motifs contain the binding sites for different cellular 
transcription factors (Gloss et al., 1989a; Chan et al., 1990; O'Connor and Bernard 1995; 
Ishiji et al., 1992; O'Connor et al., 1996; Bernard, 2013). 
The E2 binding sites in LCR have similar ACCGN- NNNCGGT topology (Bernard, 2013). 
The E2 binding site 1 (E2BS1) and E2BS2 lies 50 bp upstream of the transcription start 
site whereas E2BS3 is 100 bp further upstream. The E2BS4 resides in 5'segment (Bernard, 
2013). The 5' segment is ~ 300 bp long and contains L1 termination codon besides having 
E2 binding site. It also contains polyadenylation sites for late transcripts and negative 
regulatory elements for late mRNA regulation (Furth and Baker, 1991; Kennedy et al., 
1991). The central segment is ~ 400 bp long and functions as transcription enhancer (Chin 
et al., 1989; Cid et al., 1993; Cripe et al., 1987; Gloss et al., 1987). Different cellular 
transcription factors including activator protein 1 (AP1), CCAAT/enhancer-binding 
protein (cEBP), glucocorticoid receptor, progesterone receptor, nuclear factor 1 (NFI), 
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nuclear factor for IL-6 (NF-IL6), octamer binding protein (Oct-1), PEF-1, thyrotroph 
embryonic factor 1 (Tef-1), TEF-2, and Yin Yang-1 (YY1) binds to this region of LCR 
(Chan et al., 1989; Chan et al., 1990; Chin et al., 1989; Chong et al.,1990; Chong et 
al.,1991; Cuthill et al.,1993; Garcia-Carranca et al.,1988; Gloss et al.,1987; Gloss et 
al.,1989b; Ishiji et al., 1992; Kyo et al., 1993; O’Connor and Bernard ,1995; Sibbet and 
Campo ,1990). The 3' segment is ~ 140 bp in length, contains another E2 binding site, 
which plays a role in initiating virus replication (Chiang et al., 1992; Russel and Botchan 
,1995; Sverdrup and Khan ,1995) and may also modulate transcription of the E6 and E7 
genes (Romanczuk et al., 1990). 
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Figure 1.3: Structural organisation of the HPV long control region (LCR; modified from 
Bernard, 2013). A schematic representation of the HPV LCR shows that 5' segment holds 
E2BS4 whereas, the central segment act as enhancer and have the binding sites for 
transcription factors including YY1, SP1 and OCT1. The origin of replication lies between 
the central segment and 3' segment. The 3' segment holds the promoter for E6 and involves 
in transcription of E6/E7 genes. The other 3 ESBS lies in central segment and 3' segment.    
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1.2.2 The E7 protein 
E7 is 98 amino acid small acidic oncoprotein, involved in binding to retinoblastoma (Rb) 
family of tumor suppressors, as well as to other proteins involved in cell cycle regulation 
(Dyson et al., 1989; Münger et al., 1989). It consists of three domains (Figure 1.4) based 
on its conserved regions, that is, CR1 (1-15 amino acids), CR2 (16-37 amino acids) and 
CR3 (38-98 amino acids; Moran and Mathews, 1987). The CR1 binds to cellular protein 
p600 and mediates anchorage independent cells proliferation (DeMasi et al., 2005). The N 
terminus of CR2 contains a motif LXCXE (22-26 aa) required for association with pRb 
(Phelps et al., 1992; Jones et al., 1990; Münger et al., 1989). This region also contains the 
sequence which helps in E7 protein phosphorylation by casein kinase II (CKII; Firzlaff et 
al., 1989; Münger et al., 1989). CR3 domain mediates oligomerization and it is important 
for protein stability and transforming activity (Liu et al., 2005; Barbosa et al., 1990; 
Clemens et al., 1995). It contains two CXXC regions which are capable of zinc binding. 
Moreover, this CXXC motif in CR3 region holds another binding site for Rb and is 
responsible for E7 protein dimerization (Alonso et al., 2004; Clemens et al., 1995; Patrick 
et al., 1994). This region is also known for down regulation of cellular proteins including 
p300/CBP, p21 and p27 (Funk et al., 1997; Zerfass-Thome et al., 1996). 
E7 is neither involved in DNA binding activities, nor it has any enzymatic effects; however 
it functions as an oncoprotein by interacting with cellular proteins (Figure 1.4). For 
instance, E7 directly interacts with elongation factor 2 (E2F) and histone deacetylases 
(HDACs) to influence the expression of S phase genes (Hwang et al., 2002; Brehm et al., 
1999). E7 binds to E2F6 transcriptional repressor (McLaughlin-Drubin et al., 2008), that 
recruits polycomb group (PcG) complexes, hence E7–E2F6 interaction prevent repression 
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by E2F6–PcG complexes and E7 keeps cell in S phase to maintain the environment for 
viral replication. As a result of E7-HDAC association virus transcription is repressed, 
whereas removal of HDAC activates transcription (Longworth et al., 2004; Brehm et al., 
1999; Brehm et al., 1998; Longworth et al., 2005). Moreover, this interaction keeps the 
genome in episomal form and maintains an S phase environment on differentiation 
(Longworth et al., 2004; Longworth et al., 2005). Binding of E7 to Rb tumour suppressor 
protein is one of the well characterised interactions. Rb member of the pocket protein 
family controls the G1-S cell cycle check. High risk E7 binds to Rb, disrupts E2F-Rb 
complexes (Chellappan et al., 1992), causes expression of E2F-responsive genes and leads 
to premature S phase entry (Cheng et al., 1995; Zerfass et al., 1995; Stevaux et al., 2002). 
E7 also targets Rb family members for proteasomal degradation through the ubiquitin-
dependent pathway (Boyer et al., 1996; Jones et al., 1997). This implies that E7 abrogates 
other Rb activities, such as DNA repair and the maintenance of genomic integrity.  
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Figure1.4 The organisation of functional domains of E7 protein (adapted from Wise-
Draper and Wells, 2008). HPV E7 protein is divided into three conserved regions: CR1, 
CR2 and CR3. CR1 binds with p600 and has ubiquitination site at the same end. The 
LXCXE motif in the CR2 region and the zinc finger containing two CXXC motifs in CR3 
are important for binding with Rb. The CXXC in CR3 also binds to zinc finger binding 
proteins 
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1.2.3 The E6 protein 
E6 is 158 amino acid oncoprotein, contains a conserved structural scaffold but have highly 
variable surfaces participating in specialized functions (Nomine et al., 2006). It is 
composed of two zinc binding domains, each having a Cystein-X-X-Cystein (CXXC-X29-
CXXC) sequence. The CXXC motifs are essential for the activity of the HPV E6 proteins 
and the cysteines are necessary for the nuclear localisation of these proteins, as well as for 
their zinc binding ability (Kanda et al., 1991). E6 interacts with tumor suppressing cellular 
proteins p53 (Werness et al., 1990) and ubiquitin-ligase E6-AP (Scheffner et al., 1993). 
The N- and C-terminal domains of the HPV E6 protein are required for its interaction with 
p53 (Crook et al., 1991; Li and Coffino, 1996; Mietz et al., 1992). The E6/E6-AP/p53 
complex degrades p53 via ubiquitin-mediated proteolysis pathway which primarily is 
responsible for E6 regulated oncogensis. In E6 transfected cell lines p53 independent 
telomerase activation has been observed (Klingelhutz et al., 1996). It is also involved in 
regulating transcriptional activation of cellular and viral promoters (Sedman et al., 1991; 
Morosow et al., 1994; Dey et al., 1997). This data is suggestive of E6 involvement towards 
oncogenic activity in more than one way.  
The HR HPV E6 C-terminal domain contains a PDZ-binding motif that mediates 
interactions with members of the PDZ family of proteins and a phosphorylation site 
targeted by protein kinase A (PKA; Lee et al., 1997; Songyang et al., 1997). The HR HPV 
E6 PDZ-binding motif is associated with the oncogenic properties of the E6 proteins, and 
is important for the replication and episomal maintenance of the HPV genome (Lee and 
Laimins, 2004; Watson et al., 2003). Schematic representation of E6 and few of binding 
partners are shown in Figure 1.5.  
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Figure 1.5: Structure of the HPV E6 protein (adapted from Wise-Draper and Wells, 2008). 
The HPV E6 protein is formed by an N-terminal hydrophilic domain connected to a 
hydrophobic linker. The C terminus has the PDZ-binding motif which is important for 
interaction with PDZ proteins. The zinc fingers containing two CXXC motifs, each are 
important for binding with P53, E6AP and other cellular proteins.  
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1.2.4 The E4 proteins 
The E4 is a small 95 amino acid cytoplasmic protein. It is a phospho-protein (Bryan and 
Brown, 2000; Grand et al., 1989) and exist as oligomers (Doorbar et al., 1989). The motif 
12-15 amino acid makes an association with host cytokeratins, whereas the region 20-48 
amino acid is involved in cell cycle arrest. The N terminus contains another motif LLXLL 
which is responsible for the association with host cytokeratins (Davy et al., 2002). The 
open reading frame which encodes E4 is diverse among different HPVs (Roberts et al., 
1994; Roberts et al., 1997).   
Increased E4 protein expression has been observed during late viral infection, which 
coincides with onset of viral DNA amplification in the upper layers (Doorbar et al., 1997). 
Viral DNA amplification is impaired in the absence of E4, which further supports its role 
in vegetative DNA amplification (Nakahara et al., 2005; Peh et al., 2004; Wilson et al., 
2005, Wilson et al., 2007). 
The E4 protein assists apoptosis by interfering with mitochondrial functions. After binding 
to mitochondria, E4 protein assists reduction in membrane potential of mitochondria which 
then induces apoptosis (Raj et al., 2004). 
E4 is also known for the  inhibition of G2-M cell cycle transition (Knight et al., 2004; Davy 
et al., 2002; Nakahara et al., 2002) and down regulation of cellular DNA synthesis (Knight 
et al., 2004; Roberts et al., 2008).  
E4 protein is involved in changing the distribution of promyelocytic leukemia protein 
(PML) from nuclear domains 10 (ND10) bodies (Roberts et al., 2003). The ND10 bodies 
are considered as the site of virus genome amplification and virion assembly. The role of 
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E4 with respect to ND10 suggests that the reorganisation of PML possibly plays role in 
enhancing virus life cycle (Roberts et al., 2003). 
E4 from many PVs binds to serine arginine specific kinase (SRPK1; Bell et al., 2007), 
which could influence important cellular processes. Bell et al. (2007) suggested that E4 
phosphorylation by SRPK1 may have role in E4 mediated functions. More over the SPRK1 
may affect vegetative viral amplification (Bell et al., 2007).  
The motif in E4 which is identified for G2-M cell cycle arrest also binds to cyclin and is 
not important for viral genome amplification (Knight et al., 2011). 
1.2.5 The E5 protein  
The E5 protein is 83 amino acid long hydrophobic protein. It localises in different cellular 
compartments including nuclear membranes, golgi apparatus and endoplasmic reticulum 
(Conrad et al., 1993; Oelze et al., 1995; Oetke et al., 2000). It contains three 
transmembrane domains spanning between amino acid region 9-29, 42-62 and 63-83. E5 
is also considered as an oncogene and plays a role during early infection. Some reports 
says, E5 by itself has a weak ability to transform cells (Chen and Mounts, 1990), however 
it enhances the transforming ability of E6 and E7 (Bouvard et al., 1994b; Valle and Banks, 
1995; Straight et al., 1993). On the contrary, the role of E5 in oncogenesis is confirmed in 
transgenic mouse, where E5 alone has induced cancer (Genther Williams et al., 2005). The 
E5 excites cell growth by forming a complex with the epidermal growth factor receptor 
(EGFR), the platelet-derived growth factor-β receptor (PDGF –β) and the colony-
stimulating factor-1 receptor (CSF-1; Hwang et al., 1995). The EGFR activation is 
important for transcriptional regulation, cell proliferation, apoptosis and angiogenesis 
(Dannenberg et al., 2005). The E5 protein has an ability to trigger extracellular-signal-
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regulated kinases (ERK1, ERK2) and mitogen-activated protein (MAP) kinase p38 in 
human keratinocytes regardless of EGF activation (Crusius et al., 2000). HPV 16 E5 
interacts with erythroblastic leukemia viral oncogene (ErbB) family receptors, however the 
exact role of this interaction is not known (Hwang et al., 1995; Chen et al., 2007; Crusius 
et al., 1998). 
HPV 16 E5 also plays a role in modulating tumour suppressor proteins by down regulation 
of p27 and p21 which in turn leads to cell cycle progression and enhanced expression of c-
Jun respectively (Tsao et al., 1996; Pedroza-Saavedra et al., 2010). The E5 protein affect 
the expression of vascular endothelial growth factor (VEGF) as well, which in turns 
activates mitogen activated kinase (MEK) signaling cascade (Kim et al., 2006). 
The E5 protein has shown to prevent apoptosis following DNA damage (Zhang et al., 
2002). For inhibition of apoptosis, it interferes with Fas ligand (FasL) and TNF-related 
apoptosis-inducing ligand (TRAIL) signal cascade by reducing the expression of Fas and 
altering TRAIL pathway (Kabsch and Alonso 2002). Moreover, E5 mediates the 
degradation of Bax, which assists in apoptosis inhibition (Oh et al., 2010).  
1.2.6 The E1 protein  
The E1 is highly conserved 644 amino acids cytoplasmic protein (Wilson et al, 2002). It 
consists of four domains: an N-terminal domain, an origin binding domain, an 
oligomerization domain and an ATPase domain (Figure 1.6). The N-terminal domain has 
an important regulatory functions since it contains nuclear localisation signals (NLSs) and 
nuclear export signals (NESs) that assists the subcellular localisation of E1 (Amin et al., 
2000; Deng et al., 2004; Fradet-Turcotte et al., 2010; Hsu et al., 2007; Yu et al., 2007a). 
The N terminus also contains an amino acid residues that can be phosphorylated by cyclin-
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CDK complexes and regulates E1 functions (McShan and Wilson, 2000; Zanardi et al., 
1997). Furthermore, these elements also assist in DNA replication (Cueille et al., 1998; Ma 
et al., 1999; Morin et al., 2011).  
The origin binding domain (OBD) contains DNA binding domain (DBD) and is required 
for the oligomerization of E1 (Titolo et al., 2003). The structure of the E1 DBD shows that 
it has a DNA-binding loop and a DNA-binding helix that binds to DNA (Chen and 
Stenlund, 2001; Enemark et al., 2002). The C-terminal region of E1 protein contains 
helicase motifs and ATPase that, together with the OBD domain are required for viral DNA 
replication (Amin et al., 2000; Ferran and McBride, 1998; Hall and Matson, 1999; Sun et 
al., 1998). Furthermore, this domain of E1 contains the sequences essential for its 
interaction with the HPV E2 protein, DNA polymerase α (DNAPα) and Topoisomerase I 
(Amin et al., 2000; Clower et al., 2006). The helicase activity of E1 protein involved the 
unwinding of DNA in 3'-5' direction. It recognizes various double stranded conformations 
of DNA for this purpose (Wilson et al., 2002). The amino acid residues 46-49 contains 
caspase cleavage site which plays a role in vegetative viral amplification (Moody et al., 
2007).  
1.2.7 The E2 protein  
The E2 protein is 365 amino acids and consists of three distinct domains: N terminus 
transactivation domain, hinge region and C terminus DNA binding domain (Figure 1.7; 
Giri and Yaniv, 1988). The N-terminal domain is a highly conserved region and plays role 
in transcriptional activation and replication activities of genome, whereas C terminus 
region is involved in binding to DNA (Antson et al., 2000; Cooper et al., 1998; Harris and 
Botchan, 1999; Winokur and McBride, 1996). 
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Figure 1.6: Structure of the HPV E1 protein (modified from D’Abramo et al., 2012; 
Fradet-Turcotte et al., 2009). The HPV E1 protein is composed of four main regions: the 
N-terminal domain, the origin binding domain, the oligomerization domain and the ATPase 
domain. These regions are important for nuclear export, DNA replication, and protein- 
protein interactions as indicated in the Figure.  
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Figure 1.7: Structure of the HPV E2 protein (modified from Dell and Gaston, 2001). The 
HPV E2 protein consists of three domains: the N-terminal transcription and replication 
domain (TAD), the flexible hinge region and the DNA binding domain (DBD). Each 
domain is involved in specific functions of activating viral transcription, regulating 
replication and protein-protein interactions. Some of the interacting partners are indicated 
with black dots. 
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1.2.8 The L1 and L2 proteins  
Papilloma virions consist of two capsid proteins i.e. L1 and L2, also known as major and 
minor capsid proteins respectively. The L1 protein is 531 amino acid long, whereas L2 is 
473 amino acid. The outer shell of the virion (which is L1) made up of 72 pentamers, 
centered on the vertices of T=7 icosahedral symmetry (Baker et al., 1991; Trus et al., 
1997). The L2 protein is incorporated into VLP. The L2 and L1 when co expressed gives 
4 fold higher VLP expression than L1 alone (Kirnbauer et al., 1993). The capsid 
organisation resembles murine polyomavirus and simian virus 40 (SV40), which have 72 
pentamers of viral protein (VP1) capsid protein (Rayment et al., 1982). VLP from 
papillomavirus are larger than polyoma virions (600A° diameter rather than 500A°), and 
their genome encapsidation is different in terms of size (8 Kbp rather than 5 Kbp; Knipe et 
al., 2007). Although there is considerable resemblance between VLPs structure from 
papillomavirus (L1:500 residues) and polyomavirus (VP1: 370 residues), nevertheless, the 
sequence of both viruses is very different (Belnap et al., 1996). L1 has an ability to form 
virus like particle both in vivo and in vitro, using vaccinia virus, baculovirus, or yeast 
systems (Zhou et al., 1991a; Kirnbauer et al., 1992; Hagensee et al., 1993; Rose et al., 
1993; Sasagawa et al., 1995). These VLPs are able to produce neutralizing antibodies and 
protects from subsequent viral infection (Breitburd et al., 1995; Suzich et al., 1995; 
Christensen et al., 1996). Therefore, VLPs are being used for the production of 
papillomavirus vaccines. 
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1.3 The life cycle of human papillomaviruses  
The squamous epithelium is composed of different layers of keratinocytes, which 
undergoes various stages of differentiation and expresses different proteins (Chow et al., 
2010). Cells in the basal layer are responsible to maintain the integrity of the epithelium, 
including cell cycling and contact inhibition (Chow et al., 2010). These cells undergoes 
division horizontally where one of the cells keeps its attachment to the basal membrane, 
whereas the other cells moves towards the upper layers of the epithelium and undergoes 
replication (Hamid et al., 2009). The keratinocytes in the upper strata undergoes a change 
in morphology and gene expression followed by programmed cell death (Doorbar, 2005). 
HPV infects the basal stem cells of the epithelium that becomes exposed through micro 
wounds. The alpha 6 integrin, heparan and cell surface glycosaminoglycans on 
keratinocytes may provide the platform for initial binding of papillomavirus virions 
(Bousarghin et al., 2003; Joyce et al., 1999; Shafti-Keramat et al., 2003). After attachment, 
conformational changes occurs in L1 and L2. It exposes the N terminus of L2 which is then 
cleaved by furin convertase that exists on the cell surface. This is considered an essential 
step for infectious internalization of HPV (Day et al., 2008a; Richards et al., 2006). The 
virions then bind to an unknown secondary receptor for uptake (Day et al., 2008b; Yang et 
al., 2003). The virus internaliztion is still controversial and it is suggested that it enters the 
cell both by clathrin dependent and independent endocytosis (Day et al., 2003). During the 
onset of infection, the viral genome remains in the nucleus as low copy episomes and early 
viral genes are expressed. The viral genome is replicated simultaneously with cellular DNA 
replication (Doorbar, 2005). The viral E1 and E2 proteins are expressed in this stage and 
they cooperate to initiate replication of the viral genome and the generation of a low copy 
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number of episomes (Wilson et al., 2002). After cell division, one daughter cell migrates 
from the basal layer and undergoes differentiation to form lower spinous layer. When HPV 
positive basal cells differentiates, it triggers the productive phase of the virus life cycle, 
which depends on the host DNA synthesis machinery. The cell cycle controls are 
deregulated by the E6 and E7 proteins which keeps the differentiating cells into S phase, 
hence driving virus genome amplification in cells that normally would have exited the cell 
cycle (Graham and Gaston, 2012). In the upper layers of the epithelium, E1 and E2 are 
expressed at high levels in order to increase the viral genome copy number, whilst the E4 
and E5 proteins promote cytokeratin network remodeling and achieve the evasion of the 
host immune response (Ashrafi et al., 2006; Doorbar et al., 1991; Middleton et al., 2003; 
Roberts et al., 1993).  The late-phase L1 and L2 proteins are expressed in upper spinous 
layers. They encapsidate virus genome and virions particles are sheded from the stratum 
corneum of the epithelium (Doorbar, 2005). The synthesis of capsid protein, virion 
assembly and vegetative virus amplification are exclusive to differentiated keratinocytes. 
The assembly and release of virus is not clearly known, but the virions cannot be released 
before the cornified layers of keratinizing epithelium (Doorbar, 2005). The virus life cycle 
is briefly described in Figure 1.8. 
Papillomavirus transcription is a complex process because of the presence of multiple 
promoters, alternate splicing and differential production of messenger RNA in different 
cells. Analysis of the viral RNA expression in different levels of epithelium cells in warts 
(Barksdale and Baker, 1993; Chow and Broker, 1997) and studies on infected keratinocytes 
using organotypic culture system showed that the transcription is coupled with 
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differentiation state of the epithelial cells (Dollard et al., 1992; Klumpp and Laimins., 
1999; Meyers et al., 1992). 
 
 
Figure 1.8: The life cycle of human papillomaviruses (adapted from Chow and Broker, 
1997). Differentiation of normal squamous epithelium and papillomavirus expression in 
benign lesions. Infection requires the availability of a basal layer cell. This usually occurs 
in microlesions of skin or mucosa. The infected cell divides and some of the new viral 
particles move into the suprabasal differentiating cell layers, where viral genes are 
activated, viral DNA is replicated and viral capsid are formed. Viral particle formation 
arises and particles are released at the surface that might then infect additional tissues. 
Granular layer is not found in non-keratinized squamous epithelia. 
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1.3.1 The onset of infection to tumour initiation 
The virus genome remains in episomal form in low grade lesions, however in high grade 
pre-cancerous lesions or cancers, the virus genome integrates into host DNA. This 
integration can take place anywhere in genome, but genomic fragile sites are more prone 
to it (Thorland et al., 2003; Wentzensen et al., 2004). During integration fragments of virus 
DNA that is E2 and L2 are deleted (Baker et al., 1987; Schwarz et al., 1985). Contrarily, 
E6 and E7 remain intact during integration in host DNA and are transcribed from LCR, 
which resides in upstream of integration site. As a result of E2 disruption, transcription of 
E6 and E7 increases (Desaintes et al., 1997; Jeon and Lambert, 1995; Romanczuk and 
Howley, 1992). Schematic representation of virus genome integration is shown in Figure 
1.9. Contrarily, in episomal form, E2 represses expression of E6 and E7 genes in order to 
regulate copy number of virus (Stubenrauch et al., 1998). During carcinogenesis HPV 
exists both as episomal and integrated forms (Kadaja et al., 2009a). Expression of the E1 
and E2 proteins from virus episome can start DNA replication of incorporated viral origins 
that might lead to the induction of chromosomal abnormalities (Stubenrauch et al., 1998). 
Replication of integrated origins also activates DNA repair and recombination systems, 
which increase the chances of harboring cellular mutations and genomic instability which 
eventually causes malignant transformation (Hanahan and Weinberg, 2000; Thierry and 
Yaniv, 1987). 
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Figure 1.9: Episomal form of HPV DNA and its integration into host-cell DNA (modified 
from Moody and Laimins, 2010). During progression to cancer, the virus becomes 
integrated into host DNA. The virus genome is opened within the E2 open reading frame, 
interrupting the continuity of that gene. Part of E2 and open reading frames that are adjacent 
to E2 that is E4, E5 and part of L2 are regularly deleted after integration. Transcription of 
viral E6/E7, might be modulated /enhanced by flanking host-cell promoters. 
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1.4 The E2 protein structure 
1.4.1 Transactivation domain 
HPV 16 E2 transactivation domain is 200 amino acids. It exists as a dimer, formed from 
subdomains N1 (1–91aa) and N2 (110–201aa; Antson et al., 2000). The region between 
N1 and N2 (93–109aa) is known as the “fulcrum” and consists of a two α-helices. The N1 
consists mainly of three glutamine-rich α-helices in an antiparallel fashion, separated from 
each other by loops. Moreover, the N2 primarily comprised of antiparallel β-sheets (Antson 
et al., 2000; Harris and Botchan, 1999). The helices α2 and α3 of the N1 domain and region 
142–144 aa from N2 are involved in dimerization (Antson et al., 2000). This dimerization 
might play a role in regulating transcription since it brings cellular proteins (involved in 
transcription), closer to promoter site (Antson et al., 2000; Desaintes and Demeret, 1996). 
Structural information shows that residues important for transcriptional regulation (e.g. 
R37 and I73) are present on convex side of the domain. Conversely, a residue important 
for replication and interaction with the E1 protein (E39) is found on the concave side of 
the structure (Mcbride, 2013). 
1.4.2 The DNA binding and dimerization 
HPV 16 E2 binding domain is ~100 amino acids long conserved domain which binds to 
specific DNA sequence (ACCGN4CGGT or ACCN6GGT) located in LCR (Androphy et 
al., 1987; Hawley-Nelson et al., 1988; McBride et al., 1988; Moskaluk and Bastia; 1987; 
Moskaluk and Bastia, 1988). This domain exist as dimer like TAD (Dostatni et al., 1988; 
McBride et al., 1989; Moskaluk and Bastia, 1989). The secondary structure of E2 DBD 
comprised of β1-α1-β2-β3-α2-β4. The helix α1 are well recognized for direct interactions 
with DNA (Hegde, 2002). Two E2 monomers (one per DNA strand) form a β-barrel, in 
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which two α-helices of each dimer bind specifically to two consecutive major grooves of 
the DNA (Figure 1.10; Hegde et al., 1992; Hegde and Androphy, 1998). The β-barrel core 
is hydrophobic and they are important for stability of dimer (Hegde, 2002; Thain et al., 
1997). 
1.4.3 The hinge region 
The hinge region is ~90 bp long and varies in length and sequence among different PVs 
Giri and Yaniv, 1988; McBride et al., 1989). It forms a bridge between transactivation and 
DNA binding domain (Gauthier et al., 1991). It is meant to provide the spacing between 
TAD and DBD to avoid steric hindrance, thus has a significant role in transcription and 
replication functions of E2. It is rich in serine, threonine, proline, glycine and arginine 
residues (Winokur and McBride, 1992). The hinge region goes through phosphorylation 
which might play auxiliary role in chromatin binding and protein stability (Sekhar and 
McBride, 2012; Pepinsky et al., 1997). In addition, this region has been reported for 
association with cellular proteins such as stable protein 1 (Sp1), Transportin-3 (TNPO3) 
and p300, although the interaction with the p300 also occurs through the N- and C-terminal 
domains of this protein in vitro (Müller et al., 2002; Steger et al., 2002; Lai et al., 1999). 
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Figure 1.10: The HPV E2 DBD-DNA complex (obtained from Hooley et al., 2006; Hegde 
and Androphy, 1998). A) The HPV 16 DNA binding domain monomer showing the anti-
parallel β-sheet and the α1, α2 helices. B) The HPV 6 DNA binding domain dimer bound 
to a DNA.  The polypeptide fold of a dimer indicates the binding of α1 subunit to a DNA.  
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1.5 The E2 functions 
1.5.1 Transcription 
The E2 proteins are main regulators of viral transcription (Chin et al., 1988; Choe et al., 
1989; Cripe et al., 1987; Lambert et al., 1987; Phelps and Howley, 1987; Spalholz et al., 
1985). In order to activate E2-dependent transcription, E2 binds to sites within the LCR 
(Bouvard et al., 1994a; Phelps and Howley, 1987; Ushikai et al., 1994). It is believed that 
the E2 protein is expressed variably during virus life cycle and hence regulates viral 
genome transcription (Dell et al., 2003). During the initial stage of infection, the E2 protein 
is present at a low concentration and binds to a site distal to the promoter termed E2 binding 
site 4 (E2BS4; Bouvard et al., 1994a; Hamid et al., 2009). It was suggested that this 
interaction plays an important role in virus replication and activation of early viral protein 
expression (Hegde, 2002). 
As the cells differentiate, the concentration of E2 protein increases, which promotes 
binding to the low affinity binding sites within the LCR (E2BS1 and 2). This results in 
down regulation of early gene transcription and an increase in viral replication (Bouvard 
et al., 1994a; Graham and Gaston, 2012). The interaction of E2 with E2BS1 stops the 
factors including transcription factor IID (TFIID) and TATA binding protein (TBP) to bind 
to transcriptional pre-initiation complex therefore hinders transcription (Dostatni et al., 
1991; Tan et al., 1992; Tan et al., 1994). Similarly, the binding between E2 and E2BS2 
results in dislodging of transcriptional activators Sp1 and activator protein 1 (AP-1) from 
their respective binding sites and hence down regulate transcription (Demeret et al., 1997; 
Oldak et al., 2004; Tan et al., 1994). The third binding site E2BS3 has also been reported 
to be important for early gene repression, however, this site is also important for the 
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recruitment of the E1 helicase required for the initiation of virus replication (Demeret et 
al, 1997). Several truncated forms of the E2 protein have also been reported from various 
PV types, which can regulate the transcription function of E2 (Choe et al., 1989; Fertey et 
al., 2010; Lace et al., 2008a; Lambert et al., 1987).For instance,  HPV 16-E8∧E2 represses 
transcription from P97 promoter (Lace et al., 2008a).  
1.5.2 Initiation of viral DNA replication 
During the initial stage of virus replication, the E2 protein helps in recognizing the 
sequence that meant to be replicated (Mohr et al., 1990; Sedman and Stenlund 1995; 
Stenlund 2003b; Ustav and Stenlund, 1991). When the E2 protein binds to E2BS3 in LCR, 
it brings the E1 helicase to origin of virus replication (Mohr et al., 1990; Sanders and 
Stenlund, 1998; Yang et al., 1991a; Yang et al., 1991b). The E2-E1 interaction helps in 
creating a stable E1-DNA complex and increases E1 specificity due to blockage of helicase 
site by E2 (Bonne-Andrea et al., 1997; Dixon et al., 2000; Frattini and Laimins, 1994a; 
Frattini and Laimins, 1994b; Sedman and Stenlund, 1995; Stenlund, 2003a).  
Besides DNA recognition, the E2 protein helps in DNA melting and DNA unwinding as a 
result of its interaction to E1 (Gillette et al., 1994; Sanders and Stenlund, 2000; Seo et al., 
1993). 
The E1 protein is a monomer in solution. However it oligomerises upon binding to DNA. 
The ability of E1 to oligomerise brings other E1 molecules to the site of initiation of 
replication (Stenlund, 2003b). The oligomerization of E1 has an important consequences 
since the replication complex needs additional E1 molecules (Stenlund, 2003b).  
When E1 oligomerises at the origin of replication, E2 becomes dissociated from E1 as a 
result of ATP hydrolysis (Lusky et al., 1994; Sanders and Stenlund, 1998, Sanders and 
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Stenlund, 2000). The E1 ATPase activity is believed to help trimer formation with an 
association between E1 monomers (Chen and Stenlund, 2002; Enemark et al., 2002; 
Sanders and Stenlund, 1998). Two trimers takes a double hexameric form, which acts on 
double strands of DNA and separates the strands, so that replication could take place 
(Sedman and Stenlund, 1998). This denaturation occurs at DNA which is adjacent to E1 
bound origin of replication and virus replicates using bidirectional mode (Sedman and 
Stenlund, 1998; Sanders and Stenlund, 2000). These steps are explained schematically in 
Figure 1.11.  
Nuclear foci is the site of viral DNA replication and formation of foci depends on presence 
of E2 protein (Fradet-Turcotte et al., 2011; Reinson et al., 2013; Sakakibara et al., 2011; 
Swindle et al., 1999). As a results of viral DNA amplification, DNA damage response takes 
place within those foci, which act as a signal to recruits cellular repair protein to synthesize 
viral DNA (Fradet-Turcotte et al., 2011; Gillespie et al., 2012; Moody and Laimins, 2009; 
Reinson et al., 2013; Sakakibara et al., 2011). 
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Figure 1.11: Schematic model of the replication initiation complex. Figure modified from 
Stenlund, 2003b. (1) The E2 proteins binds to E2BS, adjacent to origin of replication at 
LCR. (2) The E2 protein recruits E1 to origin of replication. The E1-E2 binding increase 
the complex stability and allows specific binding at respective sites. (3) Additional 
molecules of E1 will bind to the complex and ATP hydrolysis will displace E2. (4) The 
ATPase aids in assembly of the double hexameric form of E1 protein which performs 
helicase activity. Finally, the cellular factors including DNA polymerase are recruited 
which achieves replication.  
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1.5.3 E2 role in genome maintenance, partitioning and tethering 
The E2 protein ties the viral genome to mitotic chromosome via protein-protein interaction 
after it binds to binding sites in viral genome (Bastien and McBride, 2000; Ilves et al., 
1999; Lehman and Botchan, 1998; Skiadopoulos and McBride, 1998). The cellular targets 
involved in tethering of E2 proteins includes ChlR1 (an ATP-dependent DNA helicase 
important for sister chromatid cohesion; Parish et al., 2006a), a mitotic kinesin like protein 
(MKlp2; Yu et al., 2007b), the chromatin adapter protein, Brd4 (Ilves et al., 2006; You et 
al., 2004) and topoisomerase II binding protein (TopBP1; Donaldson et al., 2007). E2 
proteins stabilize the Brd4-chromatin association by co-localising with Brd4 on mitotic 
chromatin (McPhillips et al., 2006; Oliveira et al., 2006; McPhillips et al., 2005). Any 
disruption of the E2-Brd4 complex results in genomes displacement from chromosomes 
(Abbate et al., 2006).  
1.5.4 Vegetative viral DNA replication 
Studies have suggested that E2 is required for vegetative viral DNA amplification. E2 
transcripts are encoded through the late promoter and early polyadenylation site (Johansson 
and Schwartz, 2013) and high expression of E2 was found in the stratum spinosum of a 
bovine wart (Burnett et al., 1990; Penrose and McBride, 2000). It has been shown in mouse 
cells transformed by BPV 1 where growth arrest results in a large induction in E2 
expression (Burnett et al., 1990). The mutant E2 expression in BPV 1 system demonstrates 
that only the replication function is required for genome amplification and transactivation 
function does not play a role there (DiMaio and Settleman, 1988; Alderborn et al., 1992). 
During the vegetative amplification the mode of replication changes from bidirectional 
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theta mode in maintenance replication to recombination-directed replication (Flores and 
Lambert, 1997). 
1.5.5 Packaging viral DNA 
E2 protein helps packaging of viral genomes in virion particles (Zhao et al., 2000). The 
role of E2 in this regard is still not clear, but there is enough clue to investigate the exact 
mechanism. Such as, E2 forms an association with the minor capsid protein L2 at ND10 
bodies, the phenomena that might be significant both for genome establishment during 
early infection and augmentation of packaging during late infection (Day et al., 2004; Day 
et al., 1998).  
1.5.6 Post-transcriptional RNA processing 
Different studies reported the involvement of E2 in processing viral transcripts. For 
instance, it promotes the transcription of late gene via read through of early 
polyadenylation (Johansson et al., 2012). It has been noted that E2 expression increases 
during differentiation (Mcbride, 2013) which further supports the theory. The finding 
correlates well with the HPV 16 E2 interaction with cellular SR splicing factors and 
enhancement their expression (Bodaghi et al., 2009; Lai et al., 1999; McPhillips et al., 
2004). 
1.5.7 Growth inhibition and E2-mediated apoptosis  
The ability of E2 protein to inhibit the cell growth was reported first time in BPV 1 in HeLa 
and SiHa cells (Dowhanick et al., 1995; Hwang et al., 1993; Hwang et al., 1996). Both of 
these cell lines are derived from cervical cancer and have integrated HPV 18 and 16 
genome respectively. It was later established more clearly, that high risk HPV E2 causes 
apoptosis (Desaintes et al., 1997; Sanchez-Perez et al., 1997). E2 inhibits the growth in 
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both HPV positive and negative cells. Very few cell lines (C33a, U2OS) sustains the 
survival with low amount of E2 expression. HPV positive cells sustainability depends on 
expression of oncogene and in those cells, E2 down-regulates E6 and E7 expression by 
inhibiting the early viral promoter (Desaintes et al., 1997; Dowhanick et al., 1995; 
Goodwin and DiMaio, 2000; Goodwin et al., 1998; Goodwin et al., 2000). However, in 
HPV negative cell the E2 induces apoptosis through p53 dependent and independent 
pathways (Webster et al., 2000; Parish et al., 2006b). Keratinocytes that sustains in the 
presence of E2, develops characteristic phenotypes of terminally differentiated cells, which 
suggest E2 might use this to enhance viral late functions (Burns et al., 2010). Furthermore, 
E2 activates caspase-8 which in turn triggers extrinsic apoptotic pathway (Demeret et al., 
2003). Functions mediated by E2 are shown schematically in Figure 1.12. 
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Figure 1.12: Schematic representation of the functions of HPV E2 protein. The HPV E2 
protein regulates the transcription of viral genome after binding to the sites in LCR. The 
E2 assists in viral replication. This function is also achieved by binding to respective site 
in LCR and recruiting HPV E1 to origin of replication, which is major player of viral 
genome replication. Gene regulation function are carried out by E2 after it blocks 
polyadenylation site PAE which in turn enhances the expression of HPV L1 and L2. E2 is 
also recognized for its role in viral genome tethering and segregation. This activity is 
achieved by E2 interaction to the cellular proteins Brd4 and ChlR1.   
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1.6 E2 interacting proteins 
1.6.1 E2 and cellular proteins  
E2 interacts with a variety of cellular proteins to accomplish its functions (Figure 1.13). 
These proteins come under different categories including transcriptional regulation, cell 
cycle, apoptosis, nuclear import and protein degradation. The E2 has been found to make 
direct association with basal transcription machinery, such as TATA binding protein (TBP) 
and transcription factor IIB (TFIIB; Rank and Lambert, 1995; Steger et al., 1995). E2 also 
interacts with proteins that play a role in modulating gene expression. Some of these factors 
which regulate E2-dependent transcription are TopBP1, p300/CBP, smooth muscle actin 
(SMA), human T-cell leukemia virus type I binding protein 1 (Tax1BP1)  and human 
nucleosome assembly protein-1 (hNAP-1; Boner et al., 2002; Breiding et al., 1997; 
Krüppel et al., 2008; Lee et al., 2000; Rehtanz et al., 2004; Strasswimmer et al., 1999; 
Wang et al., 2009). Tax1BP1 plays an additional role of inhibiting the proteasomal 
degradation of E2 (Wang et al., 2009).  
Some proteins interacts with E2 and down regulate E2 dependent transcription. The 
bromodomain-containing protein 4 (Brd4) and the E1A-binding protein p400 (EP400) are 
two of these co-repressors (Smith et al., 2010; Wu et al., 2006). Brd4 also plays a role in 
viral genome segregation and assist E2 to tether BPV 1 and HPV 16 genomes to the cellular 
mitotic chromosomes (You et al., 2004). In addition, TopBP1 also activates E2 dependent 
replication (Boner et al., 2002) and it also mediate the interaction of HPV 16 E2 with 
chromatin (Donaldson et al., 2007). Similarly, the DNA helicase ChlR1, assist in genome 
maintenance and segregation of E2-mediated BPV 1 and HPV 11 (Parish et al., 2006b).  
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Figure 1.13: The schematic representation of cellular partners of HPV E2 protein. The 
slim arrows indicate the various cellular interacting partners of E2.  The Brd4 and E1A 
protein inhibits E2 mediated viral transcription. Brd4 plays a role in genome tethering after 
interacting with E2. The cellular protein TBP, hNP1, TOPBP1 and other as indicated, 
enhances E2 mediated transcription. The TAXBP1 also inhibits proteasomal degradation 
of E2, however the site of mechanism is not known.  
 
 
 
Chapter 1  Introduction and literature review 
 
41 
 
1.6.2 E2 and viral proteins  
1.6.2.1 E2-E6 interaction 
The HPV 16 DNA binding domain of E2 protein interacts with E6 oncoprotein (Grm et al., 
2005) and affect each other’s activities. E6 protein expression is regulated by E2 protein 
and the interaction changes the sub-nuclear location of both E2 and E6 proteins (Grm et 
al., 2005; Phelps and Howley, 1987; Thierry and Yaniv, 1987). The association helps in 
E2 and E6 protein stability as well. Moreover, E2 modulates the E6 function by degradation 
of PDZ containing proteins (Grm et al., 2005).  
1.6.2.2 E2-E7 interaction 
HPV 16 E2 interacts with N terminus of E7 protein and recruits E7 to mitotic chromosomes 
in mitosis. The interaction is observed both in low risk and high risk types, however, high 
risk have shown high binding affinity between E2 and E7 (Gammoh et al., 2006).  
Interaction between the hinge of HPV 16 E2 and the zinc binding region of E7 has also 
been reported (Gammoh et al., 2006). HPV 16 E2 protein down-regulates E7 protein which 
in turn represses E7 mediated transformation (Gammoh et al., 2006). This association 
stabilizes E7 protein (Gammoh et al., 2006; Gammoh et al., 2009a). E7 protein is known 
for causing centrosome abnormality. However, interaction with E2 weakens this potential 
of E7 (Gammoh et al., 2009a).  
1.6.2.3 E1-E2 interaction 
The E2-E1 interaction is required for viral DNA replication (Mohr et al., 1990) and has 
been well characterized and studied by several groups. In HPV, E2-E1 interaction has been 
reported between N-terminal region of E2 and C-terminal region of E1 (Berg and Stenlund, 
1997; Hibma et al., 1995; Titolo et al., 1999; Yasugi et al., 1997). In BPV 1, E2-E1 
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interaction has been previously reported between: the E1 C-terminal region and E2 N-
terminal domain, the E1 N-terminal region and E2 N-terminal domain, or the E1 DBD with 
the E2 DBD (Berg and Stenlund, 1997; Chen and Stenlund, 1998; Hibma et al., 1995; 
Moscufo et al., 1999; Woytek et al., 2001). It has been observed that mutation of arginine 
37 in E2 to alanine disrupt the E2-E1 interaction (Sakai et al., 1996).  
1.6.2.4 E2-L2 interaction 
E2 has also been found to interact with the minor capsid protein L2. The first 50 amino 
acids of L2 are involved in interaction with E2 (Okoye et al., 2005). The N terminal 50 
residues of E2 and the hinge region, are involved in interaction with the L2 protein (Heino 
et al., 2000). As a result of this interaction L2 recruits E1 and E2 to ND10 nuclear bodies 
and co-localises with L2.  Initially it was considered important for viral genome packaging 
(Day et al., 1998) but later studies showed that the association plays a role in establishment 
of infection (Day et al., 2004). L2 does not change the replication role of E2 but it can 
inhibit the transactivation (Heino et al., 2000; Okoye et al., 2005).  
1.7 Late gene expression 
The L1 protein after its synthesis in cytoplasm assembles itself into pentamers, which then 
combine and forms a capsomeres. The capsomeres are imported into the nucleus with the 
help of cellular factors namely α and β karyopherins (Bird et al., 2008).  
Both the L1 and L2 contains the nuclear localisation signals. HPV 16 L2 has two NLSs, 
one of which is located in N terminus and another one is in C terminus. The minor capsid 
protein L2 interacts with karyopherins through NLSs and enters the nucleus (Darshan et 
al., 2004; Klucevsek et al., 2006). L1 is translocated into nucleus through its NLS. The 
ND10 are punctate nuclear structures, found prominently in the nuclei of normal and 
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malignant cells (Brasch and Ochs, 1992). These ND10 are believed to play an important 
role in HPV life cycle. It has been suggested that these are the sites for viral infection and 
viral DNA amplification (Day et al., 1998; Day et al., 2004; Swindle et al., 1999; Florin et 
al., 2002; Roberts et al., 2003). The L2 protein is brought into ND10 through interaction 
with Daxx which is an important transcriptional repressor (Becker et al., 2003; Becker et 
al., 2004). The L1 is later translocated to ND10 by L2 protein (Florin et al., 2002). Another 
protein, known as heat shock cognate protein 70 (Hsc70) interacts with L2 C terminus and 
helps in nuclear translocation of L2 (Florin et al., 2004). After the virus assembly takes 
place, Hsc70 is displaced from virions (Florin et al., 2004).  
1.8 L1 structure 
1.8.1 The L1 monomer 
The L1 monomer (Figure 1.14) from amino acid residue 20–382 mainly consists of β sheets 
(B, C, D, E, F, G, H and I) which gives it “jelly roll” appearance. The secondary structure 
of C terminal residues from position 383–475aa is an α helix (Chen et al., 2000). The 
helices h2, h3 and h4 are important for interaction with other L1 monomers, whereas α 
helix 5 along with βJ strand takes the projection back to jellyroll. In pentameric structure, 
this α helix 5, folds with the base sheet BIDG and is hydrophobic. The βJ strand sits at C 
terminus of CHEF sheet (Chen et al., 2000).   
The last 31 residues at C terminus is variable among PVs, rich in basic residues, serine and 
threonine. It folds toward the interior of the particle. This region contains L1 nuclear 
localisation signal (Zhou et al., 1991b) and has been observed to undergo cleavage as well. 
The similar observation was made in another study, in which when L1 was fused at its C 
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terminus, which stabilizes the protein overall. It had then assembled into VLPs without 
degradation (Muller et al., 1997). 
 
 
Figure 1.14: The L1 monomer (obtained from Chen et al., 2000). The start and end residue 
are labelled N (20) and C (474), respectively. The strands (B-F) of the β jelly roll are blue; 
the small helix, h1, in the EF loop is blue; the connecting loops are pink; the G1 strand is 
red (this segment is near the CHEF sheet of the subunit); the F strand is green (this is 
important for binding the neighbouring monomer via hydrogen bond); the C-terminal 
domain is yellow.  
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1.8.2 The pentamer  
The monomers interact through polypeptide backbones. The G strand from BIDG sheet 
binds to neighboring CHEF sheet. The loops also play role in connecting monomers (Chen 
et al., 2000). The HI loop of one monomer attaches between FG and EF loops of 
anticlockwise neighbour and FG loop of the next neighbour. The EF loop creates a “five 
points of the star-like cap” by extending towards outside of edge of the pentamer (Chen et 
al., 2000).  
1.8.3 Pentamer–pentamer contacts 
The pentamer interacts with each other using h2, h3 and h4 helices in lateral domains and 
forms a capsomere (Figure 1.15). The contacts are maintained via hydrophobic interactions 
(Chen et al., 2000). 
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Figure 1.15: The T 5 1 particle of HPV 16 L1 (obtained from Chen et al., 2000). The 12 
identical L1 pentamers are assembled and shown in a different colours. The triangles 
indicate three-fold axes.  
 
 
 
 
 
Chapter 1  Introduction and literature review 
 
47 
 
1.9 Potential receptor sites for L1 
The receptors for papillomavirus are not vastly known. The alpha 6 integrin and heparan 
sulfate have been reported to assist VLPs attachment to cell surface to initiate infection 
(Evander et al., 1997; Dasgupta et al., 2011). Moreover, the loops BC, EF and FG creates 
pockets on the outer surface of pentamer which is susceptible for receptor binding (Chen 
et al., 2000). In polyomavirus VP1 pentamer, the receptor binding pockets are in 
structurally homologous positions to HPV 16 and 18 heparin binding pockets (Stehle et al., 
1994; Stehle and Harrison, 1996). Evander et al., (1997) confirmed the finding, by 
determining the HPV 16 and HPV 18 L1 bound heparin molecules. It has been found that 
the outer surface and top rim of L1 is involved in that interaction. The loops FG, HI and 
BC plays role in this particular binding. The residues participating in the process are Lys-
278, Thr, 266, Asn-285, and Lys-361, Lys-356, Thr-358, Thr-266, Lys-54, and Asn-56 
(Dasgupta et al., 2011). 
1.10 Virus assembly and release 
The proteins L1 and L2 are expressed in upper layers of infected keratinocytes after virus 
completes its amplification (Ozbun and Meyers, 1998). L1 and L2 proteins are transported 
to nucleus after their synthesis in cytoplasm. In the nucleus they assemble the viral DNA 
into virions. The in vivo experiments has suggested that the virus assembly takes place 
primarily through these proteins without any aid of packaging signals (Stauffer et al., 
1998). 
1.11 Neutralizing epitopes with in L1 
L1 can produce neutralization of papillomaviruses by two different mechanisms. The 
monoclonal antibodies (mAbs), binds to the outer surface of pentamer and blocks virus 
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attachment to receptor. As an alternative the mAbs binds across the groove between 
pentamers, cross linking, neutralizing antibodies against the virus and inhibits uncoating 
(Roden et al., 1994; Christensen et al., 1995; Booy et al., 1998; Trus et al., 1997; Roden 
et al., 1996). Epitope mapping has been carried out for neutralizing mAbs raised against 
HPV 16 and HPV 11 VLPs (Ludmerer et al., 1996; Roden et al., 1997; White et al., 1999). 
1.12 L1 variability 
The comparison between the sequence and structure of the L1 sequences from 49 different 
HPV types revealed that variable region are sparse among conserved region (Chen et al., 
2000). Mapping of these regions showed that variable regions are located on outer exposed 
surface of pentameric structure. This variability might be due to escape mechanism evolved 
by virus to evade immunity (Chen et al., 2000).  
1.13 L1 interactions with other proteins 
The major capsid protein interaction studies has not been studied comprehensively. Few 
interacting partners have been reported thus far. The L1 binds with L2 protein and helps 
genome encapsidation (Griffith et al., 1992; Finnen et al., 2003). The “conical hollow on 
L1 that faces inward along the fivefold axis” probably involves in interaction with L2 
(Griffith et al., 1992). The N terminus half of the L2 is conserved and both the N and C 
terminus have most of positively charged residues. Both of these ends are susceptible for 
interaction with genome (Campo et al., 1997; Kawana et al., 1999). The region mapped on 
L1 that binds with L2 in HPV 11 (aa 396-439) and HPV 16 (aa 412-455) is hydrophobic. 
Site directed mutagenesis in this region has shown the disruption of the binding between 
L1 and L2 (Finnen et al., 2003). 
Chapter 1  Introduction and literature review 
 
49 
 
The L1 protein from HPV 16, 45 and 11 interacts with Kapa2b1 heterodimers with the help 
of adaptor Kapa2. This complex enters the nucleus through Kapa2b1 mediated import 
pathway (Merle et al., 1999; Nelson et al., 2000; Nelson et al., 2002; Nelson et al., 2003). 
1.14 Aims and objectives 
It is difficult to prevent transmission of high risk HPV; therefore screening for persistent 
HPV infection and cytological analysis is considered as the main defense against cervical 
cancer and is widely practiced in the developed world. General population and health care 
practitioners in Pakistan have very little information and understanding about HPV 
infection, HPV associated cancers, their prevention and HPV vaccination. Hence, it was 
required to investigate the incidence of virus in cervical lesions.  
Variation exists in HPV genome and such differences could be accountable for difference 
in pathogenicity and immunogenicity (Giannoudis and Herrington, 2001). Based on 
variation among HPV 16 genome the variants are divided into five phylogenetic groups 
namely European (E), Asian (As), Asian-American (As-Am), African-1 (Af-1), and 
African-2 (Af-2; Chan et al., 1992b; Ho et al., 1993). Sequence information is not available 
for Pakistan, therefore genome analysis was required to investigate mutations and to 
establish phylogenetic linkage.  
Much work has been carried out on L1 to explore its potential as a prophylactic vaccine, 
however there is paucity of available data regarding its role in virion assembly, its 
interactions with host cells and with other HPV proteins. Based on previously reported 
interaction of E2 with other viral proteins, it was important to determine whether E2 
interacts with L1 protein and if this association influences the activity of the E2 protein in 
differentiating epithelium.  
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Taken all this data together, the brief aims of this research project are mentioned below: 
1. To detect the prevalence/genotype of HPV 16 and 18 in cervical cancer lesions and 
establish the association between HPV and cervical cancer in Pakistan.  
2. To analyse the full length HPV 16 genome using cervical lesion samples from Pakistan 
and determine the phylogenetic linkage.  
3. To investigate the HPV 16 L1 and E2 interaction.  
4.  To investigate the effect of this association in E2 mediated transcription/replication 
functions and subcellular localisation.  
5. To determine the co-localisation of E2 and L1 protein in differentiating epithelium.  
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 Common media and solutions 
2.1.1 General use buffers 
2.1.1.1     10 % (w/v) SDS 10 g of SDS was dissolved in 100 ml of  
  
distilled water, stored at room temperature. 
 
2.1.1.2     1 M NaOH 20 g of NaOH dissolved in 500 ml of  
 
distilled water and stored at room 
 
 temperature. 
 
2.1.1.3     0.5 M EDTA pH 8 93.05 g EDTA was dissolved in 400 ml of  
 
distilled water. The pH was adjusted to 8.0  
 
with NaOH, and final volume was brought  
 
up to 500 ml. The solution was stored at  
 
room temperature. 
 
2.1.1.4     1 M KCl 
 
3.7 g of KCl dissolved in 50 ml of distilled 
 
water and stored at room temperature. 
 
2.1.1.5     500 mM Tris-HCl pH 7.4 
 
40 g of Tris-HCl was dissolved in 400 ml  
 
of distilled water and pH was adjusted to  
 
7.4. The final volume was adjusted to  
 
500 ml. The solution was stored at room  
 
temperature. 
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2.1.1.6     500 mM NaCl 
 
14.6 g of NaCl was dissolved in 500 ml of 
 
 distilled water and stored at room  
 
temperature. 
 
2.1.1.7     50 mM CaCl2    5.5 g of CaCl2 was dissolved in 1 L of 
 
 distilled water. The solution is autoclaved 
 
 for sterilization and stored at 4 °C. 
 
 2.1.1.8     3 % (w/v) Bovine serum  
 
albumin (BSA) 
 
0.3 g of BSA was dissolved in 10 ml of 1X  
 
PBS (for immunofloroscence assays) or  
 
distilled water. The solution was stored at  
 
4 °C.  
 
2.1.1.9     10 %(w/v) NP40 
 
5 g of NP40 was dissolved in 50 ml of  
 
distilled water and stored at room  
 
temperature. 
 
2.1.1.10     10 % Triton X-100 (w/v)  
 
5 g of Triton X-100 was dissolved in 50 ml  
 
of distilled water and stored at room  
 
temperature. 
 
2.1.1.11     50 % Glycerol (v/v) 
 
50 ml of glycerol was dissolved in 50 ml of  
 
distilled water, stored at room temperature. 
 
2.1.1.12     1 M Dithiothreitol  
 
(DTT) 
 
1.54 g of DTT was dissolved in 10 ml of  
 
distilled water and stored at -20 °C in  
 
aliquots of 1 ml.  
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2.1.1.13     10 M Urea 300 g of Urea was dissolved in 500 ml of  
 
distilled water and stored at room  
 
temperature. 
 
2.1.1.14     1 X Phosphate buffer  
 
saline (PBS) pH 7.4  
 
137 mM NaCl  
 
2.7 mM KCl  
 
10 mM Na2HPO4  
 
2 mM KH2PO4 
 
8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, 0.24 g of KH2PO4 were dissolved in 
 
 800 ml distilled water. The pH was adjusted to 7.4 with HCl and final volume was  
 
adjusted to 1 L. The solution is autoclaved for sterilization. Alternatively one tablet  
 
(Sigma Aldrich) was dissolved in 200 ml of distilled water and sterilized by   
 
autoclaving. The PBS was stored at room temperature or at 4 °C according to the  
 
experimental requirements. 
 
2.1.2 Buffers for agarose gel electrophoresis 
 
2.1.2.1     50 X TAE 2 M Tris-base  
 
950 mM glacial acetic acid  
 
50 mM EDTA pH 8 
 
242.2 g Tris base and 100 ml of 0.5 M EDTA (pH 8) were dissolved in 800 ml of  
 
distilled water. 57.1 ml Glacial acetic acid was slowly added and the final volume was  
 
brought up to 1 L with distilled water. 1 X working solution of TAE was made by  
 
adding 20 ml of 50 X TAE to 980 ml of distilled water. The buffers were stored at  
 
room temperature.  
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2.1.2.2     10 X TE 100 mM Tris-HCl  
  
10 mM EDTA pH 8.0  
 
7.8 g of Tris-HCl and 10 ml of 0.5 M EDTA(pH 8) were dissolved in 490 ml of  
 
distilled water to make a final volume of 500 ml. TE was stored at room temperature. 
 
2.1.2.3     10 X TBE buffer  890 mM Tris-HCl 
 
890 mM Boric acid  
 
20 mM EDTA pH 8 
 
108 g of Tris base, 55 g of Boric acid were dissolved 800 ml of distilled water. 40 ml  
 
of 0.5 M EDTA (pH 8.0) was added and the final volume was made up to 1 L stored at  
 
room temperature. 
 
2.1.2.4     1 % or 2 % Agarose gel 0.4 g of agarose was dissolved in 40 ml of  
 
1 X TBE/TAE buffer. Gel was allowed 
 
 to cool down and ethidium bromide  
 
(0.5 μg/ml) is poured. 2 % agarose gel  
 
was made in same way, with double  
 
amount of agarose. The gel was then  
 
poured onto a gel tray and left to set for 20  
 
minutes. 
 
2.1.2.5     DNA loading dye 0.25 % (w/v) Bromophenol blue  
 
40 % (v/v) Glycerol solution 
 
8 ml of 50 % Glycerol was dissolved in 2 ml of distilled water. Bromophenol blue was  
 
added with a tip of pipette and mixed thoroughly. The dye was aliquoted and stored  
 
at 4 °C. 
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2.1.3 Buffers used for SDS-PAGE  
 
2.1.3.1     Resolving buffer 1.5 M Tris-HCl pH 8.8  
 
236.64 g of Tris-HCl was dissolved in 800 ml of distilled water. The pH was adjusted  
 
to 8.8 and final volume was made up to 1 L, stored at room temperature. 
 
 
2.1.3.2     Stacking buffer 0.5 M Tris-HCl pH 6.8 
 
78.78 g of Tris-HCl was dissolved in 800 ml of distilled water, pH was adjusted to 6.8  
 
and final volume was made up to 1 L, stored at room temperature.  
 
2.1.3.3     6 X SDS loading dye 300 mM Tris pH 6.8  
 
12 % (w/v) SDS  
 
60 % (v/v) Glycerol  
 
0.01 % (w/v) Bromophenol blue  
 
600 mM DTT  
 
6 ml of 0.5 M Tris-HCl pH 6.8, 1.2 g of SDS, 0.93 g of DTT, were mixed with 6 ml of 
glycerol. Bromophenol blue was added with a pipette tip and total volume was adjusted 
to 10 ml. The solution was incubated at 37 °C, until SDS was completely dissolved. 1 
ml aliquots were made and stored at –20 °C for further use.  
2.1.3.4     10 % Ammonium per  
 
sulphate (APS; w/v) 
 
10 %APS 
 
10 ml distilled water 
 
1 g of APS were dissolved in 10 ml of distilled water and kept at 4 °C for storage  
 
purpose. 
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2.1.3.5     10 X SDS running buffer 25 mM Tris 
 
192 mM Glycine 
 
0.1 % (w/v) SDS 
 
30 g of Tris-base, 144 g Glycine and 10 g of SDS were dissolved in 1 L of distilled  
 
water. 
 
2.1.3.6     1 X SDS running buffer 100 ml of 10 X SDS running buffer was  
 
added 900 ml of distilled water. 
 
2.1.4 Buffers used for Western blotting 
  
2.1.4.1     10 X Transfer buffer 0.25 M Tris base  
 
2 M Glycine 
 
30 g of Tris, 144 g of Glycine were dissolved in 1 L of distilled water stored at room  
 
temperature. 
 
2.1.4.2     1 X Transfer buffer 1 X Transfer buffer 
 
5 % Methanol  
 
100 ml of 10 X transfer buffer was added in 100 ml of Methanol and 800 ml of distilled  
 
water.  
 
2.1.4.3     10 X TBS/T 1 M Tris pH 7.6 
 
1.5 M NaCl 
 
1 % Tween 20  
 
24.2 g of Tris and 80 g of NaCl were dissolved in 800 ml of distilled water. The pH was 
 
 adjusted to 7.6 with HCl. 10 ml of Tween 20 was added and final volume was made up to  
 
1 L.1 X TBS/T was prepared by adding 100 ml of 10 X TBS/T in 900 ml of distilled water,  
 
kept at room temperature.  
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2.1.4.4     Milk blocking buffer 1 X TBS/T  
 
5 % (w/v) Fat free skimmed milk  
 
2.5 g of skimmed milk was dissolved in 50 ml 1 X TBS/T. The solution was kept at  
 
4 °C for use within 2-3 days.  
 
2.1.5 Media used for bacterial culture 
 
2.1.5.1     Luria Bertani (LB) broth  
 
(powder)  
1 % (w/v) Tryptone 
 
0.5 % (w/v) Yeast extract 
 
1 % (w/v) NaCl 
 
2.1.5.2     LB agar  1 % (w/v) Tryptone 
 
0.5 % (w/v) Yeast extract 
 
1.5 % (w/v) Agar 
 
0.15 % (w/v) Tris HCl pH 7.5 
 
1 % (w/v) NaCl 
 
LB broth was prepared by adding the 25 g of LB powder to 1 L of distilled water and 
autoclaved at 121 ºC for 15 minutes and subsequently stored at 4 ºC. LB agar was prepared 
by adding 200 g of LB agar to 100 ml of distilled water. It was autoclaved at 121 ºC for 15 
minutes. Antibiotics were added to the molten agar that had cooled to below 60 ºC and 
once mixed, approximately 20 ml were poured into 10 cm diameter petri dishes. Agar was 
allowed to solidify at room temperature for 30 minutes. The plates were then placed 
inverted inside an incubator at 37 ºC and left to dry for two hours. Plates were stored at 4 
ºC. 
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2.1.6 Buffers used for extraction and purification of DNA 
 
2.1.6.1     Digestion buffer 50 mM Tris-HCl pH 8.5 
 
1 mM EDTA 
 
0.5 % (v/v) Tween 20 
 
3.93 g of Tris-HCl, 0.14 g of EDTA were added in 400 ml of distilled water. The pH  
 
was adjusted to 8.5 with NaOH, which dissolves EDTA. Tween 20 (2.5 ml) was  
 
dissolved and the final volume was adjusted to 500 ml with distilled water. The buffer  
 
was kept at 4 °C. 
 
2.1.6.2     Hirt solution 0.6 % (w/v) SDS  
 
10 mM EDTA 
 
3 g of SDS and 10 ml of 0.5 M EDTA (pH 8) were dissolved in 500 ml of distilled water.  
 
2.1.6.3     Solution I 50 mM Tris-HCl pH 8.0 
 
10 mM EDTA  
 
0.5 M glucose  
 
3.93 g of Tris-HCl, 10 ml of 0.5M EDTA (pH 8) and 45 g of glucose were dissolved in  
 
500 ml of distilled water and kept at room temperature. 
 
2.1.6.4     Solution II  0.1 % (w/v) SDS 
  
20 mM NaOH 
  
Solution II was freshly prepared by dissolving 1 ml of 10 % SDS and 2 ml of 1M NaOH 
 
in 7 ml of distilled water.  
 
2.1.6.5     Solution III  3 M Potassium Acetate pH 5.5 
 
11.5 ml Glacial acetic acid 
 
147.21 g of Potassium acetate and 11.5 ml of Glacial acetic acid dissolved in 400 ml of 
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distilled water. The pH was adjusted to 5.5 and the volume was made up to 500 ml. The  
 
solution was kept at 4 °C.  
 
2.1.7 Solutions used for transformation 
 
2.1.7.1     Transformation storage 
  
solution (TSS) 
10 % (w/v) Polyethylene glycol  
 
(PEG)8000 
  
51 %(v/v) Dimethyl sulfoxide (DMSO)  
  
1 M MgCl2 
1 g PEG 8000, 0.5 ml Dimethyl sulphoxide (DMSO) and 0.5 ml MgCl2 (1 M) were 
 
 dissolved in 5 ml 2 X LB and 3 ml sterilized distilled water. The media was freshly 
 
 prepared and stored at 4 °C for 2-3 days storage. 
 
2.1.7.2     1 M IPTG 1 M IPTG  
 
Distilled water 
 
2.38 g of IPTG dissolved in 8 ml of distilled water and final volume was made upto  
 
10 ml. The solution was sterilize using 22 μm syringe filter and 1 ml aliquots were 
made. The IPTG was stored at -20 °C. 
2.1.7.3     X-Gal  
 
X-Gal 20 mg 
 
DMSO 1 ml  
 
60 mg of X-Gal was dissolved in 3 ml of DMSO and filtered using 22 μm syringe  
 
filter. The tube was wrapped in aluminum foil to avoid damage by light and kept at – 
 
20 °C. 
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2.1.8 Buffers used for extraction and purification of protein  
 
2.1.8.1     Lysis buffer 25 mM Tris pH 8 
  
250 mM NaCl 
 
10 % Protease inhibitor 
 
5 mM DTT 
 
30 g of Tris, 14.6 g of NaCl were dissolved in 800 ml of distilled water and pH was  
 
adjusted to 8 with NaOH. The buffer was kept at 4 °C ; DTT and protease inhibitors  
 
were added at the time of experiment.  
 
2.1.8.2     Wash buffer I  25 mM Tris pH 8 
 
250 mM NaCl 
 
10 % Protease inhibitor  
 
30 g of Tris, 14.6 g of NaCl were dissolved in 800 ml of distilled water and pH was  
 
adjusted to 8 with NaOH and stored at room temperature. 10 % protease inhibitors  
 
were added at the time of experiment.  
 
2.1.8.3     Wash buffer II 100 mM Tris-HCl pH 7.4 
 
100 mM NaCl 
 
1 % (w/v) NP40 
 
200 mM KCl 
 
5 mM DTT 
 
10 ml of 500 mM Tris-HCl (pH 7.4), 10 ml of 500 mM NaCl, 0.5 g of NP40 and 0.7 g  
 
of KCl were dissolved in 50 ml of distilled water. Buffer was kept at room temperature.  
 
DTT was added at the time of experiment. 
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2.1.8.4     Urea lysis buffer  50 mM Tris-HCl pH 7.4 
 
9 M Urea 
 
5 mM DTT 
 
1 ml of 500 mM Tris-HCl was dissolved in 9 ml of 10 M urea to which 50 µl of 1 M  
 
DTT was added. 
 
2.1.9 Media used for cell culture 
 
2.1.9.1     Freezing medium 10 % (v/v) DMSO  
 
10 % (v/v) FBS  
 
80 % (v/v) DMEM or RPMI-1640  
  
10 ml of DMSO and 10 ml of FBS were dissolved in 80 ml of DMEM. 
 
2.1.10 Buffers used for co-imunoprecipitation assay 
 
2.1.10.1     Lysis buffer  50 mM Tris–HCl 7.4 
 
100 mM NaCl  
 
20 mM NaF  
 
10 mM KH2PO4  
 
1 % Triton X-100 
  
10 % Glycerol  
 
Protease inhibitors  
 
0.1 mM DTT  
 
5 ml of 500 mM Tris-HCl (pH 7.4), 10 ml of 500 mM NaCl, 0.042 g of NaF, 0.068 g  
 
of KH2PO4, 5 ml of 10 % Triton X-100 and 10 ml of 50 % Glycerol were dissolved and  
 
volume was made up to 50 ml. The buffer was kept at 4 °C. DTT and protease  
 
inhibitors were added at the time of experiment.  
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2.1.10.2     Binding buffer 50 mM Tris–HCl 7.4 
 
100 mM KCl 
 
0.1 mM EDTA 
 
0.2 % (w/v) NP40  
 
0.1 % (w/v) BSA  
 
2.5 % Glycerol  
 
2 mM DTT  
 
Protease inhibitors 
 
5 ml of 500 mM Tris-HCl (pH 7.4), 5 ml of 1M KCl, 10 µl of 0.5 M EDTA, 1 ml of 10  
 
% NP40, 1.6 ml of 3 %BSA and 2.5 ml of 50 % Glycerol were mixed and final volume  
 
was made up to 50 ml. The buffer was stored at 4 °C. DTT and protease inhibitors were  
 
added at the time of the experiment.  
 
2.1.10.3     Wash buffer  100 mM Tris–HCl 7.4  
 
100 mM NaCl  
 
0.5 % NP40  
 
2 mM DTT 
 
Protease inhibitors 
 
5 ml of 500 mM Tris-HCl (pH 7.4), 10 ml of 500 mM NaCl and 2.5 ml of NP40 were  
 
mixed and total volume was made up to 50 ml using distilled water. The buffer was  
 
stored at 4 °C. DTT and protease inhibitors were added at the time of the experiment. 
 
2.1.11 Buffers used for immunofluorescence protocols 
 
2.1.11.1     4 % Formaldehyde 1x PBS  
 
4 % (v/v) Formaldehyde  
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2 ml of formaldehyde was dissolved in 48 ml of 1X PBS. 
 
2.1.11.2     Immunofluorescence (IF)  
 
block solution  
20 % HINGS 
 
0.1 % BSA) 
 
2 ml of HINGS was dissolved in 300 µl of 3 % BSA and 8ml of 1X PBS. The block  
 
solution was sterilized using 0.22 μm  sterile filter and  stored at 4 °C to be used in 7- 
 
14 days. 
  
2.1.11.3     0.2 % Triton® X-100  
 
1 X PBS 
 
0.2 % (v/v) Triton® X-100 
 
200 µl of 10 % Triton X-100 was dissolved in 10 ml of 1 X PBS and sterilized using  
 
0.22 μm sterile filter and stored at room temperature to be used in 7-14 days. 
 
2.1.13      Antibiotic stocks 
 
2.1.13.1      Ampicillin/Kanamycin stock  
 
solution (100 mg/ml) 
Ampicillin/Kanamycin  
 
Distilled water 
 
1 gm of ampicillin/kanamycin was dissolved in 10 ml of distilled water and  
 
Sterilized using 0.22 μm sterile filter. The 1 ml aliquots were stored at -20 °C. 
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2.2 Sample collection 
2.2.1 Formalin fixed paraffin embedded (FFPE) cervical cancer tissues 
The formalin-fixed paraffin-embedded (FFPE) samples of cervical cancer tissue biopsies 
(n=80) were collected. These samples were obtained from different hospitals in Punjab, 
Pakistan, namely, Pakistan institute of medical science (PIMS) Islamabad, Holy family 
Rawalpindi, Shifa hospital Islamabad, Nishtar hospital Multan, Allied hospital Faisalabad  
and Mayo hospital Lahore. The patients were aged 25-70 years, visited hospital from 2007- 
2011. The patients were from different cultural, social, and economic background and their 
consent for the use of samples for research was also obtained. 
2.2.2 Fresh cervical cancer biopsy 
The fresh samples (n=4) of patients diagnosed with cervical cancer, were obtained from 
the Military hospital, Rawalpindi. The cervix was excised by the surgeon for the treatment 
of disease and stored in phosphate buffer saline (PBS, pH 7.4) immediately. Samples were 
sectioned in small pieces using disposable scalpels and placed in 1.5 ml microfuge tubes. 
For long term usage, the samples were stored in400 μl fetal bovine serum (FBS) with 600 
μl PBS (pH 7.4) and kept at -80 C .  
2.2.3 DNA extraction from FFPE samples 
 
The FFPE tissue samples were proceeded to obtain sections of 5-20 μm on a microtome 
(CUT 6062, SLEE Mainz) using disposable blades. These samples were placed in a 1.5 ml 
Eppendorf tube. Before obtaining the sections the tissue blocks were placed at -20 °C for 
1 hour in order to cut smoothly. The DNA extraction was carried out using methods 
described by Greer et al., (1994). 
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Deparafinizing of the tissue sections were carried out by addition of 1 ml of xylene 
followed by incubation for 10-15 minutes at room temperature. Pellet was cleared by 
centrifugation at 14432 × g for 10 minutes in a table top centrifuge (Sigma) and the 
supernatant was removed carefully. However, a second xylene wash was given to ensure 
the complete removal of paraffin. Two successive washes of 1 ml of 100 % ethanol were 
given to remove traces of xylene from the tissue. After 10 minutes, the pellet was cleared 
by centrifugation at 14432 × g.  Supernatent was discarded and the tissue pellet was air 
dried. The dried pellet was resuspended in 400 μl digestion buffer (section 2.1.6.1) and 5 
μl of 20 mg/ml proteinase K (Invitrogen, Germany) was added prior to overnight 
incubation at 56 °C. To inactivate the proteinase K the tubes were placed in Wealtec heat 
block at 95 °C for 10 minutes. The supernatant that now contains the DNA was transferred 
to a new microfuge tube and DNA was stored at -20 °C for future use. 
2.2.4 DNA extraction from fresh tissue samples 
 
Tissue section of 1 mm was homogenized and then transferred to a fresh 1.5 ml microfuge 
tube. The sample was further resuspended in 400 μl digestion buffer and 5 μl of 20 mg/ml 
proteinase K (Invitrogen, Germany) followed by overnight incubation at 56 °C to ensure 
good digestion of proteins. Later, the enzyme (proteinase K) was heat denatured (95 °C for 
10 minutes) and extracted DNA was kept at -20 °C for future use. 
2.2.5 DNA purification 
 
DNA purification was performed using phenol chloroform isoamyl alcohol (25:24:1) 
method. The volume of sample was taken into account and the equal amount of phenol 
chloroform isoamyl alcohol (Sigma-Aldrich) was added to the samples. The samples were 
centrifuged at 14432 × g for 5 minutes. The aqueous phase was separated carefully and 
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transferred to new Eppendorf tube. In order to precipitate the DNA, 3 volume of 100 % 
ethanol was added along with 1/10 volume of 6 M sodium acetate (pH 5.5). The samples 
were left at -20 °C for overnight or -80 °C for 3 hours and pellet was cleared by 
centrifugation at 14432 × g for 10 minutes. The DNA pellet was washed in 70 % ethanol, 
air dried and resuspended in 20 µl of nuclease free water. The DNA was quantified using 
Nanodrop (Eppendorf Biophotometer plus). 
2.2.6 Determination of concentration, yield and purity  
DNA concentration was measured by Nanodrop (Eppendorf Biophotometer plus) at 260 
nm. Purity of the sample was calculated by obtaining the ratio of absorbance at 260 nm to 
absorbance at 280 nm. Samples with ratio 1.7-2.0 at A260/280 and concentration of ≥ 100 
ng/μl were subjected to further experiments. Samples outside this range were either 
purified again or proceeded again for DNA extraction.  
2.3 DNA amplification 
2.3.1 Primer designing  
Reported set of primers (PC03/PC04; Saiki et al., 1988) were used to amplify β-globin 
gene as a control for determining the quality of the DNA. High risk HPV, consensus 
primers GP5+/GP6+ (de Roda Husman et al., 1995) were used to target a large spectrum 
of L1 genes from diverse high risk HPV types. Additionally, specific high risk types were 
detected by using type specific (TS) genotyping primers as described by Baay et al (1996). 
Primer TS 16 binds to the E6 gene of HPV 16 and TS 18 binds to the L1 gene of HPV 18. 
These primers sets are more specific and sensitive than the broad spectrum GP consensus 
primers (Baay et al., 1996). In order to ensure further the PCR detection sensitivity, another 
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set of primer was used which binds specifically to the E7 gene of HPV 16 (HPV16E7) and 
HPV 18 (C18E7).  
For the characterisation of high risk HPV 16, the primer sets were designed by retrieving 
consensus sequence of the specific viral gene of genotype 16 from NCBI database. These 
primer sets amplifies long control region, early (E6, E7, E1, E2, E5) and late genes (E4, 
L1, L2). The identification of restriction endonucleases sites in these sequences were 
analysed through NEBcutter V2.0 (http://tools.neb.com/NEBcutter2/index.php). Primer 
properties were checked by OligoCalc 
(http://www.basic.northwestern.edu/biotools/oligocalc.html) before they were ordered.   
A primer set was designed to amplify origin of replication of HPV 16 genome, using real 
time PCR, as described by Taylor and Morgan (2003). The sequences of these primers are 
shown in Table 2.1 
The primers were either diluted in nuclease free water or TE as follows: 
Primers original concentration in x nmol 
100 µM stock primer= 10 µl of TE * x nmol 
10 pM working primer = 90 µl NF water + 10 µl of 100 µM primer  
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Table 2.1: Primers used for PCR amplification. 
 
 
 
 
Primer Sequence (5'-3') Target Product 
Size (bp) 
Ref. 
PC03  
PC04 
ACACAACTGTGTTCACTAGC  
CAACTTCATCCACGTTCACC 
β-globin 150  (Saiki et 
al.,1988) 
 
GP5+ 
GP6+ 
 
TTTGTTACTGTGGTAGATACTAC 
GAAAAATAAACTGTAAATCATATTC 
 
L1 
150 (de Roda 
Husman et 
al.,1995) 
New TS 16 GGTCGGTGGACCGGTCGATG 
GCAATGTAGGTGTATCTCCA 
E6 HPV 
16 
96 Baay et al 
1996 
New TS 18 CCTTGGACGTAAATTTTTGG 
CACGCACACGCTTGGCAGGT 
L1 HPV 
18 
115 Current 
study 
C18E7F GGATCCGCATGGACCTAAGGCAACATT 
GAATTCGCTGCTGGGATGCACACCA 
E7 HPV 
18 
318 Current 
study 
N-LCR16-F 
N-LCR16-R 
AACTGC TAAACGCAAAAAACGTAAGCT 
AACATTGCAGTTCTCTTTTGGTGCAT 
LCR 884  Current 
study 
HPV16-E6 -F 
HPV16-E6- R 
GGG G GAT CCG  CAC CAA AAG AGA ACT GCA ATG TT 
GGGCTCGAGCAGCTGGGTTTCTCTACGT 
E6 477 
 
 
Current 
study 
HPV16-E7 -F 
HPV16-E7- R 
GGGGAATTCGCATGGAGATACACCTACATTGC   
GGGCTCGAGTGGTTTCTGAGAACAGAT GG  
 
E7 297 Current 
study 
HPV16-E1-F 
HPV16-E1-R 
AAAGAA TTCGCTGAT CCTGCAGGTACCAAT 
AAAAAG CTTTAATGTGTTAGTATTTTGTCCTGACACAC 
E1 1950  
 
 
Current 
study 
HPV16-E2 -F 
HPV16-E2- R 
GAATTCGGGGACTCTTTGCCAACGTTTA 
CTCGAGTATAGACATAAATCCAGTAGACAC 
E2 1098  Current 
study 
 
HPV16-E4-F 
HPV16-E4-R 
 
GGATCCGTATTATCATCTGTGTTTAG 
GGGAAGCTTCTATTGTAGTGTTACTA 
 
E4 290 
 
 
Current 
study 
HPV16-E5-F 
HPV16-E5-R 
AAAGGATCCACAAATCTTGATACTGCATCCACA 
AAACTCGAGTGTAATTAAAAAGCGTGCATGAGTATG 
E5 252  
 
 
Current 
study 
HPV16-L1 -F 
HPV16-L1- R 
GGGAAGCTTGAGGTGACTTTTATTTACATC 
CTCGAGCAGCTTACGTTTTTTGCGTTT  
L1 1595  Current 
study 
 
HPV16-L2-F 
HPV16-L2-R 
AAAGAATTCCGACACAAACGTTCTGCAAAAC 
AAAAAGCTTGGCAGCCAAAGAGAC ATCTG 
L2 1422  
 
 
Current 
study 
pOri16 F 
pOri16 R 
ATCGGTTGAACCGAAACCG 
TAACTTTCTGGGTCGCTCCTG 
Ori  NA Taylor and 
Morgan,2003 
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Table2.2: PCR profiles for HPV genome amplification 
 
 
 
 
 
 
 
 
 
 
 
Primer name Hot start  Denaturation Annealing Extension Final Extension 
35 cycles 
 
GP5+/GP6+, 
 
HPV16 E6 
 
94 °C, 4 min 
 
94 °C, 30s 
 
45 °C, 45s 
 
72 °C, 30s 
 
7 min, 72 °C 
 
PC03/PC04 
 
94 °C, 4 min 
 
94 °C, 30s 
 
54 °C, 45s 
 
72 °C, 30s 
 
7 min, 72 °C 
New TS 16 
New TS 18 
HPV16E7 
C18E7 
HPV16 E2 
HPV16 E5 
HPV16 E7 
 
 
 
94 °C, 4 min 
 
 
 
94 °C, 30s 
 
 
 
58 °C, 45s 
 
 
 
72 °C, 30s 
 
 
 
7 min, 72 °C 
 
HPV16 L1 
 
HPV16 L2 
 
HPV16 E1 
 
94 °C, 4 min 
 
94 °C, min 
 
60 °C, 1min 
 
72 °C, 1min 
 
7 min, 72 °C 
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2.3.2 Polymerase chain reaction 
The DNA amplification from cervical cancer tissue sample was carried out by PCR with 
the primer sets mentioned in Table 2.1. PCR was carried out in 20 μl reaction volume 
containing 100-300 ng DNA, 2 μl of 10 X Buffer (Vivantis), 1 μl of 2 mM deoxynucleotide 
triphosphate (dNTPs), 1 μl of 50 mM MgCl2, 1U of polymerase and 1 μl of 10 pmol of 
each primer. Nuclease free water was used to adjust the final reaction volume to 20 μl . 
PCR cycling profile are mentioned in Table 2.2. HPV detection and genotyping was carried 
out by using Taq DNA polymerase (Fermentas), whereas gene amplification for cloning 
purpose was carried out using high fidelity Pfu DNA polymerase (Vivantis).  
2.3.3 Agarose gel electropherosis 
The amplified products were analysed on a 1 % or 2 % (section 2.1.2.4) agarose gel 
(depending on size of amplicon). The gel was stained with ethidium bromide (10 mg/ml) 
and visualised in Wealtec Dolphin Doc (S/N470883) gel documentation system. Prior to 
loading onto gel, the samples were mixed with loading dye (section 2.1.2.5). 
Electrophoresis was carried out at 90 volts for 30 minutes in 1 X TBE running buffer. 
However, the PCR product run on gel for extraction purpose and the restriction enzyme 
digested plasmids were resolved on gel at 75 volts and 90 volts respectively, for 1 hour in 
1 X TBE running buffer.  
2.3.4 Gel extraction 
Amplicons were eluted from agarose gel according to manufacturer protocol (Invitrogen). 
Briefly, single, specific DNA fragments were excised from the gel with least amount of 
agarose present around the fragment. In order to remove agarose, the sample was treated 
with gel solubilization buffer. The DNA was washed and the product was eluted in 30 µl 
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nuclease free (NF) water. DNA wasrun on 1 or 2 % (depending on amplicon size) agarose 
gel andthe amplicons were visualised as mentioned in section 2.3.3.  
2.3.5 Real time PCR: 
Viral DNA absolute quantification (Livak and Schmittgen, 2001) was performed by real 
time two-step PCR using the Sensimix SyBr No-Rox kit (Bioline). The reactions were 
carried out in a 20 µl volume containing 10 µl of SyBr Mix, 0.125 µl of 250 nM each 
pOri16 primers, 2 µl of 100 ng DNA and 7.75 µl of nuclease free water. The initial 
denaturation was performed at 95 ºC for 10 minutes. The amplification profile was for 40 
cycles at 95 ºC for 15 seconds and 60 ºC for 50 seconds. The dissociation profile was 95 
ºC for 1 minute, 55 ºC for 30 seconds and 95 ºC for 30 seconds.  
The pOri16 plasmid was used as a standard in concentrations of 0.005, 0.05, 0.5, 5, 50 and 
500 pg. The PCR was run in Stratagene Mx 3005 (Life Technologies) and analysed by 
Stratagene software. 
2.4 Molecular cloning 
2.4.1 Preparation of competent cells 
A small aliquot of frozen E. coli (DH5α) were inoculated into sterile 10 ml LB broth 
medium (section 2.1.5.1) and allowed to grow overnight in a shaking incubator at 37 ºC. 
On the following day fresh LB (50 ml) media was inoculated with 1 ml of overnight grown 
bacterial culture and the media was subjected to further incubation (37 ºC; 180 rpm) until 
OD
600 
reaches 0.3-0.4. Grown cultures were centrifuged at 3000 × g, 4 ºC, for 15 minute 
and cell pellet was stored in ice.  
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2.4.1.1 Calcium chloride method 
 
The cell pellet was resuspended in 20 ml of ice cold 50 mM CaCl2 (section 2.1.1.7) and 
incubated on ice for 10 minutes. Cells were centrifuged at 3000 × g, 4 ºC, 15 minutes and 
pellet was resuspended in 2 ml of ice cold 50 mM CaCl2 (section 2.1.1.7). The cells were 
aliquoted in microfuge tubes that contain 50 µl 100 % glycerol, left on ice for 1 hour and 
transferred to -80 ºC freezer for future use. 
2.4.1.2 Transformation storage solution (TSS) method  
 
This method was adapted from Chung et al., (1989) for the preparation of competent cells. 
The cells were chilled on ice for 5 minutes in pre-cooled 50 ml centrifuge tubes and centrifuged 
at 3000 × g for 10 minutes at 4 °C. They were then resuspended in 5 ml chilled transformation 
storage solution (TSS; section 2.1.7.1) and aliquoted (100 microlitres) into pre chilled 
Eppendorf tubes. Later these tubes, flash-frozen with liquid nitrogen and stored at -80 ºC 
for future use. 
2.4.2 Ligation of HPV 16 amplicons in pCR®2.1 vector 
 
Cloning of high risk HPV 16 non-structural (E6, E7, E1, E2, E4, E5) and structural (L2, 
L1) genes in TOPO TA cloning vectors were carried out using dual promoter TA cloning 
kit (Invitrogen). Since these genes were amplified using Pfu DNA polymerase which has 
an ability to proof read and therefore cannot produce 3'A overhangs which are necessary 
for TA cloning vectors. Therefore, before setting up cloning reaction, the amplicons were 
subjected to produce 3' A overhangs in a 10 μl reaction containing 1 µg of DNA, 1U of 
Taq DNA polymerase (Fermentas) and 10 pmol of dATP.  
The appropriate amount of insert used for ligation was calculated by following equation:  
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[(amount of vector, ng) × (size of insert, kb) / (size of vector, kb) × (molar ratio of 
insert/vector)] = ng of insert DNA.  
The ligation reaction was carried out according to manufacturer’s protocol. Briefly, 
mixture of 10 μl was prepared by adding 2 μl of 50 ng linearised pCR®2.1 vector, 300-800 
ng DNA, 1 μl of 4U T4 DNA ligase, 1 μl of 10 X ligation buffer and nuclease free water . 
The mixture was incubated at 14 oC for overnight. 
2.4.2.1 Transformation of ligated genes in E. coli (DH5α) 
Transformation of plasmid carrying the gene was carried out by chemical transformation 
method. Briefly, 10 μl of ligation reaction was added into freshly prepared 200 μl of 
chemically competent DH5α strain of Escherichia coli cells and mixed gently. The cells 
were incubated on ice for 30 minutes and were subjected to heat shock at 42 °C for 45 
seconds which were then snap cooled. Cells were treated with 800 μl of LB media and 
incubated at 37 °C with gentle shaking at 200 rpm for 1 hour. Pellet was cleared by 
centrifugation at 500 × g for 1 minute and 800 μl of supernatant was discarded. The 
remaining 200 μl of supernatant was used to resuspend the pellet and spread on pre-warmed 
agar plates containing 100 µg/ml ampicillin and 20 mg/ml of X gal to perform ampicillin 
resistant blue/white colony selection. The plates were incubated for 14-18 hours at 37 °C. 
White colonies representing recombinant plasmids were identified and replica plates were 
made for further analysis by PCR, restriction digestion and DNA sequencing.  
2.4.3 Transformation of plasmids received on filter papers  
 
The filter paper onto which the plasmid was received was cut out around the plasmid spot 
with a sterile scalpel blade. It was placed in an Eppendorf tube and 100 µl of distilled water 
was added. The DNA concentration was taken as mentioned in section 2.2.6. The DNA 
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(50-100 ng) was used to transform DH5α cells (XL gold, Invitrogen) according to the 
manufacturer’s protocol. After transformation, 100 µl of cells were spread on agar plates 
with the required antibiotic in concentration of 100 µg/ml, and left in incubator at 37 °C 
for 14-18 hours. The single colonies were then picked and inoculated in 10 ml LB culture, 
left at 37 °C for next 14-18 hours. The plasmids were isolated and purified using a Maxi-
prep kit, following the manufacturer’s protocol (Qiagen) and subjected to sequencing 
(section 2.7). For bacterial expression, 100 ng of respective DNA was used to transform 
the plasmids in calcium chloride competent BL21 cells. Single colonies obtained were 
selected and grown in LB media.  
2.4.3.1 Glycerol stocks 
 
Glycerol stocks were made using 1 ml of culture and 1 ml of 100 % glycerol in cryovials 
followed by storage at -80 °C for long term utilization. 
2.4.4 Colony PCR 
The HPV 16 genome cloned in TA vector were confirmed using colony PCR. Atleast 3 
different colonies were picked and resuspended individually in 15 μl nuclease free water 
in PCR tubes. To lyse the cells, the tubes were incubated for 10 minutes at 94 °C followed 
by 25 oC incubation for 10 minutes . The lysate was cleared by centrifugation at 3000 × g 
for 1 minute and supernatant was used as a template in PCR. The amplification was carried 
out using optimised condition for each gene as mentioned in Table 2.2 and visualised by 
agarose gel electrophoresis (section 2.3.3). 
 
 
Chapter 2  Materials and methods 
 
75 
 
2.5    Plasmid preparation 
After transformation of E. coli XL-1 Blue or DH5α competent cells with the appropriate DNA, 
a single bacterial colony was picked from the petri dish and inoculated into the appropriate 
volume of LB broth depending on the DNA preparation as mentioned in Table 2.3. Inoculum 
was incubated for 16 hours (overnight) in orbital shaker (37 oC; 180 rpm). 
 
Table 2.3: Volume of LB broth required for the DNA preparation. 
 
DNA preparation Volume of LB Antibiotic (100μg/mL) 
 
Mini scale 10 ml 10 μl 
 
Maxi scale 50 ml 50 μl 
 
 
 
2.5.1 Isolation and purification of plasmid DNA  
 
Plasmid DNA was isolated either using QIAGEN® plasmid mini kit following the 
manufacturer’s instructions (QIAGEN® plasmid purification handbook) or by alkaline lysis 
method (section 2.5.1.1).  
2.5.1.1 Alkaline lysis method 
 
In alkaline lysis mini preparation method the culture was transferred in 15 ml centrifuge 
tube; cell pallet was obtained by centrifugation at 3000 × g for 10 minutes in centrifuge 
(Eppendorf 5810R). The pellet was resuspended in 100 µl ice cold solution I (section 
2.1.6.3). Freshly prepared 200 µl solution II (section 2.1.6.4) was added to the sample and 
mixed gently. This was followed by addition of 150 µl ice cold solution III (section 2.1.6.5) 
and then the mixture was incubated on ice for 5 minutes followed by centrifugation for 5 
minutes at 14432 × g, 4 °C. The supernatant was carefully transferred to a 1.5 ml microfuge 
tube and equal volume of phenol chloroform isopropanol (PCI) purification was performed 
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as mentioned in section 2.2.5. The DNA pellet was re-suspended in nuclease free water 
along with 1 µl RNase A (Fermentas) and incubated at 37 oC for 30 minutes to inactivate 
the RNA and visualised by agarose gel electrophoresis (section 2.3.3). 
2.5.1.2 Maxi plasmid prep  
Plasmid DNA was isolated using QIAGEN® plasmid maxi kit following the manufacturer’s 
instructions (QIAGEN® plasmid purification handbook). 
2.6 Restriction digestion of the recombinant clones 
Restriction enzyme digestion was carried out to analyse the plasmids (Table 2.4), for the 
presence and correct orientation of the insert. This was carried out by single or double 
digestion with appropriate restriction enzymes. For single digestion the final reaction 
volume of 10 µl contains 60 ng of plasmid, 1 X buffer (Fermentas), nuclease free water 
and 4U restriction enzyme (Fermentas). Double digestion reaction was set up by addition 
of two restriction enzymes at the same time to 60 ng of DNA template in the presence of 
universal buffer and incubated according to manufacturer’s protocol. The samples were 
heat inactivated when required according to each restriction enzyme’s specifications. The 
digested DNA were run on agarose gel and visualised in gel documentation system (section 
2.3.3). 
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Table 2.4: Genes digested with their respective restriction enzymes. 
 
 
 
 
 
 
Gene name Restriction enzymes used  
HPV 16 E6 BamHI (Fermentas) and XhoI (Fermentas) 
HPV 16 E7 EcoRI (Fast Digest) and XhoI 
HPV 16 E1 EcoRI and HindIII( Fast Digest) 
HPV 16 E2 EcoRI and XhoI 
HPV 16 E4 BamHI and HindIII 
HPV 16 E5 BamHI and XhoI 
HPV 16 L2 EcoRI and HindIII 
HPV 16 L1 HindIII and XhoI 
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2.7 Sequencing 
 
Sequencing was carried out by using 400 ng/µl DNA mixed with 3.2 µM/µl primer. The 
reaction volume was adjusted to 11 µl. The sequencing was performed using DNA 
sequencing facility at university of Birmingham (UK) and Eurofins, MWG/Operon (USA).  
2.8 In silico analysis 
 
The protein-protein interaction between HPV 16 L1 and E2 was analysed computationally 
using different docking servers. The PDB coordinate files for HPV 16 L1 (1DZL) and HPV 
16 E2-binding domain (1ZZF) were obtained from RCSB 
(http://www.rcsb.org/pdb/home/home.do). Based on those files, the protein interactions 
were predicted using ZDOCK 3.0.2, ClusPro 2.0 and Rosetta.  
ZDOCK is a rigid protein docking program based on fast fourier transformation (FFT) 
algorithms. It examines all possible binding models and evaluates them on basis of energy 
scores which includes IFACE statistical potential, shape complementarity and 
electrostatics. The server then returns the docked complex having the lowest energy 
profiles (Pierce et al., 2014).  
The ClusPro protein docking server uses FFT algorithm to predict interaction between 
proteins. It evaluates the possible docked complexes on the basis of surface 
complementarity, an approximation of the van der Waals contact energy, the desolvation 
free energy using the atomic contact potential and the electrostatic free energy (Comeau et 
al., 2004). Scoring is done by rotating the ligand around the receptor with 70,000 rotations 
and translated in x, y and z dimensions relative to the receptor on a grid. The translations 
with the best score from each rotation are selected and “greedy clustering” is done with 
ligand in a 9 Å C-alpha RMSD radius of receptor. The top cluster are subjected to 
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CHARMM energy minimizing functions in the presence of the receptor and combined into 
PDB NMR format (Comeau et al., 2004). 
The Rosetta protein docking program is a Monte Carlo (MC) based algorithm which gives 
reliable docking information. It generates rigid-body orientation and side-chain 
conformation (Lyskov and Gray, 2008). It starts from either a random initial orientation of 
the two partners (global docking), or an initial orientation defined by user (local 
perturbation) and selects the minimum energy complex for high-resolution refinement, 
which then undergoes further energy minimization programs (Lyskov and Gray, 2008). 
The “Van der Waals attractive and repulsive terms, a solvation term, an explicit hydrogen 
bonding term, a statistical residue-residue pair-wise interaction term, an internal side-chain 
conformational energy term and an electrostatic term” are used to score energy (Lyskov 
and Gray, 2008; Lyskov et al., 2013) .  
Phylogenetic trees were analysed through computer programes namely MRBAYES v3.0b6 
(Ronquist and Huelsenbeck, 2003) and MEGA6 (Tamura et al., 2013) for Bayesian and 
Maximum parsimony tree construction respectively. MRBAYES uses Markov chain monte 
carlo (MCMC) methods. Whereas, MEGA6 uses subtree-pruning-regrafting (SPR) 
algorithm for maximum parsimony based trees.  
2.9 Protein biochemistry 
2.9.1 Plasmids 
HPV 16 L1 protein was expressed from CMV promoter in pBK-CMV which has been 
codon optimised for better expression (obtained from Martin Mueller, Heidleburg 
Germany; Leder et al., 2001). 
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The HPV 16 E2 was expressed from cytomegalovirus (CMV) immediate early promoter 
and HPV 16 E1 was HA tagged. The firefly luciferase (p6E2-tk-Luc) was expressed under 
the control of thymidine kinase promoter containing 6 E2 binding sits in the upstream. The 
HPV 16 origin of replication (Ori16) was cloned in pSK II (-) from nucleotide 7838-139 
and named pOri16M (Taylor and Morgan, 2003; obtained from Professor Iain Morgan, 
University of Glasgow). Renilla luciferase was expressed constitutively using pRL-CMV 
(Promega) construct.  
Glutathione S-transferase (GST) fusion plasmids expressing different HPV 16 E2 
truncations in pGEX2T were kindly provided by Lawrence Banks and Cecilia Johansson. 
These truncations includes HPV 16 E2 N-terminus with hinge region from 1-257 amino 
acid, hinge region with C-terminus from 200-365 amino acid, truncated N-terminus from 
1-138 amino acid and truncated C-terminus from 202-306 and 249-365 amino acids. 
2.9.2 Sample preparation 
 
Protein samples were mixed with 1 X sample loading buffer (section 2.1.3.3) and heated 
at 90 °C for 10 minutes before loading onto the gel along with a protein ladder (PageRuler 
plus pre-stained protein ladder [10 - 250 kDa]). Samples in G sepharose resin slurry and 
glutathione S-transferase (GST) were dissolved in 2 X sample buffer. 
2.9.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were centrifuged briefly and resolved on 10-12 % polyacrylamide 
separating gels according to manufacturer protocol (Bio-Rad). The resolving gels are 
poured and a layer of isopropanol was added to the surface of the gel in order to ensure the 
uniform surface for samples. When the resolving gel had set, isopropanol was tipped off, 
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stacking gel was poured on top of it and comb inserted. The gels were run in 1 X running 
buffer (section 2.1.3.6) at 120-150 V for 1-2 hours.   
2.9.4 Coomassie staining 
The analysis of GST recombinant proteins was carried out using Coomassie brilliant blue 
(Bio-Rad) with gentle agitation at room temperature for 1 hour. Gels were de-stained with 
multiple changes of water until clear protein bands can be visualised. The bands were scanned 
and analysed using Peqlab densitometry software as mentioned in section 2.9.6.  
2.9.5 Western blotting 
After electrophoretic separation of proteins by SDS-PAGE, proteins were transferred on 
nitrocellulose polyvinalidene fluoride (PVDF) membrane (Roche) using tank blotting 
method (Bio-Rad). The membranes were soaked in methanol for 10 seconds and then 
soaked in transfer buffer (section 2.1.4.2). Sponges and filter paper were soaked in transfer 
buffer as well and a membrane sandwich was assembled as described by manufacturer. 
Care was taken while assembling the cassette and any bubbles were removed with a glass 
roller. The transfer was performed at 100 V for 1 hour. Upon completion of the run, 
cassettes were disassembled and membranes were blocked in 5 % non-fat dry milk made 
in 1 X TBS/T for 1 hour on rocker at room temperature. They were incubated with 
appropriate primary antibodies (Table 2.5) in milk for 1-2 hour at room temperature. 
Membranes were washed in 1 X TBS/T for 5 times on a rocker at 30 rpm followed by 
incubation with secondary antibody and washed again. The signal was detected for proteins 
using Supersignal west dura chemiluminescent substrate (Thermo Scientific) in Peqlab 
fusion software.   
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Table 2.5: Antibody dilutions used in western blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody name Manufacturer Species Dilution 
Anti HPV16 E2 (TVG261) Abcam 17185 Mouse 1:500 
 
Anti HPV16 E2  Parish Lab (Dundee Cell Products) Sheep 1:500 
 
Anti HPV16 L1 Abcam 30908 Mouse 1 :3000 
 
Anti HA 11 Abcam 9110 Mouse 1:1000 
 
Anti β-Actin Sigma A5441 Mouse 1:1000 
 
Anti GST Abcam 6613 Goat 1:1000 
 
Anti Grb2 Cell signaling, 3972S Rabbit 1:1000 
 
Anti H3 Bethyl, A300-823A Rabbit 1:5000 
 
Anti Orc2b  Cell signaling, 4736S) Rat  1:1000 
 
Anti vimentin Abcam, 92547 Rabbit 1:1000 
 
Anti Mouse IgG HRP conjugated Thermo Scientific  Goat 1:10,000 
 
Anti Rabbit IgG HRP conjugated Thermo Scientific  Goat 1:10,000 
 
Anti Rat IgG HRP conjugated Thermo Scientific (Kindly provided by 
Sally Roberts, University of Birmingham)  
Goat 1:10,000 
 
Anti sheep/goat IgG HRP 
conjugated 
Thermo Scientific  Rabbit 1:10,000 
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2.9.6 Densitometric analysis  
 
The SDS gels were scanned and analysed using Peqlab fusion software whereas Western 
blot images were scanned and analysed using ImageJ densitometry software. The bands 
were selected carefully by drawing squares around them in order to ensure that only the 
density of selected area would be taken into account. Moreover, in order to remain within 
the detection limit of software the overexposed gels or bands were not used. The 
percentages of protein expression were calculated by comparing the values of each sample 
to the control set to 100 %. The readings were taken for at least 3 independent experiments, 
and the average was sought which is then analysed statistically.   
2.9.7 Bradford assay for protein concentration determination 
Protein concentration was determined using the Bradford method. Bovine serum albumin 
(BSA; Sigma) was used as standard at a concentration of 0, 0.0625, 0.125, 0.25 and 0.5 
mg/ml. Moreover, fivefold dilution of protein lysates was prepared in water. The standard 
and unknown samples were mixed with Bradford reagent and absorbance was taken 
according to manufacturer protocol at 595 nm in microtiter plate reader. The absorbance 
obtained for standard protein was used to plot the linear graph. The absorbance value was 
used as the dependent variable (y-axis) and concentration as the independent variable (x-
axis). This gives the equation of the line as follows: Y = ax + b, where solving for x 
determines the protein concentration of the sample. Knowing the concentration, the equal 
amount of protein was used for running on gel to determine the proteins using Western 
blot. 
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2.9.8 Protein expression in bacterial cultures 
 
The bacterial colony containing constructs were cultured in 10 ml LB containing 100 µg/ml 
ampicillin overnight at 37 °C at 210 rpm. The next day, cultures were transferred in 50 ml 
LB and were grown at 37 °C, 210 rpm until the optical density reached 0.6. Cultures were 
induced with 0.5 mM IPTG and grown at 37 °C, 210 rpm for 4 hours. Samples were cleared 
by centrifugation at 1200 × g at 4 °C for 15 minutes. The pellet was re suspended in 1 ml 
of lysis buffer (section 2.1.8.1) and incubated on ice for 30 minutes. The lysed samples 
were sonicated for 30 seconds with 10 seconds on 10 seconds off at 30 % amplitude. 
Lysates were centrifuged at 20000 × g, 4 °C for 10 minutes. 
2.9.8.1 Protein binding to resin 
 
In order to bind the expressed proteins to resin, 30 µl of 50 % glutathione agarose (Sigma) 
slurry was washed with wash buffer I (section 2.1.8.2) followed by addition of protein 
lysate (1 ml) to the washed beads. They were left at 4 °C for 2-6 hours with gentle agitation. 
Sample was cleared by centrifugation at 2000 × g for 2 minutes and washed three times 
with wash buffer I (section 2.1.8.2). The 15 µl of resin slurry was prepared in protein dye 
to run on SDS gel and stained with Coomassie dye (section 2.9.4). The bound proteins 
were quantified using Peqlab densitometric analysis (section 2.9.6) and the equal amount 
of protein in terms of expression was used for the pull down assay. 
2.9.9 Pull down assay 
 
GST pull-down assays were performed as follows: GST, GST-E2-1-257(E2-NH), GST-
E2-200-365(E2-HC), GST-E2-1-365, GST-E2-200-365, GST-E2-202-306 and GST-E2-
249-365 proteins were expressed and immobilised on beads as described above in section 
2.9.8.1. The immobilised proteins were mixed with 100 µl of mammalian expressed L1 
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(HPV 16 L1 expression plasmid was transfected in C33a cells and harvested as mentioned 
in section 2.10.3.1) and 100 µl of binding buffer (section 2.1.10.2). Samples were left at 4 
°C for 2 hours with gentle shaking. They were cleared by centrifugation at 2000 × g for 2 
minutes and washed three times with wash buffer II (section 2.1.8.3). Proteins pulled down 
were separated by SDS-PAGE and analysed by Western bloting.  
2.10    Cell culture  
Cervical carcinoma-derived cell line, C33a and human bone osteosarcoma epithelial cells 
U20S were grown in Dulbecco's modified eagle medium DMEM-6429 (Sigma) 
supplemented with 10 % fetal bovine serum (FBS). 
Normal primary human foreskin keratinocytes (HFK) were isolated from neonatal foreskin 
following the protocol described by Meyers and Laimins (Meyers & Laimins, 1994). HFKs 
were cultured in serum-free keratinocyte growth medium (KGM; Invitrogen-Gibco), 
supplemented with human recombinant epidermal growth factor 1-53 (EGF 1-53) and 
bovine pituitary extract (BPE). The media was changed every 2 days until the cells reached 
the 80 % confluency. They were incubated at 37 °C with 5 % CO2.  
2.10.1 Passaging of cells 
 
When the cell density reached 75-80 %, media was removed and cells were washed with 
PBS. Cells were trypsinized using 0.05 % trypsin EDTA (Gibco-Invitrogen) with gentle 
tapping over an approximately 5 minute incubation at 37 °C until the cells had detached. 
The cell adhesion was monitored under the microscope and trypsin was neutralised by 
addition of the appropriate growth media. The number of cells were counted in a 
haemocytometer and seeded at the required density according to the experimental 
requirements.  
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Passaging of the HFK cells was a little different. They were trypsinised using 1X TrypLE™ 
Express enzyme followed by incubation at 37 °C. After 5-10 minutes, the trypsin was 
inactivated by addition of trypsin-neutralising solution (TNS, Invitrogen 0.25 mg/ml soybean 
trypsin inhibitor in PBS (Dulbeccos) without calcium or magnesium, pH 7.2) in a ratio double 
than TrypLE. The cells were rinsed twice with 2 ml keratinocyte serum free medium (K-SFM) 
and the cells pelleted by centrifugation at 500 × g for 5 minutes at room temperature. The 
supernatant was subsequently removed and the pellet re-suspended in 10 ml K-SFM and seeded 
according to experimental details. 
2.10.2 Freezing and thawing of cells 
The cells were grown to 75-80 % density and harvested in DMEM. After counting the cell 
number, they were re-suspended to a concentration of 2 x 106 cells/ml in 85 % (v/v) FBS, 
15 % DMSO. The cells were transferred to cryovials (Nalgene-Nunc) and stored at -80 °C 
in Mr Frosty (Nalgene), a slow-cool freezing chamber with isopropanol for 16-18 hours 
before being transferred to liquid nitrogen for long term storage. 
For defrosting the cells, the cryovials were taken out from liquid nitrogen tank and thawed 
at 37 °C for 1 minute. The cells were transferred into a universal tube and 10 ml of growth 
media added. To remove the DMSO, the cells were pelleted by centrifugation at 500 × g 
for 5 minutes and re-suspended in 10 ml of the appropriate media. The cells were then 
transferred to 10 cm tissue culture dish and placed at 37 °C, 5 % CO2 to recover. 
2.10.3 Transient transfection 
Cells were seeded at an appropriate density (Table 2.6) in required plates and allowed to 
adhere for few hours at 37 °C in 5 % CO2. The HFKs were left to adhere overnight. 
Transient transfections were performed using the appropriate reagent and following the 
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manufacturer’s protocol in each case. The cells (C33a or U2OS) were transfected using X-
tremeGENE 9 reagent (Roche) at a DNA: X-tremeGENE ratio of 1:2. The transfections for 
immunofluorescence experiments were carried out using Lipofectamine® 2000 (Life 
Technologies) in a ratio of 1:3 or 1:1 for C33a and primary cells respectively. After 
transfections cells were incubated at 37 °C in 5 % CO2 for as long as required. 
2.10.3.1 Harvesting of transfected cells 
After 24 or 48 hours following transfection, the cells were harvested in PBS and 
centrifuged at 500 × g for 5 minutes. The cell pellet was resuspended in 300 µl of freshly 
prepared lysis buffer (section 2.1.10.1) and incubated in ice for 30 minutes. After lysis, 
cells were sonicated for 2 × 10 seconds at 30 % amplitude and cleared by centrifugation at 
1000 × g for 10 minutes. 
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Table 2.6: Number of cells required for the techniques performed and the amount of DNA 
transfected. An asterisk (*) indicates DNA being normalised with salmon sperm. 
 
Cell type 
and 
number 
Plate size Assay  Plasmids   
 
C33a 
3 × 106 
 
 
10 cm dish 
Co IP Expression plasmids for HPV 16 E2 (5 µg) 
and L1 (5 µg) 
 
Fractionation Expressing plasmids for HPV 16 E2 (500 ng) 
and HPV 16 L1 (500 ng) * 
 
C33a 
 
3 × 105 
6 well plate Transcription pRL-CMV(15 ng), p6E2-tk-Luc (100 ng), 
expression plasmids for E2 (50 ng) and  
L1(100, 250, 500 ng)* 
 
C33a 
 
2.50 × 105   
6 well plate Replication, using 
luciferase reporter 
pRL-CMV (15 ng), pOri (25 ng), expression 
plasmids for  HPV 16 E1 (600ng), L1 (100, 
250, 500 ng) , and E2 (10 ng)* 
 
  Replication, using real time 
PCR 
pOri16M (25ng), expression plasmids for  
HPV 16 E1 (600ng), L1 (100, 250, 500 ng)  
and E2 (10 ng)* 
 
C33a,  
U20S 
6 × 106 
 
15 cm dish Half-life Expression plasmids for HPV 16 E2 (10 µg), 
for HPV 16 L1 (10 µg)* 
C33a 
2 × 106 
6 cm dish Immunofluorescence Expression plasmids for HPV 16 E2 (1.5 µg), 
for HPV 16 L1 (1.5 µg)* 
 
C33a 
2 × 106 
6 cm dish Immunofluorescence pOri16M (75ng), expression plasmids for 
HPV 16 E2 (1 µg), HPV 16 L1 (1 µg), and 
HPV 16 E1 (1 µg ) * 
 
HFKs 
1× 105 
12 well plate  Expression plasmids for HPV 16 E2 (1.5 µg), 
for HPV 16 L1 (1.5 µg)* 
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2.10.4 Co-immunoprecipitation assays 
 
C33a cells were seeded and co-transfected as stated in Table 2.6. After 48 hours following 
transfection, cells were harvested as stated in section 2.10.3.1. For co-
immunoprecipitation, 200 μl of lysate was mixed with 200 μl binding buffer (section 
2.1.10.2), 30 μl of protein G sepharose (Sigma) and appropriate antibody (Table 2.7). 
Protein G sepharose beads were washed thrice with binding buffer (section 2.1.10.2) prior 
to use. Samples were incubated at 4 °C for 2 hours with gentle agitation. Samples were 
cleared by centrifugation at 2000 × g for 2 minutes followed by 3 washes with wash buffer 
(section 2.1.10.3). Co-immunoprecipitating proteins were separated by SDS-PAGE and 
detected by Western blot. Membranes were subsequently stripped and re-probed with β-
actin antibody. 
Table 2.7: Antibody dilutions used in immunoprecipitation assay. 
Antibody name Manufacturer Species Dilution 
 
Anti IgG  Santa Cruz Rabbit 1 µl 
 
Mouse 1 µl 
 
Anti HPV 16 E2 Parish lab (Dundee Cell 
Products) 
Sheep 4 µl 
 
 
Anti HPV 16 L1 Abcam 30908 Mouse 1 µl 
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2.10.5 Transcription assay 
 
Transcription assays were performed by seeding C33a cells,  6 hours prior  to transfection 
with specified plasmids, as mentioned in Table 2.6. Twenty four hours following 
transfection, the cells were washed twice with 1 X PBS and harvested using dual luciferase 
assay kit according to manufacturer protocol (Promega). The cell lysis was performed 
using 100 μl of 1 X passive lysis buffer (Promega) and cells were scrapped from the culture 
plates. The cell lysate was transferred to a 1.5 ml Eppendorf tube and centrifuged at 2000 
× g for 2 minutes. 20 μl of the supernatant was transferred to a 96 well plastic plate. It is 
mixed with 100 μl of the luciferase assay reagent II (LAR II, Promega) in order to quantify 
the Firefly luciferase activity which was measured in a Centro LB 960 Microplate 
Luminometer (Berthold technologies). The Stop & Glo reagent (100 μl) was then added to 
the sample mixture and the Renilla luciferase activity was also determined. Renilla 
luciferase was an internal control for Firefly luciferase activity. The relative luciferase 
activity for each experiment was then determined by dividing the readings obtained for 
Firefly luciferase activity by the Renilla luciferase. The cell lysates were run on SDS PAGE 
and Western blot was performed to ensure appropriate expression of the specific proteins.  
2.10.6 Replication assay  
Replication assay was performed using both a luciferase reporter system and real time 
PCR. For this, C33a cells were transfected with specific plasmids as mentioned in Table 
2.6.  
2.10.6.1 Luciferase reporter assay 
 
To perform the assay using a luciferase system, the cells were harvested 48 hours following 
transfection using dual luciferase assay kit according to manufacturer protocol (Promega) 
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as mentioned in section 2.10.5. Luciferase activity was measured using 2 μl of lysate 
because of high replication efficiency. The cell lysates were run on SDS PAGE and 
Western blot was performed to detect the specific proteins.  
2.10.6.2 Real time PCR reporter assay 
 
The cells were plated and transfected in duplicate and one set was used for DNA 
quantification and the other set was used for Western blotting. To extract the DNA, the 
cells were harvested 48 hours following transfection and washed twice with 1 X PBS and 
lysed using 250 µl of Hirt solution (section 2.1.6.2) .The lysed cells are treated with 63 µl 
of 5 M NaCl and samples were left at 4 °C for overnight. The next day, DNA was exacted 
by centrifuging the samples at 14432 × g for 10 minutes. The supernatant was transferred 
into Eppendorf tubes and purified as mentioned in section 2.2.5. To digest input DNA 
samples were treated with DpnI (Fermentas) at 37 °C for 4 hours and analysed by real time 
PCR (section 2.3.5). 
To extract proteins, the transfected cells were harvested and lysed as mentioned in section 
2.10.3.1 using 250 µl of lysis buffer. 10 % of the total sample was run on SDS gel and 
proteins were detected by Western blotting.  
2.10.7 Immunofluorescence 
 
Transfections were carried out in C33a and HFKs for immunofluorescence assays. In the 
case of C33a, 22 mm rectangular coverslips were placed in 6 cm dishes in a sterile manner, 
whereas for HFKs, 16 mm rectangular cover slips were placed in 12 well plate and cells 
were transfected as mentioned in Table 2.6. 24 hours following transfection, the cells were 
washed twice with PBS. C33a cells were fixed with 4 % formaldehyde (Sigma) in PBS for 
10 minutes. The HFKs were fixed with 3.6 % formaldehyde in serum-free K-SFM. The 
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cells were then permeabilized using 0.2 % Triton X-100 for 10 minutes at room 
temperature. They were blocked in HINGS (heat-inactivated goat serum) made in PBS for 
one hour. The cells were incubated in primary antibody (Table 2.8) for 2 hours at room 
temperature. The cells were then incubated in the dark with an appropriate secondary 
antibody (Table 2.8) at room temperature for 1 hour and washed thrice with 1 X PBS. They 
were incubated in Hoechst (10 µg/ml) for half an hour and washed thrice with 1 X PBS. 
The coverslips were recovered from the 6-well plates and mounted onto glass slides by 
adding diamidino-2-phenylindole (DAPI) containing Prolong gold (Invitrogen) and 
visualised by epi-fluorescence or Confocal microscopy.  
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Table 2.8: Antibody dilutions used in immunofluorescence assay 
 
 
 
 
 
 
 
 
 
Antibody name Manufacturer Species Dilution 
 
 
Anti HPV 16 E2  
 
Parish lab (Dundee cell 
products) 
Sheep 1:200 
 
Gift by Françoise Thierry Rabbit 1:50 
 
Anti HPV 16 E2 
(TVG261) 
Abcam 17185 Mouse 1:100 
 
Anti HPV 16 L1 Abcam 30908 Mouse 1:1000 
1:2000 
Anti HA   Abcam 9110 Rabbit 1:1000 
 
Anti C23((H-6) Santa Cruz 
Biotechnologysc-55486 
Mouse 1:50 
Anti-mouse AlexaFluor 
488 
Life Technologies Goat 1:500 
Anti-mouse AlexaFluor 
647  
Invitrogen Goat 1:500 
Anti-sheep AlexaFluor 
594  
Invitrogen Donkey 1:500 
 
Anti-rabbit AlexaFluor 
488 
Invitrogen Goat 1:500 
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2.10.8 Subcellular protein fractionation 
The assay separates the subcellular fractions from cultured cells. These fraction yields 
proteins from cytoplasmic, membrane bound, nuclear soluble, chromatin bound and 
cytoskeletal extracts. In order to perform cellular fractionation assay, C33a cells were 
seeded and transfected with plasmids mentioned in Table 2.6. 24 hours following 
transfection, cells were harvested by trypsinization and 5 ×106 cells were counted as stated 
in section 2.10.1. The cells were pelleted by centrifugation at 500 × g for 5 minutes and 
then washed twice in 1 X PBS in order to remove any media. The cells were pelleted by 
centrifugation and used to perform fractionation according to manufacturer protocol 
(Thermo Scientific). In brief, cell pellet was treated with 200 µl of cytoplasmic extraction 
buffer (CEB) containing protease inhibitors. This permeablises the cell membrane 
selectively. The pellet was gently dissolved in CEB, then incubated at 4 °C for 10 minutes 
and centrifuged at 500 × g for 5 minutes. The supernatant which contains the proteins in 
soluble part of cytoplasm was carefully taken into pre-chilled Eppendorf tube and stored 
at 4 °C until all of fractions were obtained. The pellet was treated with 200 µl of membrane 
extraction buffer (MEB) containing protease inhibitors, vortexed for 5 seconds, followed 
by 10 minutes incubation at 4 °C .The sample was centrifuged at 3000 × g for 5 minutes. 
This treatment leaves nuclear membrane intact but yields the proteins in other membranes 
including golgi, plasma and mitochondria. The supernatant was collected in pre-chilled 
Eppendorf and stored at 4 °C. The pellet was then treated with 100 µl of nuclear extraction 
buffer (NEB) containing protease inhibitor and vortexed for 15 seconds. The sample was 
incubated at 4 °C for 30 minutes followed by centrifugation at 5000 × g for 5 minutes. This 
yields proteins in soluble part of nuclear extract. The supernatant was transferred to pre 
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chilled Eppendorf tube and stored at 4 °C. The pellet was treated again with 100 μl of NEB 
containing 5 μl of 100 mM CaCl2, protease inhibitors, and 3 µl of Micrococcal nuclease 
(300U). The sample was vortexed for 15 seconds and incubated at 37 °C water bath for 5 
minute. The sample was vortexed again for 15 seconds followed by centrifugation at 
15,000 × g for 5 minutes. This yields chromatin-bound nuclear extract. The supernatant 
was stored at 4 °C and pellet was treated with 100 µl of pellet extraction buffer (PEB) 
containing protease inhibitors. The sample was vortexed for 15 seconds and incubated for 
10 minutes at room temperature. The proteins in the cytoskeletal were retrieved by 
centrifugation at 15000 × g for 5 minutes. The supernatant was transferred to Eppendorf. 
The protease inhibitor was used in 1:100. All the fractions were proceeded for analysis 
using Western blot (section 2.9.5).  
2.10.9 Growth and immunofluorescent staining of organotypic raft cultures 
Organotypic raft cultures were prepared as described in Wilson & Laimins, 2005 by Dr. 
Sally Roberts, University of Birmingham. The human tonsil keratinocyte lines used to 
create these rafts were transfected with HPV 16 genome. 14 day old rafts were embedded 
in paraffin and sectioned on to glass slides.  
Immunofluorescence was carried out by dewaxing the sections by immersion in histoclear 
for 10 minutes. The solvent was then drained off and sections were rehydrated with 
industrial methylated spirit (IMS) for 5 minutes. The slides were washed thrice in tap water 
and epitope retrieval was performed by heating the sections overnight at 65 ºC in EDTA 
buffer containing 10 % Tween 20. The slides were washed in water and treated with IF 
block solution (section 2.1.11.2) at room temperature for 1 hour. Primary antibodies in 
block solution were added for overnight incubation at 4 ºC. The slides were then washed 
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thrice in 1 X PBS prior to incubation with secondary antibodies diluted in block solution 
for 1 hour at 37 ºC. The unbound secondary antibodies were then removed by washing four 
times in 1 X PBS and DNA was stained using Hoechst (10 µg/ml) for 10 minutes at room 
temperature. The sections were drained and mounted using Prolong gold (Invitrogen) and 
visualised by Fluorescence microscopy (Nikon). 
2.10.10 Imaging 
 
The Confocal microscopy was performed on a Leica TCS LSI macro confocal using Phase 
contrast method. The images were captured with Leica DFC 310 FX digital firewire camera 
and LAS AF software was used for image analysis. The filter block A4 was used for DAPI, 
I3 for Alexa 488 (green), N2 TRITC for Alexa 594 (red) and L5 for Alexa 647 (far red). 
The images were obtained as slices and the final image was constructed as an average.  
Epifluorescence was performed using Nikon Eclipse E600 microscope. The images were 
obtained using a Nikon DXM1200F digital camera and were assembled in Adobe Photoshop 
CS2.   
2.10.11 Determination of protein half-life  
 
Protein stability assays were carried out by seeding and transfecting C33a cells with the 
plasmids stated in Table 2.6. 24 hours following transfection, the cells were harvested by 
trypsinization and seeded into 6 cm dish at a density of 2 × 106/well. 24 hours after 
reseeding, cells were treated with cycloheximide (Sigma) to a final concentration of 10 
µg/ml. The dishes were incubated for 0, 2, 4, 8, 10 and 24 hours after which the cells were 
harvested in PBS. Samples were cleared by centrifugation at 500 × g for 5 minutes and 
pellet was re-suspended in urea lysis buffer (section 2.1.8.4). Samples were sonicated for 
15 seconds at 30 % amplitude and protein was quantified using Bradford assay (section 
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2.9.7). Based on assay the equal amount of proteins were analysed on SDS gel and the 
expression was determined by Western blotting. The gel images were quantified (section 
2.9.6) and the values obtained were used to calculate non-linear regression using Graphpad 
Prism software to calculate the half-life of protein.  
2.11 Statistical analysis 
 
All the experiments were performed in triplicate and error bars were calculated as the 
standard deviation or standard error of the mean. Statistical differences were calculated 
using the two tailed Student's t-test. The * is indicated when p values were statistically 
significant.  
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CHAPTER 3 
 
INCIDENCE OF HPV IN CERVICAL LESIONS AND 
ITS GENOMIC ANALYSIS 
 
3.1 Introduction  
 
 
The HPV induced changes in keratinocytes could be either transient or persistent. These 
changes involve effect on cellular transcription factor during infection, or differentiation 
and cellular proliferation. The transient changes in cervical cells subsides in 1-3 years due 
to elimination of virus by immune system (Burd, 2003). However, persistent HPV infection 
with high-risk types can change the normal cell functions and lead to cervical intraepithelial 
neoplasia (CIN) which could even cause the invasive cancer within several years of 
infection (Kjaer et al., 2002). Detection of HPV in cervical lesions of different grades has 
been identified as a favorable prognostic marker (Alonso et al., 2012; Brunner et al., 2011). 
Therefore, the early detection of HPV or cellular abnormality could help to prevent the 
progression to cancer. Development of subsequent treatment along with cost effective and 
sensitive cervical screening protocols are important to eliminate the disease (Snijders et 
al., 2003). The mortality rate due to cervical cancer has been significantly reduced in 
developed countries due to implementation of screening of Papanicolaou (Pap) smear and 
HPV DNA testing. On the other hand the developing countries have not devised any 
significant screening and prevention strategies, neither have they adopted the already 
existing clinical programmes (Jemal et al., 2011).  
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Apart from the disease mortality rate, the reduction in disease prevalence has been 
observed in developed countries as well due to implementation of important disease 
management strategies including proper and in time screening programmes, prophylactic 
vaccination for teen age girls and better treatment options. Contrarily, in Pakistan, such 
strategies needs to be implemented. The current health care system and low financial status 
does not permit these women to come forward for diagnosis and treatment. Hence, 
prevalence of HPV in women with normal cytology, precancerous cervical lesions and 
invasive cervical cancer in Pakistan is not known largely (WHO reports). The only 
available data on HPV prevalence in cervical cancer or lesions has been reported from 
Karachi, Sindh (Yousuf et al., 2010; Khan et al., 2007; Raza et al., 2010). Hence, there is 
lack of data on prevalent HPV genotypes in other parts including Punjab, Pakistan. It is 
highly desirable to obtain vital information on the HPV strain(s) distribution and their 
correlation with cervical cancer among Pakistani women. Based on reported data it was 
hypothesised that HPV 16 and 18 are prevalent genotypes. 
Genome sequence is an important source of information. Mutagenesis studies, 
phylogenetic analysis and protein annotations are based on sequence information and 
describes its importance. For instance vaccines against specific HPV types were developed 
on the basis of conserved sequences.  The current study was carried out to determine the 
incidence of high risk HPV in cervical cancer lesions from Punjab, Pakistan. Furthermore, 
the respective genotype and genome sequence was also determined.   
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3.2 Results 
3.2.1 Identification of HPV in cervical lesions 
The total of 80 retrospective and paraffin embedded cervical lesions of different grades 
were used in this study. According to histopathological diagnosis the samples were 
squamous cell carcinoma (SCC; n = 44), adenocarcinomaadenosquamous carcinoma 
(AC/ASC; n = 5), high grade squamous intraepithelial lesion (HSIL; n = 11), low grade 
squamous intraepithelial lesion (LSIL; n = 4) and chronic cervicitis/metaplasia (n = 16).  
To identify the HPV prevalence in cervical lesions, DNA was isolated from all the samples 
as stated in section 2.2.3. Out of 80 samples, 30 were subjected to PCR using GP5+/GP6+ 
consensus primers. This primer set detects the sequence in HPV major capsid gene L1 from 
large spectrum of 44 genital HPV types (Snijders et al., 1990). In order to determine the 
genotype 16 or 18 of the virus, the type specific primers TS16, E716, TS18 and E718 
(Table 2.1) were used. The primer set TS16 and TS18 are more sensitive than GP consensus 
primer (Snijders et al., 1990). Additional primer set E716 and E718 were included to 
increase the genotyping reliability. Fifty samples out of eighty (which have been previously 
detected positive (46/50 samples) for presence of HPV using GP primers) were subjected 
to PCR using E716 and TS18 primer sets in order to determine the genotype.    
To ensure quality of reactions, the PCR was carried out in the presence of appropriate 
positive and negative controls. The sample found negative for HPV using all primer sets 
was used as PCR negative control. This HPV negative sample was incised on the 
microtome with each sample in order to eliminate the risk of false positive results.  
Furthermore, the microtome was cleaned with ethanol between every sample. The β-globin 
gene was amplified as an internal positive control. The cervical carcinoma sample positive 
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for HPV 16 was used as a positive control for type 16 genotyping. The HeLa cells are HPV 
18 positive and were processed for DNA extraction. It was used as positive control for 
HPV 18 (Figure 3.1).   
All of the samples were positive for β-globin amplification. HPV DNA detection using 
broad range detection primer set (GP) was achieved in 47 % (14/30) of the samples. 
However, when the same samples were analyzed for amplification using type specific 
primers: TS16, TS18, C16E7 or C18E7, total of 27 samples out of 30 turned out to be 
positive for HPV. The 13/30 samples have not shown detection with GP5+/GP6+ primers 
but were positive with type specific primer sets. Out of them, 4 were positive for HPV 16, 
3 were positive for HPV 18 and 6 of them have shown co-infection. Interestingly one of 
the samples was positive with consensus primer GP5+/GP6+ and internal control, but 
negative with all type specific primers for HPV 16 and 18. This indicates this sample might 
be carrying genotype other than 16 or 18. Moreover, 10 % (3 out of 30) samples were 
negative with GP5+/ GP6+ or with all four sets of the type specific primers despite 
amplifying β-globin gene. Rest of 50 samples were found 68 % (34/50) positive for HPV 
using E716 and TS18 primers.  In total 92 % samples were found positive for HPV (Figure 
3.2A). 
Overall, HPV 16 and 18 co-infection was found in 25 % (18 out of 74) samples. HPV 16 
alone was detected in 28 % (21 out of 74) samples whereas same percnetage of samples 
were positive for HPV 18 alone (Figure 3.2B).  
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Figure 3.1: Detection of HPV in cervical lesions by PCR. A representative image of HPV 
detection and genotyping with all primer sets is shown. Lane 1 shows the molecular weight 
marker (bp). Lane 2 represents HPV 18 positive control. The TS18 primer was used to 
amplify the DNA extracted from the HeLa cells. Lane 3 is the PCR negative control. 
GP5+/6+ primer set was used to amplify L1 gene as shown in lane 4. Lanes 5 and 6 shows 
the HPV 16 E6 and E7 amplicons produced by using TS16 and E716 primer sets, 
respectively. Lane 7 and 8 shows the HPV 18 L1 and E7 amplicons produced by using 
TS18 and E718 primers, respectively. 
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Figure 3.2: Prevalence of HPV in cervical lesions. (A) Positive HPV detection using the 
broad range primer set GP5+/GP6+ and type specific primers for HPV 16 (TS16, E716) 
and HPV 18 (TS18, E718) was determined in 74 out of 80 samples, indicating an overall 
HPV prevalence of 92 % in the cervical lesions tested. (B) 18 samples out of 74 have shown 
co infection with HPV 16 and 18, 21 biopsies each were positive for HPV 16 and 18 alone.   
 
 
 
 
A 
0
10
20
30
40
50
60
70
80
HPV+ HPV-
N
o
. o
f 
sa
m
p
le
s
HPV prevalence
HPV16 HPV18 Co infection Untypeable HPV -
B 
Chapter 3  Incidence of HPV and its genomic analysis 
 
104 
 
3.2.2 HPV and histopathological association  
 
The frequency of HPV incidence was sought for its correlation with histopathology of the 
disease. It showed that overall proportion of SCC was higher than other histopathological 
diagnosis. 20 % of SCC samples (n=15) were associated with HPV 18, 14 % of SCC 
samples (n=11) are associated with HPV 16 whereas 10 % of samples (n = 8) have shown 
co-infection with 16 and 18 (Table 3.1, Figure 3.3). The proportion of AC and ASC were 
less common. Two of these sample has shown co-infection of HPV 16 and 18 whereas, 
other two samples have shown HPV 16 infection. 
The LSIL samples in this cohort was small (n = 4). Two of LSIL were associated with the 
co-infection of HPV 16 and 18. One of LSIL sample was positive with the GP5+/GP6+ 
primers but was found negative with all type specific primer sets, indicating that this 
sample was infected with an HPV type other than HPV 16 or 18. Out of eleven samples 
among the HSIL group 4 showed association with HPV 18 and three were positive for HPV 
16. Three of HSIL samples were found to be co-infected with HPV 16 and 18 and one was 
negative with HPV primer sets, which indicates sample might be HPV negative. Four of 
the samples among the chronic cervicitis and metaplasia (n=14) were infected with HPV 
16, two of them has shown HPV18, three were co infected with both HPV 16/18 and 3 
were found negative with all primer sets used.  
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Figure 3. 3: Occurrence of high risk HPV types in relation to disease histopathology. The 
number of SCC cases was higher and are linked either to HPV 16 and HPV 18 alone or co-
infection of both. The HPV 18 association with SCC is utmost among others. HSIL has an 
average incidence rate which is linked more with HPV 16 and 18 infection than to co-
infection. The case frequency of AC, ASC, LSIL and chronic cervisitis (Cc)/ metaplasia 
were low. AC, ASC were associated with HPV 16 and coinfection. LSIL was linked to 
undetectable HPV types. 
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Table 3.1: Distribution of HPV according to histopathology of cervical lesion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samples HPV 16 HPV 18 Coinfection Untypeable HPV - Total 
 
SCC   11 15 8 8 2 44 
 
ASC/AC    
 
2 0 2 1 0 5 
 
LSIL   
 
1 0 2 1 0 4 
 
HSIL      
 
3 4 3 0 1 11 
 
Metaplasia 
/Cervicitis   
4 2 3 4 3 16 
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3.3 Genomic analysis of HPV 16  
Human papillomavirus (HPV) type 16 is most prevalent and is the major causative agent 
of cervical cancer globally (Bosch et al., 1995; Muñoz et al., 2003). The HPV 16 genome 
has been identified from different cervical and skin lesions. Virus genomic sequence 
similarities had been used for making distinctions between types, subtypes and variants. 
Isolates which differ within the same type (2-10 %) in comparison to prototype, were 
referred as subtypes. However, a difference of less than 2 % was considered as a variant 
(de Villiers et al., 2004). 
Currently, the genome sequence information is available for HPV 16 variants prevalent in 
the United States, United Kingdom, Japan, Thailand, China, India, Germany, South Africa, 
Iran, Croatia and Canada. HPV 16 variants were also isolated from different ethnic groups 
and geographic locations (Ho et al., 1991; Icenogle et al., 1991; Picconi et al., 2003; 
Yamada et al., 1997). Based on phylogenetic analysis, these variants are divided into five 
branches namely, European (E), Asian (As), Asian-American (As-Am), African-1 (Af-1), 
and African-2 (Af-2; Chan et al., 1992b; Ho et al., 1993). The HPV 16 reference genome 
is a German isolate and is from European lineage (Chan et al., 1992a; Ho et al., 1993; 
Seedorf et al., 1985). Variation studies in the HPV 16 genome have shown differences in 
in vitro biological properties and could be accountable for difference in pathogenicity and 
immunogenicity (Giannoudis and Herrington, 2001). Moreover, these variants are 
associated with increased risk of cervical cancer development (Berumen et al., 2001; 
Hildesheim et al., 2001; Villa et al., 2000; Xi et al., 1997).  
The virus genome used to be retrieved from epithelial lesions using cloning methods (de 
Villiers et al., 2004). However, with the advent of new techniques including rolling circle 
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amplification, whole genome amplification and shotgun sequencing, identification of virus 
has become easier (Rector et al., 2004; Li et al., 2009). These technologies have helped in 
retrieving even minute quantities of viral genome in clinical samples. 
It has been found that HPV 16 and 18 are prevalent genotypes in cervical cancer lesions in 
Pakistan (section 3.2.1). The presence of HPV 16 gene sequences in public databases from 
different countries makes it more predictable in terms of function. However, no such 
sequence study has been reported from Pakistan. In order to leverage the wealth of 
information, the HPV 16 genome sequence was determined from cervical cancer 
specimens. The sequences are analysed in silico to determine any change in the HPV 16 
genome from Pakistani isolates. In addition, L1 sequence based phylogenetic analysis was 
carried out to analyse evolutionary relationships between isolates and known strains.   
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3.4 Results 
3.4.1 Amplification of HPV 16 genes 
A total of 30 cervical cancers and lesions out of 80 were used to amplify the full length 
genome of HPV 16. The samples were identified histopathologically as squamous cell 
carcinoma (SCC; n=25) and high grade squamous intraepithelial lesion (HSIL; n=5). They 
were paraffin embedded cervical cancer lesions (n =26) and fresh cervical cancer biopsies 
(n=4).  
β-globin gene amplification was used as an internal control. The HPV 16 prevalence in 
those samples was confirmed using TS16 and E716 which amplifies the E6 and E7 regions, 
respectively. Positive detection of the β-globin gene was achieved in all samples. Only 
those 30 samples out of 80 were used for full viral genome amplification which gave better 
amplification of TS16 and E716 than other samples. Furthermore their DNA concentration 
was good (>100 ng/µl). The DNA positive control (β-globin gene amplification) and PCR 
negative control (all PCR ingredients without DNA or without polymerase) were included 
in all amplification reactions. 
Out of 30 samples, the complete HPV 16 ORFs were only amplified in 1 fresh sample of 
squamous cell carcinoma of cervix (stage I). It is possible that in rest of samples either the 
genome is degraded due to formalin fixation or it is integrated into cellular genome. The 
LCR region and 8 other genes were amplified using gene specific primers (Table 2.1) along 
with PCR conditions as mentioned in Table 2.2. The amplicons generated were analysed 
on agarose gel (Figure 3.4).  
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3.4.2 Cloning of HPV 16 genes 
The amplified HPV 16 genes were cloned in the TA vector (pCR®2.1 TOPO) as mentioned 
in section 2.4.2. The recombinant pCR®2.1TOPO clones were selected on the basis of 
blue/white colony selection. The white colonies were streaked onto fresh agar and colony 
PCR was performed. The positive colonies were cultured and plasmid was prepared. These 
plasmids were digested with restriction enzymes and analysed on agarose gel as shown in 
Figure 3.5.  
 
 
 
 
 
 
 
 
Figure 3.4. HPV 16 genes and LCR amplification by PCR. Agarose gel electrophoresis 
of amplicons generated by gene specific oligonucleotides designed to amplify regions of 
the HPV 16 genome. Samples were run on same gel. Lane 1 contain molecular weight 
marker (Fermentas); lane 2 is the negative control for PCR reactions using template DNA 
extracted from a known HPV negative tumor biopsy with primer set GP5+/6+; lane 3 
represents the DNA control amplified using β-globin primers (positive control); lanes 4 
represents the HPV 16 long control region produced from LCR primer set. Lane 5-12 are 
amplicons of different HPV 16 genes produced with their respective primer sets. 
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Figure 3.5. Agarose gel electrophoresis showing restriction digestion of pCR2.1 TOPO 
plasmid, containing inserts of different HPV 16 genes (lanes 2-5). The bottom panel shows 
the restriction enzymes used for plasmid digestion. Lane 1 contain molecular weight 
marker (Fermentas). 
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3.4.3 Sequencing and mutational analysis 
 
After confirmation of inserts through restriction digestion, the recombinant clones were 
sequenced (section 2.7) in triplicates to obtain the nucleotide information. Each gene 
sequence was not only sequenced with type specific primers in both the forward and 
reverse directions but also confirmed via universal M13 primers set. The E1 gene is 1950 
bp long, therefore the primers that anneal to the start and the end of the gene only, were 
not enough to sequence the complete gene. Additional primers were designed to anneal to 
the middle of gene and products were sequenced repeatedly in parts. One of these primer 
was designed from nucleotide position 981-1007 of E1 ORF to sequence the region 
between nucleotide 981- 1950. The second primer was designed from nucleotide 970-939 
of E1 ORF to sequence the region from nucleotide 981-1.  
The HPV 16 E6, E7 gene and protein sequences were conserved with the exception of a 
valine to leucine substitution at position 90 (V90L) in the E6 ORF. No change in sequence 
was observed in the HPV 16 major and minor capsid proteins L1 and L2.  
Silent and point mutations were observed in other parts of HPV 16 genome compared to 
the reference HPV 16 sequence. The transactivation protein E2 was found to have a 
methionine at position 238 instead of isoleucine (I238M). This mutation is conservative 
and does not change the side chain polarity and charge. Mutation of proline at position 219 
to a serine (P219S) was also identified in E2 in Pakistani strain. The E5 sequencing 
demonstrated an amino acid change at position 44, where isoleucine was coded instead of 
leucine. Again, this mutation is conservative and does not change the side chain polarity 
and charge. The E4 protein had a point mutation at amino acid position 46, where serine 
was replaced by a cysteine therefore changing side chain from polar to slightly polar. 
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Another silent mutation was observed in the nucleotide sequence at position 32, where 
guanine is present instead of adenine. The HPV 16 E1 ORF from Pakistani cancer patients 
contained 1 substitution and 2 silent mutations. In that sequence, isoleucine is changed into 
threonine at position 186 and hence modified the nonpolar side chain to polar. However, it 
does not affect the side chain charge. The silent mutations were observed at nucleotide 
position 557 and 1731 where thymine was changed to cysteine and guanine, respectively. 
The long control region contained sequence changes at nucleotide position 201 and 647. 
Adenine is changed to cysteine at nucleotide position 201 and cysteine is changed to 
guanine at nucleotide position 647 of LCR. . These changes are summarised in Table 3.2. 
The sequences with complete information for annotation were submitted to NCBI and have 
been assigned accession numbers which are shown in Table 3.3. 
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Table 3.2: Nucleotide and amino acid sequence variation in sequences of HPV 16. 
 
 
 
 
 
 
Gene Mutation SHIFT Type of change 
HPV 16 E2 I238M 
Isoleucine→ Methionine 
Non polar (neutral)→ Non polar 
(neutral) 
Novel mutation 
 P219S 
Proline→Serine 
Non polar (neutral)→Polar 
(neutral) 
Sequence conflict 
HPV 16E5 L44I  
Leucine →Isoleucine 
Non polar (neutral) → Non 
polar (neutral)  
Also reported  
by Eriksson  
et al., (1999).   
HPV 16 E4 S46C 
Serine→Cysteine 
Polar (neutral) → Slightly polar 
(neutral)  
Novel mutation 
 Nucleotide change: A 
32G, no change in amino 
acid 
 Novel mutation 
HPV 16 E1 I186T 
Isoleucine →Threonine 
T1731G 
Non polar(neutral) →Polar 
(neutral) 
Novel mutation 
HPV 16 LCR A201C 
C647G 
 Novel mutation 
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Table 3.3: The accession numbers for the HPV 16 sequences reported on NCBI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Nucleotide accession No. Protein accession No. 
HPV 16 long control region KF181718.1 --- 
 
HPV 16 E6  KC736930.1 AGK72246.1 
 
HPV 16 E7  KC736931.1 AGK72247.1 
 
HPV 16 E4  
 
KC736932.1 AGK72248.1 
 
HPV 16 E5  KC832496.1 AGQ42626.1 
 
HPV 16 E1  KF181717.1 AGW21771.1 
 
HPV 16 E2 gene 
 
KC736929.1 AGK72245.1 
 
HPV 16 L2 gene KF181716.1 AGW21770.1 
 
HPV 16 L1 gene 
 
KC166220.1 AGC65525.1 
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3.4.4 Phylogenetic analyses  
In order to make the evolutionary analysis of the HPV 16 sequences from Pakistani isolates, 
the L1 protein sequence that contained at least one unique amino acid sequence variation 
in comparison to other isolates of the same type were retrieved from GenBank. Sequences 
were obtained for Asian (As), European (E), Asian American (As-Am), Asian-American-
European (As-Am-E), African 1 (Af-1) and African 2 (Af-2) strains. The analysis was also 
carried out on the basis of sequence reported from different countries including Germany, 
China, India, Thailand, Canada, Iran, Brazil, South Africa, Japan and Croatia. The 
sequences were aligned using CLUSTALW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). For the construction of Bayesian trees 
computer program MRBAYES v3.0b6 (Ronquist and Huelsenbeck, 2003) was used. 
Models were iterated for 100,000 generations and gamma modeling was used for site rate 
variations. The posterior probability estimates across 2 independent runs after 100,000 
generations was 0.01. Trees were sampled every 100 generations. The maximum 
parsimony-based trees were constructed using MEGA6 (Tamura et al., 2013) with the 
subtree-pruning-regrafting (SPR) algorithm (Nei and Kumar, 2000). The trees were 
bootstrap resampled 1,000 times (Felsenstein, 1985) and a consensus tree model was 
generated. The trees were visualised using TreeView (Page, 1996). Trees with > 0.90 
posterior probability in the Bayesian analysis and nodes with ≥ 50 % bootstrap support in 
Maximum parsimony were considered statistically significant.  
The tree constructed using Bayesian method has shown that African strain 1 (AFP44638.1, 
AAQ10727.1) are clustered together. Asian-American taxon showed the most diverse 
evolution rate; two of these strains (AFP44294.1, AFP44606.1) are evolved from African 
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strain 2 (AFP44198.1) whereas, one of  Asian-American (ACN91169.1) and Asian-
American-European (ACN91168.1) strains were clustered with European and Asian taxa 
(Figure  3.6A bottom part). Rest of Asian-American strain 1, 2 and Asian-American-
European strain (ACN91171.1) were grouped in one clade. The African strain 2 
(AFP44198.1) evolved from this clade. All of European and Asian strains were in single 
clade.    
Tree generated using maximum parsimony methods showed (Figure 3.6B) African strain 
1 and 2 (AFP44638, AFP44198) clustered with Asian-American strain 1 and 2 (AFP44310, 
AFP44438) and evolved from common Asian-American-European ancestor 
(ACN91168.1). One of the African strain 1 (AAQ10727) clustered with Asian-American 
strain 2 (AFP44414.1). Three of Asian American strain 1 (ACN91169.1, AFP44294.1, 
AFP44606.1) were clustered together and evolved from a clade representing European 
strain (ACN91179.1). Rest of European strains clustered with Asian strain AFP44342.1 
and AFP44262.1.  
Tree constructed using both methods revealed different tree topology as mentioned above, 
nevertheless inferred the same generic information, which is, Pakistani HPV taxon is in-
placed with European and Asian clade. Asian-American strain 1 and 2 were related to 
African strain 1 and 2.  
The tree constructed on the basis of country in both parsimony and Bayesian topologies 
shows two major clades (Figure 3.7). Interestingly both trees have inferred nearly the exact 
information. China has reported the largest number of L1 protein sequence variants (n= 
15). 11 of the Chinese strains were in same clade with Germany (ABF06542.1), South 
Africa (AAO19439.1), Thailand (AEZ01705.1), India (AAZ81569.1), Pakistan 
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(AGO65525.1) and Croatia (AFN85006.1, AFN85014.1) as shown in Figure 3.7A and B. 
The strains BAO18702.1 (Japan), AFS53335.1 and AFS33336.1 (China) are clustered 
together from which several other strains evolved (Figure 3.7A and B). The immediate 
strains evolved from this clade involves strains from China (AFS33356.1, AFS33337.1). 
The distant strain includes Iranian strain ACA49854.1 which is clustered with 
ACV84004.1 and BAN63241.1 from Canada and Japan respectively, evolved from clade 
representing strains from Thailand (AEZ01721.1) and Canada (ACV53978.1) as depicted 
in Figure 3.7A and B (bottom half ). 
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Figure 3.6: The intratype diversity of HPV 16. Phylogenetic trees represent the 
relationship between HPV 16 variants based on a L1 protein. 19 sequences of 6 known 
variants of European (E), Asian (As), Asian-American (As-Am), African-1 (Af-1), 
African-2 (Af-2) and Asian-American-European (As-Am-E) origin are indicated. The 
accession numbers of the sequences retrieved from NCBI are specified on the tree. (A) 
Tree constructed using Bayesian method has shown the cumulative posterior probability 
of 0.90. The tree models were iterated for 100,000 generations and gamma model was used 
for site rate variations. Pakistani strain is highlighted in red box. 
 
 
A 
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Figure 3.6: (B) Tree created using Maximum parsimony based on the amino acid 
sequences of the L1. The MP tree was obtained using the subtree-pruning-regrafting (SPR) 
algorithm .The bootstrap consensus tree inferred from 1000 replicates were taken to 
represent the evolutionary history of the taxa analysed. Nodes which have shown < 50 % 
bootstrap confidence were collapsed. Gaps and missing residues were eliminated, total 499 
positions were used in the final dataset. Pakistani strain is highlighted in red box.  
 
 
 
 
B 
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Figure 3.7: Phylogenetic trees inferred from the HPV 16 L1 amino acid variants from 10 
different countries. The analysis involved 33 amino acid sequences from China, Germany, 
India, Thailand, Canada, Iran, Brazil, South Africa, Japan and Croatia. The accession 
A 
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numbers of the sequences retrieved from NCBI are specified on the tree. (A) Tree 
constructed using Bayesian method based on the amino acid sequences of the L1 is shown. 
Cumulative posterior probability for this tree was 0.90. The tree models were iterated for 
100,000 generations and gamma modeling was used for site rate variations. Pakistani strain 
is highlighted in red box. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 3.7 (B) Tree created using maximum parsimony by the subtree-pruning-regrafting 
(SPR) algorithm. The bootstrap consensus tree inferred from 1000 replicates is taken to 
represent the evolutionary history of the taxa analysed. Nodes which have shown < 50 % 
bootstrap confidence were collapsed. Gaps and missing residues were eliminated, total 499 
positions were used in the final dataset. Pakistani strain is highlighted in red box.  
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3.5 Discussion 
 
The role of high risk HPV in progression to cervical cancer has been noticeably established 
and confirmed by Professor H. zur Hausen (2002). A global study of 1000 cervical cancer 
from paraffin embedded samples show that more than 90 % contains HPV DNA (Bosch et 
al., 1995). A follow up valuation of the cancer in the worldwide study that were at first 
believed to be HPV negative indicated that either the results were false positive or that the 
DNA was too degraded so that the negative results were hardly found true representative 
of study (Walboomers et al., 1999). CIN III and invasive cancer samples were evaluated 
for the presence of HPV DNA and they have been reported for positive association with 
HPV which further supports the theory (Böhmer et al., 2003). However, the association of 
high risk HPV in cervical lesions and cancers has not been reported before from Southern 
Punjab, Pakistan. In the current study, 80 cervical lesion tissue samples were proceeded for 
HPV detection. Out of them, 92 % (n = 74/80) of samples were found infected with HPV, 
which is in line with globally reported data (Bosch et al., 1995; Walboomers et al., 1999; 
Böhmer et al., 2003). The HPV genotype analysis on same samples using different primer 
sets has shown that 21 samples (28 %) were infected with HPV type 16 alone and same 
number of samples were infected with HPV type 18 alone. The rate of confection (n=18; 
25 %) with HPV 16 and 18 was strikingly higher than reported data. This study shows first 
time the overall incidence of high risk HPV in Punjab.   
The international association for research in cancer (IARC) has conducted a global study 
and provided the data on most prevalent HPV types in cancer development. According to 
them, the most prevalent high risk HPV genotypes which infect the cervix are: HPV 16 (53 
%), HPV 18 (15 %), HPV 45 (9 %), HPV 31 (6 %), and HPV 33 (3 %; Muñoz, 2000). 
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Reports from different parts of the world clearly indicates that HPV 16 infection as the 
most common in cancer lesions followed by HPV 18 as the second most common type 
(Bosch et al., 1995; Muñoz, 2000). However, our results showed a different trend of viral 
distribution. The rate of incidence of single infection with HPV 18 and 16 is nearly same 
in Southern Punjab contrary to higher incidence rate of HPV 16 than 18 globally. 
Furthermore, the rate of incidence of HPV 16 and 18 co-infection found in this study is 
higher than reported globally where the incidence of coinfection is ≤ 15% (Alsbeih et al., 
2011; Schellekens et al., 2004; Baldez da Silva et al., 2012; Liu et al., 2010). However a 
study conducted in Thailand has shown 83.2 % HPV16 infection, 59.3 % of HPV 18 and 
28 % coinefction of 16 and 18 in women with  cervical lesions or cancer (Suthipintawong 
et al., 2011).   
The results found in Punjab were compared with the findings established in Karachi, 
Pakistan. Contrary to the results reported here, a study from Karachi has shown that HPV 
might not have a role to play in the cause of SCC of cervix (Yousuf et al., 2010). On the 
other hand, Khan et al., (2007) has shown the strong association between HPV and cervical 
infections. Their study revealed incidence of HPV to be 98 %, with 93 % of HPV 16 and 
4 % of HPV 18 (Khan et al., 2007). As far as general population is concerned the rate of 
HPV incidence was low, but carcinoma samples were associated with HPV 16 and 18 
infections (Raza et al., 2010). 
The difference observed in the results reported in this study and studies conducted in 
Karachi might be due to usage of different methods. For instance, Raza et al. used 
GP5+/GP6+ consensus primer based PCR followed by Reverse line blot analysis. Khan et 
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al. has only used GP5+/GP6+, TS16 and TS18 based HPV detection. Whereas, Yousuf et 
al. carried out GP5+/GP6+ detection followined by genotyping kit.  
In our study it was oberved that GP5+/GP6+ based detection is less sensitive. Therefore, 
the usage of additional primer set revealed difference in the incidence of HPV.   
Epidemiological studies suggests that the HPV-dependent cervical abnormalities could be 
reduced by practicing proper cervical screening procedures in the adult females (Forman 
et al., 2012). In Pakistan, the tracking of cellular changes in cervix for any abnormality, 
only involves Pap testing. This is not carried out as part of regular screening process, rather 
it is recommended only to females who visits hospital in wake of realization towards 
possible detection of disease. If the Pap smear test turns out positive for cell abnormality, 
then visual inspection of the cervix is carried out using acetic acid staining (Tayyeb et al., 
2003).  The current study has indicated the association between HPV infection and disease 
progression, like everywhere else in the world, therefore it is suggested to use HPV DNA 
detection as an effective tool to predict infectious progression. In time detection of virus 
would allow better disease management because early detection has a potential to reduce 
the disease burden (Lăără et al., 1987). 
Genetic characterisation of the large group of HPV types can provide important 
information for screening, prevention and diagnostics of disease. Studies have shown 
genetic basis of virus contributes towards pathogenesis (Zehbe et al., 1998; Hildesheim et 
al., 2001; Pista et al., 2007). Since viral genetic information gives disease insight, therefore 
storage of such information in databases might play a significant role. The viral genome 
information is available for some countries and strains. However, no such information has 
been reported from Pakistan. It was important to characterise the virus from local settings. 
Chapter 3  Incidence of HPV and its genomic analysis 
 
127 
 
In this study, the HPV 16 early genes E6, E7, E1, E2, E5 and late genes E4, L1, L2 along 
with the LCR were cloned and sequenced. The sequences were amplified individually 
using proofreading polymerase to avoid PCR generated mutations and 3'A overhangs were 
produced before cloning into TA vector. The samples were sequenced several times from 
different colonies of the same clone. The genome was assembled and reported on NCBI, 
and have been assigned the accession numbers as mentioned in Table 4.2. Genomic 
recombination was not observed in the HPV genome isolated from Pakistan. Six amino 
acid changes were identified and 3 of them were novel mutations found in E2, E4 and E1.  
The E4 protein is contained within the hinge region of E2, therefore it was suggested that 
changes in hinge region have a role to bring synonymous change in E4 protein (Narechania 
et al., 2005). Based on this, it is presumed that mutations that results in changes in E2 and 
E4 protein could be due to overlapping ORFs. Change at 1731 in E1 ORF overlaps with 
E2 ORF. Silent mutations were observed at 8 different places including within the E4 and 
E1 ORFs and the LCR.   
The mutation rate analysis of the HPV 16 genome shows that the E2 protein is under a high 
selection process and is susceptible to genetic evolution (Chen et al., 2005). The E2 protein 
plays a critical role in viral genome regulation and is likely the target of cellular and 
humoral immune system (Dillner, 1990, Konya et al., 1997). The epitopes for humoral 
immunity reside in all three regions of E2. Three of these epitopes are reported in the hinge 
region (Dillner, 1990). The hinge region does not play a role in viral transcription or 
replication rather provides spacing between transactivation and DNA binding domain to 
perform those functions (Winokur and McBride, 1992). However, phosphorylation of the 
hinge has also been shown to be important for protein stability and function (Chang et al., 
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2014; Sekhar and McBride, 2012). Also, it helps in chromatin binding (McBride, 2013) 
and this region in HPV 5, 8, 18 and BPV 1 interacts with cellular proteins (Lai et al., 1999; 
Müller et al., 2002).  
In this study, a novel mutation has been found in the HPV 16 E2 hinge region suggesting 
the potential for different humoral responses to HPVs of the Asian taxon than the African 
and Asian American taxa. Alongside this mutation, there is also a sequence alteration at 
amino acid 219 compared to the reference sequence. The amino acid alteration has been 
previously described and results in a change from a proline to serine (Eriksson et al., 1999). 
The sequence observed in this study shows a serine at that position. The mutations in the 
hinge region of E2 need further characterisation considering E2’s role in transcription and 
replication control by binding to various cellular proteins and as a potential elicitor of 
humoral immunity.  
The E2 overlapping gene, HPV 16 E4 has various epitopes which elicit the humoral 
immune response (Dillner, 1990; Suchánková et al., 1992). The amino acid region 46-65 
and 51-70 have produced a noticeable humoral immune response (Dillner, 1990; 
Suchánková et al., 1992). The change at position 46 from serine to cysteine as reported in 
this study resides in potential epitopic region and could be important for difference in 
immunity in that taxon. A serine to cysteine alteration could also have dramatic effects on 
protein function. Amino acid region 42-80 helps E4 protein to localise in cytoplasm 
(Roberts et al., 1994). Moreover, E4 protein from high risk HPV 16 and 18 is regulated by 
phosphorylation by serine/arginine protein kinase (SRPK1; Bell et al., 2007). Amino acid 
region 44-47 plays critical role in binding to SRPK1 (Bell et al., 2007). The serine residues 
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which are phosphorylated by SRPK1 are not known (Bell et al., 2007), but there is a 
possibility that S46 is a potential phosphorylation site.  
The amino acid variations in HPV 16 E6 are much more common than mutations in E7 
(DeFilippis et al., 2002; Chen et al., 2005). E6-E7 variant analysis using codon based 
genealogical method shows E6 is evolving under selective pressure (DeFilippis et al., 
2002; Chen et al., 2005). The codons involved in selection pressure for E6 are R17G, 
Q21D, I34R and V90L. In this study, only the codon change at position 90 was observed 
where leucine is present instead of valine. This variant is reported by other groups as well 
(Qmichou et al., 2013; Chen et al., 2005). It also has been reported to form an association 
with p53 gene. This association might be the reason for differences in development of a 
cancer risk (van Duin et al., 2000).   
The evolution of HPV 16 genome is likely to be linked to immune selection. The genetic 
polymorphism in HPV is regulated for antigen presentation by human leukocyte antigen 
(HLA) class I and II molecules. The E6 epitope from aa 80-90 (where L90V variant resides) 
is linked to class I HLA alleles, B*44, B*51, and B*57 (Andersson et al., 2000; Chakrabarti 
et al., 2004; Zehbe et al., 2003 ). Similarly, the R17G variant changes B*07 binding epitope 
and regulates immune response (Ellis et al., 1995). 
Although E7 is an oncogene but the codons under selective pressure are not known for it 
(DeFilippis et al., 2002; Chen et al., 2005) and no novel mutation or sequence alteration 
are observed in E7 sequences from Pakistani isolates. 
HPV 16 E5 is membrane bound protein which plays an important role during early stages 
of virus life cycle (Fehrmann et al., 2003; Genther et al., 2003). It is highly hydrophobic 
and has three transmembrane domains between aa 9-29, 42-62 and 63-83. E5 plays a role 
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in transformation by interacting with cellular proteins such as epidermal growth factor 
receptor (Conrad et al., 1993; Straight et al., 1995). It has shown higher mutational rate 
than rest of HPV genome (Chen et al., 2005). A change in the amino acid sequence of E5 
has a potential to change its transforming activity (Conrad et al., 1993; Straight et al., 
1995). L18V amino acid change was reported however its functional relevance or 
transformation ability are not indicated (Chen et al., 2005). This change has not been 
observed in sequence reported from Pakistan. A L44I mutation at transmembrane region II 
was observed, which has also been reported by Eriksson et al., (1999). The mutational and 
functional analysis of HPV 16 E5 in the transmembrane region I and II showed that the 
transforming activity of mutant E5 resembles wild type (Hsieh et al., 2000). Nevertheless, 
the variation observed in the protein can account for differences in oncogenic potential of 
E5 in different regions, and in this context the observed mutations could have significant 
role.    
HPV 16 E1 generates humoral immune responses against the epitope region in its C 
terminus (Dillner, 1990). In this study, the novel mutation found at position 186 in the 
region between C terminus (1-140) and N terminus (210-640) does not relate to region 
reported to elicit antigenic response. The amino acid mutation rate analysis of E1 from five 
different strains including Asian, African 1, African 2, Asian-American and European 
showed the proportion of amino acid variation is lower than E2, E5, E4 and E6 (Chen et 
al., 2005). The sequence conflict was reported on Uniprot in German isolate (AAQ10714) 
at V92G, M144T, S220T and I340M, however none of these conflicts were identified in 
the present study. The silent mutations found in the nucleotide sequence at positions 557 
and 1731 may account for changes occurring in the viral genome through evolution.  
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HPV 16 LCR contains the binding sites for various enhancer and promoters namely, NFI 
(Gloss et al., 1989b), AP1 (Chan et al., 1990), Oct-1 (O'Connor and Bernard 1995), Tef-1 
(Ishiji et al., 1992), YY1 (O'Connor et al., 1996) and E2 (Bernard et al., 2013). The 
nucleotide changes observed in the LCR could alter the transcriptional control of viral gene 
expression and replication of the virus by bringing change in the binding affinity of these 
or other cellular factors to the binding site (Hubert, 2005). Genetic changes in HPV 16 
LCR can therefore assist in the development of cancer including CINII and CIN III 
(Calleja-Maciaset al., 2005; Xi et al., 2006). For instance a change in nucleotide in HPV 
33’s LCR is associated with change in cellular upstream stimulatory factor (USF) binding 
site, resulting in development of CIN II (Khouadri et al., 2006). 
The nucleotide mutation found in this study does not reside within binding sites for NFI, 
AP1, Oct-1, Tef-1, YY1 or E2. However the change could have significant role regarding 
evolution over a period of time or it could affect the association of an unspecified factor to 
the LCR. 
The N terminal amino acids between 17-36 of HPV 16 L2 has been identified as an 
important epitope for eliciting neutralising antibodies (Alphs et al., 2008; Gambhira et al., 
2007). Mutagenesis experiments revealed that the cysteine residues at position 22 and 28 
are critical for infectivity in human keratinocytes (Campos and Ozbun, 2009). The amino 
terminal along with residues at position 22 and 28 are conserved in L2 identified from 
Pakistan. Moreover, no novel mutation is seen in the region.   
HPV 16 L1 contains epitopes against which cross neutralising antibodies are generated 
(Combita et al., 2002). It is the conserved region, which is why sequence homology on the 
base of L1 is considered to identify new PV type. Despite this, variants exist for HPV 16 
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in the region and is an important factor to elicit different humoral immune responses. 
Furthermore, L1 variation is one of the potent factors to derive the evolutionary rate and 
the linage of different taxa as reported in different studies (Yamada et al., 1995; Ntova et 
al., 2012). 
For instance, HPV 16 L1 sequence reported by Seedorf et al., (1985) has shown a D228H 
and A292T mutation. At position 449 there is a deletion and at position 465 an insertion 
mutation of aspartic acid was found. However, no such change is observed in L1 sequence 
from Pakistan.  
Phylogenetic trees obtaining using the Bayesian method based on the L1 protein sequence 
parsed the HPV 16 variants into two clades, consistent with previous studies (Yamada et 
al., 1995; Chen et al., 2005; Ntova et al., 2012) and support a distinction between the 
European and non-European taxa.  
Previous studies have reported HPV phylogeny on the basis of E6, E7 ORFs, LCR or partial 
nucleotide sequences of L1, L2 gene. To produce long term evolutionary relationship, 
amino acid sequence based phylogenetic trees might be more reliable based on conserved 
nature of protein (Hasegawa et al., 1993, Hashimoto et al., 1994).   
The Pakistani sequences were clustered with European taxa. However, the use of maximum 
parsimony revealed ambiguity in the placement of taxa. Despite this, the sequence from 
Pakistan is still clustered with European taxa. The Bayesian and Maximum parsimony tree 
produced on basis of L1 reported from different countries revealed two separate clades, 
where Pakistan is clustered with China, Germany, South Africa, Thailand, India and 
Croatia. The second clade has variants from Canada, Japan, Brazil and Iran. Few variants 
from China and Thailand were also clustering in the second clade.  
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This study provided new variants of HPV 16 genes and LCR. Analysis of a representative 
set of HPV 16 genomes identifies the evolutionary relationship of this sequence to other 
taxa. The analysis confirms the observation that HPV L1 gene is informative enough to 
phylogenetically evaluate high-risk types. Nevertheless, more effort is required to examine 
the evolutionary dynamics of high-risk HPV genomes from Pakistan. Moreover, to 
understand the genetic basis of viral evolution and niche adaptation that has a chance to 
indirectly lead to cancer causation. 
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CHAPTER 4 
 
INTERACTION BETWEEN HPV 16 E2 AND L1 
PROTEINS 
 
4.1   Introduction 
The life cycle of human papillomavirus type 16 and other high risks types are divided into 
early phase and late phase (Doorbar, 2005; Chow et al., 2010; Bodily and Laimins, 2011). 
It is suspected that the delay in the expression of late genes L1 and L2 represents a viral 
mechanism to evade the host immune response and hence help in establishing infection.    
Late gene expression is regulated by different cellular and viral factors (Zheng and Baker, 
2006; Schwartz, 2008; Graham, 2010; Johansson et al., 2010). For instance, human antigen 
R (HuR), an important RNA stability regulator (Brennan and Steitz, 2001), enhances L1 
capsid protein expression in the undifferentiated epithelial cells by interacting with a 79 
nucleotide late regulatory elements. On the contrary, the depletion of HuR in differentiated 
infected cells causes a decrease in L1 protein expression (Cumming et al., 2009). Role of 
E2 in regulating late gene expression has been studied by Johansson et al, (2012). The E2 
protein interacts with cellular CPSF30 which is a polyadenylation factor and disturbs the 
polyadenylation complex. It induces the late gene expression by inhibiting early 
polyadenylation (Johansson et al., 2012). Moreover, during productive viral genome 
amplification, the E2 protein accumulates to high levels, prior to late gene expression (Xue 
et al., 2010).The regulation of late gene by an early protein is not limited to HPV. The 
adenovirus E4orf4 protein interacts with cellular SR proteins and can induce the expression 
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of late genes (Somberg et al., 2009; Kanopka et al., 1996; Kanopka et al., 1998). HPV 16 
E2 has also been shown to interact with SR proteins (Lai et al., 1999; Bodaghi et al., 2009) 
and activates SRFS1 gene expression which may facilitate the expression of capsid protein 
(Mole et al., 2009).  
BPV 1 L2 protein localises to subnuclear domains known as promyelocytic leukemia 
(PML) oncogenic domains (PODs) and recruits E2 and L1 to PODs (Day et al., 1998). It 
was considered important for viral genome packaging (Day et al., 1998). Later studies 
showed that L2 protein interacts with E2 protein (Heino et al., 2000) and the association 
plays a role in establishment of infection by enhancing PML expression (Day et al., 2004). 
Early proteins have so far not been found to interact with major capsid protein L1. 
Information stated above raises the question whether the association between E2 and L1 
proteins prevails. Based on the role of E2 in regulating the L1 expression and the E2-L2 
interaction, it was hypothesised that E2 interacts with L1. Therefore in this study the 
interaction between these two proteins was investigated.  
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4.2   Results 
 
4.2.1 HPV 16 E2 binds to L1: In silico analysis 
 
Computational analysis was performed (section 2.8) in order to determine the interaction 
between HPV 16 E2 and L1. This was carried out by obtaining the protein data bank (PDB) 
co-ordinate files for HPV 16 L1 (1DZL) and HPV 16 E2-DNA binding domain (1ZZF) via 
RCSB (Berman et al., 2000; http://www.rcsb.org/pdb/home/home.do). ZDOCK 3.0.2, 
ClusPro 2.0 and Rosetta programs were used to compute likely protein-protein interactions 
and possible binding interfaces between L1 and E2. A total of 21 models were generated 
using different software including 5 from ZDOCK, 6 and 10 were obtained from ClusPro 
and Rosetta, respectively. These were lowest energy models and visualised using PyMOL. 
A representative model is shown in Figure 4.1. The α-2 domain (red) of 1DZL (green) 
shows interaction with 1ZZF (blue). The models were also analysed to identify the specific 
amino acid residues that might be playing role in the interaction. The region of E2 that lies 
within 4 Å of L1 was detected for all 21 models and homology was sought between them. 
Similarly, the residues within L1 that were in close proximity to the surface of E2 were 
traced out and shown in Figure 4.1 (colored yellow). Amino acid residues at position 335-
365 of the E2 DNA binding domain appeared as interacting residues in all 21 models. All 
of the residues that potentially interact with L1 are highlighted (red) in Figure 4.2.  
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Figure 4.1: In silico analysis of HPV 16 E2-L1 interaction. The E2-L1 complex was 
generated using PDB coordinate files 1DZL (blue) for L1 and 1ZZF (green/red) for E2. 
The program used was ZDOCK and the complex was rendered using PyMOL. The E2 
residues within 4 Å of L1 are believed to be involved in interaction (colored red). These 
residues lie in an α-2 domain of E2. The L1 residues within 4 Å of E2 are colored yellow.  
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Figure 4.2: Sequence alignment of HPV 16 E2 DNA binding domain (1ZZF) from 21 
models, generated computationally. The numbers on the extreme left are model numbers. 
The first 10 models were generated using Rosetta, models 11-15 were generated using 
ZDOCK and 16-21 were produced using ClusPro. The residues highlighted in red were 
found within 4 Å of L1, which makes them potential interacting residues.  
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4.2.2 HPV 16 E2 binds L1 in vivo 
 
Having shown that HPV 16 E2 and L1 form a plausible low energy complex in silico, it 
was interesting to ascertain if this interaction could be obtained in vivo. To do this, plasmids 
expressing HPV 16 E2 and L1 were transiently transfected in C33a cells. After 48 hours 
the cells were harvested and co-immunoprecipitation was performed (section 2.10.4) using 
sheep anti-HPV 16 E2 (lane 4) and mouse anti-HPV 16 L1 (lane 6) antibodies as shown in 
Figure 4.3. Western blot analysis with mouse anti-HPV 16 E2 (TVG261) are shown in 
bottom panel, whereas blotting with mouse anti-HPV 16 L1 is shown in top and middle 
panel as short and long exposures. This analysis revealed that L1 protein was successfully 
co-immunoprecipitated with ‘sheep anti-HPV 16 E2 antibody-E2 protein’ complex as can 
be seen in Figure 4.3 (lane 4). Similarly, the E2 protein (lane 6, bottom panel) was isolated 
with mouse anti-HPV 16 L1-L1 protein complex (lane 6, top panel, short exposure). The 
rabbit and mouse IgG antibodies (lane 3 and 5 respectively) were used as a control. Input 
proteins level of un-transfected cells (UT; lane 1) and co-transfected cells with E2 and L1 
(lane 2) were also detected. All of the samples were run on same membrane and experiment 
was repeated thrice. The results were consistent in all three repeats and supports the 
hypothesis that E2 and L1 interacts with each other.   
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Figure 4.3: HPV 16 E2 and L1 interact in vivo. Co-immunoprecipitation assay was 
performed by co-transfecting the expression plasmids for HPV 16 E2 and L1 in C33a cells. 
Whole cell extracts were immunoprecipitated with sheep anti-HPV 16 E2 antibody (lane 
4), mouse anti-HPV 16 L1 antibody (lane 6) or a non-specific antibody (IgG; lane 3 and 5) 
all linked to agarose beads. Western blots were performed and the co-precipitating L1 
protein was detected using anti-L1 mouse (top two panels are long and short exposure of 
same membrane) and E2 was detected using TVG261 (bottom panel). Lane 1 shows the 10 
% input protein from un-transfected cells whereas lane 2 shows 10 % input of E2 (TVG261 
antibody) and L1 (mouse anti-HPV 16 L1) proteins.  
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4.2.3 HPV 16 E2 C terminus binds to L1 in vitro  
 
After establishing the fact that E2 and L1 interact both in silico and in vivo it was important 
to map the region of E2 which binds with L1. A GST pull down assay was performed 
(section 2.9.9) using both the transactivation and DNA binding domains of E2. Both of 
these constructs also encode hinge region. GST (pGEX2T; positive control), GST-E2NH 
(pGEX2T-E2 1-257) and GST-E2HC (pGEX2T-E2 200-365) were expressed, 
immobilised on resin and separated by SDS-PAGE. The gel was stained with coomassie 
brilliant blue dye (Figure 4.4A). GST alone (lane 1) was expressed 60 times more than 
GST-E2HC (lane 2) and GST-E2NH (lane 3). The proteins were quantified by 
densitometry and an approximately equal amount of immobilised proteins were used for 
each binding assay. The amount of resin in each sample was normalised by the addition of 
unbound Glutathione sepharose beads. The binding reaction was incubated for 2 hours and 
samples were washed with detergent and salt before transferring the protein on 
nitrocellulose membrane for detection (Figure 4.4B). The input levels of L1 is shown in 
lane 1. Resin alone was used as a negative control (lane 2).  L1 protein was clearly pulled 
down with E2 C terminus (lane 4).  
The Western blot image was quantified using ImageJ. L1 protein bound with higher affinity 
to GST-E2HC than GST-E2NH. The pull down assay was performed 3 times and the 
results obtained were averaged and standard error of the mean was calculated (Figure 
4.4C).  
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Figure 4.4: HPV 16 E2 and L1 interact in vitro. GST pull down assay was performed using 
GST E2-HC (200-365 aa) and GST E2-NH (1-257 aa). After extensive washing, bound 
proteins were visualised by SDS-PAGE and densitometric analysis was performed. The 
size of ladder used is indicated on the left. A) The expression levels of GST alone, E2-HC 
and E2-NH proteins from bacteria were separately examined by Coomassie blue (lane 1-
3). B) Equal amount of resin bound proteins were incubated with mammalian expressed 
L1 protein. Resin and GST alone were used as negative and positive controls respectively. 
The results were analysed by Western blotting using mouse anti HPV 16 L1 antibody. (C) 
Based on densitometric analysis of three independent repeats, graphical representation of 
the amount of L1 bound to E2 truncations is shown,. The error bars represent standard error 
of the mean.  
A B 
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4.2.3.1  335-365 amino acid region of E2 C terminus binds to L1 in vitro 
 
Having shown that the C-terminal DNA binding domain binds to L1 in vitro, the interacting 
domain was further mapped. For this, a GST pull down assay was performed using 4 new 
and 2 already above mentioned truncations namely; GST(control), GST-E2NH (1-257), 
GST-E2HC (200-365), GST-E2 1-138, GST-E2 200-365, GST-E2 202-306 and GST-E2 
249-365 (Figure 4.5B). The GST tagged proteins were immobilised on resin as previously 
described. The amino acids regions 1-257 and 202-306 did not show binding to L1, 
whereas amino acids region 1-138, 200-365 and 249-365 all pulled down L1 successfully 
(Figure 4.5A; top panel). Binding of L1 with aa 1-138 of E2, while it failed to pulled down 
with aa 1-257 suggests that aa region 1-138 might not represent native E2 configuration. 
Use of more N terminus truncations might give better conclusion.  
To ensure that similar amounts of each protein was present in each sample, the GST tagged 
E2 proteins were visualised by Western blot using a goat anti-GST antibody (Figure 4.5A; 
central panel). On the basis of the results of these experiments, the amino acid regions 
important for binding to L1 were mapped on the two- and three- dimensional structures of 
the E2 DNA binding domain (1ZZF) and shown in Figure 4.5B and C. The α-1 and α-2 
domains are indicated.   
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Figure 4.5: Domain mapping of HPV 16 E2. Truncated forms of GST tagged E2 protein 
were bound to resin and incubated with mammalian expressed L1 protein. (A) Glutathione 
resin-bound E2 truncations were detected with anti-GST antibody, asterisks marking the 
respective protein. (B) The pulled down L1 protein was detected with mouse anti-HPV 16 
L1 antibody by Western blot. (C) A schematic representation of the truncated E2 proteins 
used in this study. Those proteins highlighted in black were successful in binding to L1. 
(D) A three dimensional image of E2 binding domain (1ZZF) obtained from RCSB. The 
red color indicates the E2 aa region 335-365, which is important for the interaction with 
L1.  
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4.3 Discussion 
The major capsid protein L1 of HPV 16 and some other high risk HPV types have been 
thoroughly studied for generating neutralising antibodies including its role in viral entry 
and attachment (Doorbar, 2005; Breitburd et al., 1995; Suzich et al., 1995). This protein is 
structurally similar to VP1 of polyomaviruses (Chen et al., 2000). Like the capsid proteins 
from other human DNA viruses (including L1), VP1 is also reported for virion assembly 
and attachment, accomplished through interaction with cellular protein (Gordon-Shaag et 
al., 2002). Protein-protein interactions are important for various functions. The potential 
role of HPV L1 protein and any interactions that occur with early viral proteins in virus life 
cycle has not yet been investigated. However, the E2 protein has been reported to interact 
with various cellular and viral proteins, which assists E2 to accomplish its functions (Grm 
et al., 2005; Gammoh et al., 2006; Heino, et al., 2000; Okoye et al., 2005). 
This is the first study that shows the interaction between the HPV 16 E2 and L1 proteins. 
Computational methods were initially used to establish whether these proteins have the 
potential to interact and to define the binding interface. The in silico findings were 
confirmed by co-immunoprecipitation experiments. The L1 protein was successfully 
precipitated with E2 and vice versa. The experiment was repeated thrice in the presence of 
appropriate controls and the overall findings were consistent.  
Both the transactivation and DNA binding domains of E2 are involved in establishing an 
association with cellular and viral proteins. For instance, the transactivation domain 
interacts with HPV E1, cellular replication factor TopBP1, caspase-8,  cell division cycle 
protein 20 homolog (CDC20), nucleosome assembly protein 1 (NAP1; Boner et al., 2002, 
Berg and Stenlund, 1997; Thierry and Demeret, 2008; Bellanger et al., 2005; Rehtanz et 
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al., 2004) and other proteins, whereas the DNA binding domain is involved in interaction  
with serine/ arginine rich splicing factor 4 (SRSF4) , cellular tumor antigen p53, E3 
ubiquitin protein ligase Mdm2 (Bodaghi et al., 2009; Gammoh et al., 2009b; Massimi et 
al., 1999). The role of the hinge region in facilitating protein-protein interactions is less 
defined, however it has shown interaction with cellular proteins such as stable protein 1 
(Sp1), Transportin-3 (TNPO3) and p300 (although the interaction with the p300 also occurs 
through the N- and C-terminal domains of this protein in vitro) (Müller et al., 2002; Steger 
et al., 2002; Lai et al., 1999; Steger and Corbach, 1997). The DNA binding domain is also 
responsible for binding of the E2 protein to DNA (Giri and Yaniv, 1988).  
In this study, computational analysis of 21 models obtained from three different tools 
(ZDOCK, ClusPro and Rosetta) generated models in which amino acids 335-365 of E2 
associated with the L1 protein. The region of the E2 protein important for this interaction 
was further characterised by domain mapping using GST pull down assays. The amino acid 
regions 1-257 and 202-306 did not show any interaction whereas amino acids 200-365 and 
249-365 interacted with L1. The latter truncations of E2 contain amino acid residues 335-
365 that were predicted to bind L1 in the in silico analysis. P53 has also been reported to 
bind the same amino acid region 335-365 of HPV 16 E2 (Parish et al., 2006b). The 
secondary structure of the HPV 16 E2 DNA binding domain is defined as β1-α1-β2-β3-α2-
β4, where the helix α1 is the helix required for interaction with DNA (Hegde, 2002). The 
three dimensional E2 binding domain structure (1ZZF) visualisation in accordance to L1 
interaction showed the potential binding regions lies in α2 domain of E2.  
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The mapping of L1 residues that interact with E2 (on the models) suggests that β strands E 
and G1, helix h1, loops between h1-E-F and F-G1 on 1DZL have shown the binding 
affinity.  
Previous studies have shown that E2 interacts with the viral oncoproteins E6 and E7. The 
DNA binding domain of HPV 16 E2 protein interacts with E6 between residues 307–322 
aa (Grm et al., 2005), whereas the hinge region binds to the zinc binding region of E7 
(Gammoh et al., 2006). E2-E6 interaction inhibits the degradation of PDZ domain 
containing proteins. It suggests that when virus genome integrates into cellular genome, 
disruption of E2 would assist E6-PDZ domain containing proteins interactions to 
contribute the malignant progression (Grm et al., 2005). E2-E7 association helps the re-
localisation of E7 to mitotic chromosomes at telophase. Attachment of E7 to mitotic 
chromosomes might be the mechanism to evade cell cycle arrest that might have activated 
in presence of E2 on mitotic chromosomes (Gammoh et al., 2006).  
In addition, both E2 and L1 have been found to interact with the minor capsid protein L2. 
The N terminal 50 residues of E2, and the hinge region are involved in interaction with the 
L2 protein (Heino et al., 2000) and its functional consequence are mentioned above 
(section 4.1). L1 interacts with the minor capsid proteins L2 for viral genome encapsidation 
(Heino, et al., 2000; Bousarghin, et al., 2003). The reported HPV 16 L2-L1 interactions 
involve the aa 412-455 of L1 (Finnen et al., 2003) which lies in h4 helix and β strand J. 
HPV E2 also interacts with E4 via its N terminus, resulting in re-localisation of E2 from 
nucleus to cytoplasm (Davy et al., 2009).  
This study sheds light on a novel binding partner of HPV 16 E2. Such analyses may be 
important in assessing the roles of capsid protein in completion of the HPV life cycle. 
Chapter 5                                   Functional characterisation of HPV 16 E2-L1 interaction 
 
150 
 
 
CHAPTER 5 
 
FUNCTIONAL CHARACTERISATION OF HPV 16 
E2-L1 INTERACTION 
 
5.1 Introduction 
 
Interaction of PV E2 with cellular and viral proteins helps in regulation of its functions in 
the virus life cycle. Two important functions of the E2 protein includes regulation of virus 
transcription and replication (Bernard et al., 1989; Bouvard et al., 1994a; Lehman and 
Botchan 1998; Mohr et al., 1990; Skiadopoulos and McBride, 1998; Thierry and Yaniv, 
1987; Ushikai et al., 1994). E2 binds in sequence specific manner and recruits different 
cellular factors to viral genome which in turn regulates the transcription. Some studies has 
shown that E2 represses transcription when it recruits factors which have a role in 
manipulation of cellular chromatin process (Nishimura et al., 2000; Schweiger et al., 2007; 
Smith et al., 2010; Wu et al., 2006). Virus replication takes place during different stages 
of viral life cycle (Kadaja et al., 2009b) and the E1-E2 protein interaction plays a key role 
in this process. E2 loads E1 helicase onto origin of replication (Mohr et al., 1990; Sanders 
and Stenlund, 2000). Replication origin consists of A/T rich region, E1 and E2 binding site 
(Ustav et al., 1993 and Ustav et al., 1991). E2 is displaced from the complex after loading 
E1 (Sanders and Stenlund, 1998). The mechanism of E2 dependent transcription and 
replication is demonstrated briefly in Chapter 1 (section 1.5.1 and 1.5.2). 
Subcellular localisation studies are important to determine the role of proteins (Simpson et 
al., 2001). These studies have been widely conducted for PVs in cervical cancer cell lines 
Chapter 5                                   Functional characterisation of HPV 16 E2-L1 interaction 
 
151 
 
and have revealed that PV E2 proteins localises in the nucleus (Hubbert et al., 1988; Zou 
et al., 2000). However, nuclear-cytoplasmic shuttling of high risk E2 proteins has also been 
reported which causes caspase dependent apoptosis (Blachon et al., 2005). Nuclear 
localisation signals (NLS) have been mapped for HPV 16, HPV 11 and BPV 1 E2 
(Klucevsek et al., 2007; Skiadopoulos and McBride, 1996; Zou et al., 2000). There are two 
NLSs in BPV 1 E2; one is in the transactivation domain with sequence PKRCFKKGARV, 
containing two highly conserved lysine residues (amino acids 111 and 112).  The second 
is in the DNA recognition helix in the DNA binding domain and this satisfies the standard 
of classical NLSs (Skiadopoulos and McBride, 1996). Studies of HPV 16 E2 have revealed 
the presence of the NLSs identical to BPVs NLSs (Klucevsek et al., 2007). In HPV 11 a 
conserved basic residue region in the hinge (amino acids 238–242) plays a role in nuclear 
localisation (Zou et al., 2000). 
The beta-PV E2 proteins have shown sub-nuclear localisation to the SR-rich splicing 
speckles via sequences within the hinge region (Lai et al., 1999; Sekhar et al., 2010). E2 
proteins also localise to mitotic chromosomes (Ilves et al., 1999; Lehman and Botchan, 
1998; Oliveira et al., 2006; Skiadopoulos and McBride, 1998) and host chromatin 
(Donaldson et al., 2007; Jang et al., 2009; Johansson et al., 2009; Kurg et al., 2005, 
McPhillips et al., 2005; Sekhar and McBride, 2012). 
HPV 16 L1 capsomeres enter the nucleus via the classic Kap α2β1-mediated nuclear import 
pathway (Nelson et al., 2003, Nelson et al., 2002). L1 enters the nucleus twice during the 
virus life cycle; first, immediately after the virions infection in the basal epithelial cells and 
second, during the late productive phase after the newly synthesized L1 and L2 proteins 
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encapsidates the viral genome into infectious virions in terminally differentiated epithelial 
cells (Nelson et al., 2002).  
Studies conducted in cell lines by over expression of the PV proteins may be inadequate 
for identification of complete functional analysis. Studying the complete virus life cycle in 
a culture system has been difficult because of the fact that the PV life cycle is closely linked 
to the differentiation of infected keratinocytes. Early attempts to address this problem was 
based on the use of human xenografts in which the infected tissue is grafted into 
immunocompromised mice (Kreider et al., 1987). This method enabled the proliferation of 
papillomaviruses in vitro, however the system was not ideal considering the fact that 
papillomaviruses are host specific. The development of organotypic raft cultures of 
keratinocytes containing the HPV genome has provided a good model system to study the 
HPV life cycle (McCance et al., 1988). In this system, undifferentiated cells are grown in 
monolayer culture in the presence of feeder fibroblasts to maintain a non-differentiated 
state. The cells are then seeded onto a collagen matrix embedded with fibroblasts which 
then differentiate to form a stratified epithelium (Lambert et al., 2005). 
The E2-L1 association has been studied and discussed in Chapter 4. To follow on from 
these studies, it was interesting to determine whether this interaction brings any change in 
E2’s function. It was hypothesised that E2 and L1 association is important for modulation 
of E2 dependent functions. Therefore, the transcription and replication properties of E2 
were assessed. In order to ascertain whether the observed changes are due to any difference 
in protein stability, half-life of the proteins were also determined.  Although the localisation 
is reasonably well characterised for HPV 16 E2 and L1, the localisation of these proteins 
when expressed in the same cell has not been studied. Based on the observed role of L1 in 
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regulating the functions of E2, it was hypothesised that E2 and L1 proteins co-localises in 
nucleus and differentiated epithelium. Therefore, in this chapter, the co-localisation of E2 
and L1 has also been studied. The results mentioned here could be useful to clarify the role 
of E2 and L1 in HPV biology. 
5.2 Results  
5.2.1  L1 regulates E2 dependent transcription  
The functional ability of E2 to act as a transcription activator in the presence of L1 was 
assessed in a mammalian expression system. C33a cells were transiently transfected with 
expression plasmids that constitutively expresses Renilla luciferase (pRL-CMV), Firefly 
luciferase downstream of 6 E2 binding sites and a thymidine kinase enhancer (p6E2-tk-
Luc), HPV 16 E2 and HPV 16 L1. Cells were harvested and lysed 24 hours post 
transfection and luciferase activity was determined (as described in section 2.10.5). In order 
to normalise data to transfection efficiency, the Firefly luciferase activity is divided by the 
Renilla luciferase activity. The normalised values are shown as fold activation in Figure 
5.1A. The HPV 16 E2 protein activates transcription of the luciferase gene after binding to 
its respective E2BSs (lane 2). Renilla and Firefly luciferase were used as internal controls 
and did not show transcriptional activity (lane 1). Interestingly, in the presence of L1, up 
regulation of E2-dependent transcription activity was observed as shown in Figure 5.1A 
(lanes 4-6). This change is dose dependent and increased with 100 ng, 250 ng and 500 ng 
of L1, respectively. However, L1 did not activate transcription in the absence of E2 (Figure 
5.1A, lane 3) demonstrating that this effect of L1 is dependent on the presence of E2. 
Currently it can’t be stated whether the change in E2’s transcription observed in this study 
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is due to E2-L1 interactions. However the use of mutant L1 (which does not bind with E2) 
in transcription assay could help in drawing the conclusion.    
 The data indicates a 3 fold increase in transcription activity of E2 in the presence of L1.  
It was important to determine if the observed change is due to any difference in expression 
of proteins. To investigate this, the lysates used for detection of luciferase activity were 
used to determine the protein expression by Western blot (section 2.9.5). The proteins were 
detected using anti-E2 TVG261 and anti-HPV16L1 antibodies (Figure 5.1B). The blots 
were stripped and used to detect β-actin (control). The E2 expression as shown in Figure 
5.1 B was consistent, whereas the L1 expression varied due to different concentrations used 
in the assay. The results show that the up regulation in transcription activation was not due 
to any change in protein levels of HPV 16 E2. The schematic representation of E2 
dependent transcription in presence and absence of L1 is shown in Figure 5.2.   
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Figure 5.1:  Transcription analysis of HPV 16 E2 in response to L1 over-expression. (A) 
C33a cells were co-transfected with 15 ng of Renilla luciferase, 100 ng of 6E2-tk-Luc 
which is an E2-responsive Firefly luciferase reporter, 50 ng of E2 and 100, 250, 500 ng of 
L1 expression plasmid as indicated. The cells were harvested and lysed after 24 hours 
transfection. The luciferase activity was determined and the Firefly luciferase reading was 
normalised to the Renilla activity. The data shown represents the mean and standard error 
of three independent experiments. A student’s t-test showed significant results. * indicates 
p < 0.05, and *** indicates p < 0.001). The standard deviation was also calculated and 
shown as a bar. (B) Cell lysates taken from the transcription assay were separated by SDS-
PAGE. The expression of E2 and L1 were detected by Western blot using TVG261 and 
mouse anti-HPV16 L1 antibodies, respectively. The blots were stripped and β-actin 
expression was detected using mouse anti-β-actin antibody. Molecular weight standards 
are indicated on the left.  
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Figure 5.2: Schematic model of the role of L1 in E2-dependent transcription activation. 
(A) The E2 proteins binds to E2BS within LCR and initiates transcription. In differentiated 
cells, only E2, E1, E4, L2 and L1 transcripts are formed using the promoter p670. (B) The 
transcription is up regulated due to interaction between E2 and L1. It is likely that L1 binds 
to E2, after E2’s attachment to E2BS. However, the triggering factors are yet not known.  
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5.2.2 L1 stimulates E1/E2-dependent replication 
 
Having studied the role of L1 in E2-mediated transcription, the function of L1 in E1-E2 
origin dependent viral replication was subsequently analysed. A luciferase assay was 
performed by transiently transfecting C33a cells with Renilla luciferase expression vector 
pRL-CMV, a plasmid containing the HPV 31 origin of replication and the Firefly luciferase 
gene under the control of a CMV promoter (pOri31), and the expression plasmids for HPV 
16 E1, L1 and E2. A plasmid containing the HPV 16 Ori would be more ideal for these 
experiments, but this construct was not available. However, using the HPV 31 origin 
instead of the HPV 16 origin was not expected to change the result, since HPV 31 and HPV 
16 Ori sequence is highly related (Lace et al., 2008b) and HPV 16 E1is able to bind to the 
HPV 31 Ori. 48 hours following transfection, the cells were lysed and luciferase activity 
measured (as described in section 2.10.6.1). The Firefly reading was divided by the Renilla 
reading in order to obtain a normalised luciferase activity (Fradet-Turcotte et al., 2010b). 
The normalised values are shown as fold activation in Figure 5.3A. The HPV 16 E2 protein 
activates replication of the luciferase gene by recruiting E1 to origin of replication. The E1 
and E2 together showed robust replication of the HPV 31 Ori (Figure 5.3A, lane 5). In the 
absence of either E2 or E1 no replication was observed (lanes 1-3). Similarly, L1 
expression alone did not show any change in replication (lane 4). However, in the presence 
of E2, E1 and L1, an increase in replication was observed (lanes 6-8).  
The replication efficiency in presence of L1 was very high and luciferase reading was 
beyond the threshold of luminometer. Therefore the experiments were further confirmed 
through quantification of HPV 16 origin of replication as described by Taylor and Morgan 
(2003) which is more sensitive assay for replication detection. The assay was carried out 
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by transiently transfecting C33a cells with pOri16, expression plasmids for HPV 16 E1 and 
E2 and increasing amounts of the L1 expression plasmid. The cells were seeded in 
duplicate. 48 hours following transfection, half of the cells were lysed for DNA extraction 
and half were lysed for protein extraction (as described in section 2.10.6.2). The DNA was 
purified using phenol chloroform-isoamyl alcohol method and DpnI digested in order to 
get rid of input DNA. The real time PCR was performed on DpnI digested DNA products 
to quantify the HPV 16 origin of replication (section 2.10.6.2).  
To affectively evaluate PCR efficiency, a minimum of 3 replicates of each sample were 
performed. The standard curves of the assay showed an excellent correlation coefficient 
(Rseq= 0.987) between the Ct (threshold) and the log of starting viral copy number as 
shown in Figure 5.4A. The 93 % amplification efficiency determines the successful 
experiment. Quantification was performed using a standard curve from a pOri16 dilution 
series of 100 to 105 pg. An increase in replication was observed in presence of L1 (Figure 
5.4B, lanes 8-10). The increase was seen in dose dependent manner and greatest with 500 
ng of L1 plasmid (lane 10). However, with 250 ng (lane 9), there is dip in comparison to 
100 ng (lane 8) and 500 ng (lane 10). The experiment was performed three times and this 
variation was observed each time.  
The lysates from both assays were used to determine the protein expression by Western 
blot (section 2.9.5). The proteins were detected using E2-specific TVG261, anti-HA (for 
HA tagged E1 detection) and anti-HPV16L1 antibodies (Figure 5.3B, 5.4C). The blots 
were stripped and used to detect β-actin. The E2 and E1 expression as shown in Figure 
5.3B, 5.4C and were consistent in all transfected samples, whereas the L1 expression varied 
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due to different concentrations used in the assay. The result showed the up regulation in 
replication was not due to any change in protein expression of HPV 16 E2 or E1. 
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Figure 5.3: Analysis of HPV 16 E2-dependent replication in response to L1 over-
expression using luciferase assay. (A) C33a cells were co-transfected with Renilla 
luciferase expression plasmid pRL-CMV (15 ng), the HPV 16 origin of replication 
combined with Firefly luciferase under the control of a CMV promoter (pOri; 25 ng) and 
the expression plasmids for HPV16 E1 (600 ng), L1 (100, 250, 500 ng) and E2 (10 ng). 
The cells were harvested and lysed after 48 hours of transfection. The luciferase activity 
was determined and Firefly luciferase reading was normalised to the Renilla activity. The 
data shown represents the mean and standard error of three independent experiments. 
Student’s t-test showed the results were significant (p <0.001). (B) Cell lysates taken from 
the replication assay were separated by SDS-PAGE. The expression of E1, E2 and L1 were 
detected by Western blot using mouse anti HA (E1), TVG261 (E2) and mouse anti-HPV16 
L1 antibodies, respectively. The blots were stripped and β-actin expression was detected 
using mouse anti β-actin antibody. Molecular weight standards are indicated on the left. 
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Figure 5.4:  The effect of L1 over-expression on HPV 16 E2-dependent replication using 
real time PCR. C33a cells were co-transfected with 25 ng of HPV 16 origin of replication-
containing plasmid, 10 ng of E2, 600 ng of E1 and 100, 250 or 500 ng of L1 expression 
plasmid. 48 hours following transfection, DNA was extracted and digested with DpnI 
enzyme. The amount of replicated pOri16 was determined using real time PCR. (A) The 
linear graph shows the standard curve indicting the Ct values plotted against the p16Ori 
standards. (B) The bar chart represents the p16Ori amplification as an average of three 
independent experiments. The bars show the standard error of the mean. Student t-test 
indicated that the results were significant * indicates p < 0.05, and *** indicates p < 0.001. 
(C) Cell lysates taken from the replication assay was separated by SDS-PAGE. The 
expression of E1, E2 and L1 was detected by Western blot using mouse anti HA (E1), 
TVG261 (E2) and mouse anti-HPV16 L1 antibodies respectively. The blot was stripped 
and β-actin expression was detected using mouse anti β-actin antibody. Molecular weight 
standards are indicated on the left.  
 
C 
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5.2.3 Half-life assay 
 
Having established that HPV 16 L1 is stimulating E2’s function, it was essential to know 
if this change results from any difference in protein stability. The C33a cells were 
transfected with expression plasmids for E2 alone and in combination with L1. They were 
treated with cycloheximide to stop the protein synthesis and hence to determine any 
difference in protein expression. The cells were harvested at time point 0, 2, 4, 8, 10, 24 
hours as mentioned in section 2.10.11. Total cell extracts were retrieved and analysed by 
Western blotting as described in section 2.9.5 (Figure 5.5; bottom panel). Prior to Western 
blotting the proteins were quantified (section 2.9.6). The band intensities were determined 
using ImageJ software. The ratio of E2 expression either alone or in presence of L1 was 
calculated against actin protein at respective hour. The 0 hour samples were not treated 
with cycloheximide and therefore considered 100 % expressed. The percentage expression 
for rest of the samples was calculated with reference to 0 hour sample. The following 
formula was used for expressional analysis:  
Y= E2 expression at x hour/ Actin expression at x hour 
% E2 expression at x hour= (Y*100) /Y at 0 hour 
Based on the percentage expression, data analysis was carried out with GraphPad Prism 4 
software. It is interesting to note that E2 expression level did not change in presence of L1. 
The half-life of E2 was 4 hours and it was determined using one-phase exponential decay 
model in Graph Pad software. It is important to note that the proteins were quantified and 
then analysed against actin, therefore it was ensured to load same amount of protein onto 
gel and the observations made are not the artefact of loading.  
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Figure 5.5: Determination of E2 protein stability in response to interaction with L1. The 
C33a cells were co-transfected with expression vectors for HPV 16 E2 alone and with L1. 
After 24 hours transfection, cells were harvested at different times (0, 2, 4, 8, 10, 24 hour) 
A 
B 
C 
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once treated with cycloheximide. (A) The standard curve was plotted using protein 
concentration against absorbance. (B) The levels of E2 protein were analysed by Western 
blot using TVG261 antibody against E2 or mouse anti β-Actin antibody. (C)The intensities 
of the bands were measured with imageJ software. The ratio of E2 expression over total 
protein expression was calculated and the values used to construct exponential decay by 
GraphPad.  
5.2.4 L1 co-localises with E2 
E2 and L1 co-localisation was studied in C33a cells. The cells were transfected with 
expression plasmids for E2 or L1 or both (as described in section 2.10.3). The coverslips 
were retrieved 24 hours post transfection and immunostaining of E2 and L1 was performed 
using sheep anti-HPV16 E2 antibody made in the Parish lab and mouse anti-HPV16 L1 
antibody. In order to eliminate the possibility that the labeling was non-specific, several 
controls were used. The specificity of primary antibody was determined by 
immunostaining of both transfected and un-transfected cells. The un-transfected cells did 
not show specific labeling showing specificity of the antibodies used. In addition, a 
secondary antibody control (no primary antibody) was run in parallel with each experiment 
to ensure that the signal produced is only due to the specific binding between secondary 
and primary antibodies. No signal was observed showing specificity of the secondary 
antibody under the conditions used. In experiments where the localisation of more than one 
proteins were assessed, the secondary antibody control was carried out to ensure that the 
secondary antibody is not cross reacting with any of the primary antibody. This control was 
carried out by omitting one of the primary antibodies, but incubation with both of the 
secondary antibodies was involved. These controls were carried out for each antibody 
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combination used in the following experiments and it was ensured that no signal was 
detected in each case.  
HPV 16 E2 alone showed a nuclear staining and in many cells a strong nucleolar 
localisation was observed. L1 expressed in the absence of E2 was limited to the nucleus 
with very weak nucleolar staining (Figure 5.6 A). However, when co-expressed with L1, 
the strong nucleolar staining of E2 was dramatically reduced and in the majority of cells 
E2 was concentrated in nucleus with weak nucleolar staining (Figure 5.6 A, bottom panel). 
Moreover, the number of cells with strong nucleolar E2 staining and those with nuclear E2 
with weak nucleolar staining were quantified in the absence and presence of L1. A 
significant change in nucleolar E2 localisation in the presence of L1 was observed in three 
independent experiments (p <0.001; Figure 5.7).  
The sheep anti-HPV16 E2 antibody used in these experiments has not been previously 
characterised. Therefore, to ensure the localisation of E2 is not an artefact of this particular 
antibody, the cells were stained with commercially available mouse anti-HPV16 E2 
antibody TVG261. No differences in staining were observed; E2 again appeared nuclear 
with strong nucleolar staining in a sub-set of cells (Figure 5.6 C).  
To ensure that the bright, large foci nucleolar-like structures to which E2 appeared to 
localise were nucleoli, double staining was carried out using mouse anti-C23 antibody and 
sheep anti-E2 antibody (Figure. 5.6 B). Nucleolin (C23) is known as eukaryotic nucleolar 
phosphoprotein that influences the synthesis and maturation of ribosomes (Hadjiolov, 
1985). E2 and C23 proteins co-localised in nucleolus suggesting the nucleolar association 
of E2 protein. 
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It was important to determine the protein expression in all transfections using Western blot, 
so that the expression could be related to results obtained through immunofluorescence. 
After removing the cover slips from tissue culture dish, the rest of the cells were harvested 
and lysate was obtained as mentioned in section 2.10.3.1. The protein expression was 
determined through Western blot (2.9.5). The proteins were detected using TVG261 and 
mouse anti HPV16L1 antibodies (Figure 5.6 D). The result showed that the E2 and L1 
proteins were expressed well.  
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Table 5.1: The use of primary and secondary antibodies in immunofluorescence. 
 
 
 
 
Conditions Primary antibody Secondary antibody Labelling 
 
 
 
Single staining 
Sheep anti HPV16 E2 Donkey anti sheep AlexaFluor 594 Red 
Mouse anti HPV16 E2 Goat anti mouse AlexaFluor 488 Green 
Rabbit anti HPV16 E2 Goat anti rabbit AlexaFluor 594 Red 
Mouse anti HPV16 L1 Goat anti mouse AlexaFluor 488 Green 
Mouse anti HPV16 L1 Goat anti mouse AlexaFluor 647 Far red 
Mouse anti C23((H-6) Goat anti mouse AlexaFluor 488 Green 
Rabbit anti HA   Goat anti rabbit AlexaFluor 488 Green 
 
Double staining 
Sheep anti HPV16 E2 
Mouse anti HPV16 L1 
Donkey anti sheep AlexaFluor 594 
Goat anti mouse AlexaFluor 488 
Red  
Green 
Sheep anti HPV16 E2 
Mouse anti C23((H-6) 
Donkey anti sheep AlexaFluor 594 
Goat anti mouse AlexaFluor 488 
Red 
Green 
 
Multiple staining 
Sheep anti HPV16 E2 
Mouse anti HPV16 L1 
Rabbit anti HA   
Donkey anti sheep AlexaFluor 594 
Goat anti mouse AlexaFluor 647 
Goat anti rabbit AlexaFluor 488 
Red 
Far red 
Green 
Primary 
antibody  
Control 
Primary antibody on un-
transfected cells 
Secondary antibody on  un-
transfected cells 
No specific signal 
 
Secondary 
antibody  
Control 
One primary antibody 
 
All secondary antibodies Signal obtained only for 
the secondary antibodies 
that were specific to 
primary antibody 
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Figure 5.6: Cellular localisation of HPV 16 E2 and L1. C33a cells were transfected with 
E2 and L1 expression plasmids. (A) The cells were stained with sheep anti-E2 and mouse 
anti-L1 antibodies. Staining for E2 protein is shown in red and L1 in green.  High resolution 
images were constructed using confocal microscopy. (B) The cells were stained using 
antibodies against nucleolar marker C23 and viral E2 protein. Staining of C23 and E2 are 
shown in green and red respectively. (C) Cells were stained using TVG261 antibody 
against E2. It is shown in green.  The 10 µm scale was used. (D) The expression of E2 and 
L1 was detected by Western blot using anti-E2 antibody TVG261 and mouse anti-HPV16 
L1 antibodies respectively. Molecular weight standards are indicated on the left. 
 
 
 
D 
C 
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Figure 5.7: Sub-cellular localisation of E2 changes in the presence of L1. C33a cells were 
transfected with E2 and L1 expression plasmids. Cells were scored for either strong 
nucleolar E2 staining in the presence of nuclear E2 (Nucleolar) or weak nucleolar E2 
staining with nuclear E2 (Nuclear) in the presence and absence of L1. The graph represents 
the mean and standard error of three independent experiments. Significance was calculated 
using a Student’s t-test (p <0.001). 
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5.2.5 Cellular fractionation  
 
Cellular fractionation allows sequential retrieval of subcellular compartments which is 
helpful in ascertaining the association of proteins with distinct sub-cellular structures 
(Sawasdichai et al., 2010). The fractionation assay was carried out in C33a cells (as 
described in section 2.10.8). The cells were harvested 24 hours post transfection and 
subcellular fractions were retrieved. The cellular extracts obtained from each step of 
fractionation were used to perform Western blotting using anti-E2 antibody TVG261 and 
cellular markers. The markers used for cytoplasmic extracts (CE; growth factor receptor-
bound protein 2: Grb2), chromatin bound extracts (CB; histone H3) and cytoskeletal pellet 
(PE; vimentin) were detected using rabbit anti-Grb2, anti-H3, and anti-vimentin antibodies, 
respectively. The soluble nuclear extract (NE) marker (origin recognition complex subunit 
2: Orc2b) was detected using rat anti-Orc2b antibody.  
Clear fractionations of each protein with low cross contamination between fractions was 
achieved (Figure 5.8 A). The band intensities for E2 protein across each fraction either 
alone or in the presence of L1 were determined using ImageJ software. The percentage 
expression of E2 or E2+L1 were calculated in each fraction by the following formula: 
% protein = (Band intensity in fraction x / Sum of band intensity in all fractions)*100 
where x = CE, ME, NE, CB, PE 
The results of these experiments show that the nuclear E2 distribution changes in the 
presence of L1, with a decrease in the amount of soluble nuclear E2 (NE fraction) observed 
in the presence of L1. Furthermore, the amount of insoluble of E2 protein (PE fraction) 
was significantly increased in presence of L1. Proteins in this fraction could either be 
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insoluble aggregates or bound to the nuclear matrix or cytoskeleton. No significant changes 
were observed in the soluble cytoplasmic or membrane-associated extracts (Figure 5.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CE: Cytoplasmic extract 
ME: Membrane extract 
NE: Nuclear extract 
CB: Chromatin-bound extract 
PE: Cytoskeletal/insoluble protein Pellet extract 
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Figure 5.8:  L1 expression causes a redistribution of nuclear and insoluble E2 protein. 
C33a cells were transfected with expression plasmids for HPV 16 E2 and L1. Cells were 
lysed and fractionated using the subcellular protein fractionation kit. (A) Proteins from 
each extract were analysed by Western blotting using specific antibodies against various 
cellular compartments including cytoplasmic (Grb2), nuclear soluble (Orc2); chromatin-
bound (histone 3); and cytoskeleton (vimentin).  (B) The intensities of the bands were 
measured in three independent experiments with ImageJ software. The ratio of E2 
expression over total protein expression was calculated and the data plotted as the mean 
percentage protein in each fraction. The error bars represent standard error of the mean. 
Statistical significance was calculated using a Student’s t- test. * represents statistical 
significance (p < 0.05) whereas NS indicates no significant differences.  
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5.2.6 L1 does not associate with E1 and E2 replication foci 
          
Viral DNA replication requires the function of both the E1 and E2 proteins (Ustav and 
Stenlund, 1991; Sedman and Stenlund, 1995). It has been reported that E1 and E2 proteins 
can be seen in foci in nucleus, which are considered as replication sites (Kadaja et al., 
2009b). The localisation of HPV 16 L1 protein was determined in the presence of E2 and 
E1. To ascertain this function, C33a cells were transfected in the presence and absence of 
the HPV origin of replication (Ori) either with E1, E2, and L1 alone or in combination as 
mentioned in section 2.10.3. Coverslips were retrieved 24 hours post transfection and the 
cells were fixed and immunofluorescence performed using sheep anti-HPV16 E2 antibody 
to detect E2, mouse anti-HPV16 L1 antibody to detect L1 and a rabbit monoclonal HA 
antibody to detect HA-tagged E1 proteins. Proteins were visualised by Confocal 
microscopy.   
The E1 protein was predominantly localised in punctate foci within the nucleus of C33a 
cells, in the presence of E2 and Ori.  It is important to note that E2 protein expressed alone 
was widely distributed throughout the nucleus, with strong nucleolar staining in many cells 
in agreement with earlier studies (Figure 5.9 A). However, in the presence of E1, E2 was 
localised in distinct E1-positive nuclear foci in many cells as shown in Figure 5.9A middle 
panel, which is in agreement with Kadaja et al., (2009b). L1 expressed alone was nuclear 
as previously documented and localisation did not alter when L1 was expressed with E1 
and E2; co-localisation to E1 and E2 foci was not observed (Figure 5.9A; top panel). The 
localisation of the three proteins was also analysed in the absence of Ori, and no changes 
in the localisation of any proteins were observed in comparison to experiment performed 
with inclusion of Ori.  
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In order to ensure the protein expression in Western blot analysis, the cells were harvested 
after removing the coverslips from tissue culture dish and lysates were obtained. The 
expression of E2, E1 and L1 was detected by Western blot using E2-specific TVG261 
antibody, mouse anti-HA and mouse anti-HPV16 L1 antibodies, respectively (Figure 5.9 
B). The result showed that these proteins were expressed well.   
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Figure 5.9: A) Nuclear localisation of HPV 16 E1, E2 and L1 in the presence of origin of 
viral replication. C33a cells were co-transfected with expression vectors for HPV 16 
replication origin with HPV 16 L1 alone (top panel), HPV 16 E1 and E2 (middle panel) 
HPV 16 L1, HPV 16 E1 and E2 (bottom panel).  Cells were stained by immunofluorescence 
with sheep anti-E2 (red), mouse anti-L1 (far red) and rabbit anti-HA antibodies (green).  
High resolution images were constructed using Confocal microscopy, scale was 10 µm. 
(B) The expression of E2, E1 and L1 was detected by Western blot using E2-specific 
TVG261, mouse anti-HA and mouse anti-HPV16 L1 antibodies, respectively. Molecular 
weight standards are indicated on the left. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5                                   Functional characterisation of HPV 16 E2-L1 interaction 
 
180 
 
5.2.7 E2 and L1 co-localise in organotypic raft cultures 
The protein localisation studies in cervical cell line is a good system, however it does not 
relate to the entire HPV life cycle and the proteins are artificially over-expressed. The 
organotypic raft culture system can be used in which a differentiated tissue is grown, thus 
providing the  morphological and physiological environment that is required for 
completion of the differentiation-dependent HPV life cycle (McCance et al., 1988; Meyers 
et al., 1992). The organotypic raft cultures were established and sectioned by Dr Sally 
Roberts. Antigen retrieval was performed as described in section 2.10.9 and the staining 
was performed using rabbit anti-HPV16 E2 (gift from Professor F Thierry, Singapore) and 
mouse anti-HPV16 L1 antibodies.   
L1 protein was clearly seen in the nucleus within the intermediate layer of the sections 
(Figure 5.10, middle panel). E2 protein was observed as punctate nuclear staining in the 
intermediate layers and cytoplasmic E2 was also observed in upper layers (Figure 5.10; left 
panel). Interestingly, L1 and E2 were seen to co-localise in the intermediate layers of the 
rafts sections (Figure 5.10; right panel and expanded panels below). Neither E2 or L1 
staining was not seen in basal cells, either because it was either expressed at low levels or 
might not have expressed at all.  
. 
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Figure 5.10: Detection of E2 and L1 expression by immunofluorescence in sections of 
HPV 16 organotypic raft cultures. The raft cultures were generated from episomal HPV 16 
genome containing primary tonsil keratinocytes by Dr Sally Roberts. The sections were 
stained with rabbit anti-HPV E2 (red) to detect E2 and mouse anti-HPV16 L1 to detect L1 
(green). The images were obtained using Fluorescence microscope (Nikon eclipse E600), 
scale was 5 µm. The overlay represents the co-localisation of E2 and L1 proteins in raft 
sections.  
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5.3 Discussion 
 
The HPV E2 protein depends on its association with cellular and viral factors, to modulate 
virus transcription and replication (Dell and Gaston, 2001). In this report, it is shown that 
the HPV 16 capsid protein L1 is enhancing E2 depended transcription.  The luciferase 
based assay was performed in C33a cells. The luciferase activity was determined and has 
shown E2 alone enhances transcription, whereas in the presence of L1 the transcription up 
regulates up to 3 folds. Studies on PV E2 and viral protein interaction had reported that E2 
dependent transcription is modulated by other viral proteins as well. The HPV 16 E6 
enhances E2 dependent transcription (Grm et al., 2005) whereas, HPV 16 L2 inhibits 
transcription (Okoye et al., 2005) and HPV 16 E7 does not affect this function (Gammoh 
et al., 2006).  
The role of capsid protein towards enhancement of viral transcription is not limited to HPV 
only. For instance, in adenovirusses the capsid protein VI has also shown a role in 
mediating the gene expression by regulating the promoter for E1A as well as by enhancing 
the expression of E1A gene (Schreiner et al., 2012) where E1A is transcriptional activator 
and modulates adenovirus genome expression (Nevins, 1981).  
The L1 has also shown to affect E1-E2 dependent replication. The luciferase assay was 
performed using C33a cells. The luciferase activity indicates threefold increase in 
replication in presence of L1. The results were further confirmed using quantification of 
HPV 16 ori, after transfecting cells with HPV 16 ori, E1, E2 and L1. The fold induction 
was consistent as seen in luciferase assay. However, the 250 ng of L1 has shown a dip in 
comparison to 100 ng and 500 ng in replication assay carried out with real time PCR. 
Whereas no such change is observed in luciferase based replication assay. Quantification 
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assay is more sensitive, therefore it is much likely to detect minute changes in fold 
induction or reduction, which provides the reason to observe change in one assay but not 
in the other. The exact reason for such change in virus life cycle is not known yet, however 
the triggering of molecular process like replication and transcription depends on the 
specific amount of promoters, enhancers and other proteins. It is likely that 250 ng of L1 
was not enough for Ori activation.   
Previous studies has shown that HPV 16 E2’s association with E6 represses transient 
replication (Grm et al., 2005), whereas its association with L2 does not change replication 
(Okoye et al., 2005). This implies that E2 protein association with other viral proteins 
effects E2 dependent functions.    
The PV E2 protein is reported to have a short half-life (Bellanger et al., 2001; Penrose and 
Mcbride, 2000). The E2 protein stability was accessed in presence and absence of L1 in 
C33a and U2OS cells. The E2 protein’s half-life found was 4 hours in both cell lines and 
presence or absence of L1 was not making any difference. The half –life (4 hours) found 
in this study is consistent to other reported data (Johansson et al., 2009; King et al., 2011). 
No change in E2 protein stability supports the fact that L1 mediated functions were specific 
and were not due to alterations in protein expression. The other E2 interacting viral and 
cellular partners have shown that protein-protein interaction could produce varied results 
in protein stability. The E2-E7 interaction stabilizes E7 protein (Gammoh et al., 2006), 
whereas E2-E1 interaction stabilizes E2 protein (King et al., 2011).   
The papillomavirus life cycle is related to the differentiation stage of the epithelium. The 
change which induces the virus to undergo to productive life cycle from episomal 
maintenance is not known. When cells infected with HPV 16 migrate to upper level of the 
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epithelium, cellular signals for differentiation activates viral promoter p670 (Spink and 
Laimins, 2005). This promoter lacks the ability to transcribe oncogenes E6 and E7, due to 
its position in the genome. However, it transcribes E1, E2, and E4 efficiently. The higher 
E2 expression inhibits the early promoter p97 but the late promoter p670 remains 
unaffected (Bernard, 2002). The late promoter also expresses late capsid proteins L1 and 
L2. During this stage, the efficient viral replication takes place in infected cells. In the 
upper layers, high levels of E2 and E4 have been reported, whereas E1 has not been an 
easy target to detect (Doorbar, 2005; Xue et al., 2010; Deng et al., 2003). 
Replication in papillomavirus is complex process and takes place in three different ways. 
First time, it occurs in very limited fashion when enters into the host cell. In second stage, 
virus genome replicates at constant rate in the proliferating basal cells. Finally, genome 
amplifies in very large number in the differentiated cells (Mcbride, 2013). 
The L1 protein expressed in differentiated cells, where the vegetative virus amplification 
takes place as well. It is quite believable that E2 interacts with L1 in differentiated cells 
and modulates E2 dependent transcription and replication in those cells.  
The purpose of the subcellular localisation experiments described in this chapter was to 
determine whether L1 co-localises with E2 and whether L1 manipulates the nuclear 
localisation of E2. In order to define the protein localisation more precisely, analysis was 
performed using immunfloroscence microscopy. The immunofluorescence assay was 
performed after transfecting the E2 and L1 expression plasmids in C33a cells. These 
experiments have revealed some interesting phenomena. The E2 and L1 proteins co-
localised in the nucleus, which is in accordance with previously reported L1 localisation 
when expressed alone as reported by Day et al. (1998). The nucleus to cytoplamsic 
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shuttling has been reported (Blachon et al., 2005) along with E2’s role in forming 
cytoplasmic speckles (Thierry and Demeret, 2008). The E2 protein has been widely known 
to have nuclear localisation (Hubbert et al., 1988), in a nucleolar excluded pattern (Burnett 
et al., 1990; Sekine et al., 1989; Skiadopoulos and McBride, 1996; Zou et al., 2000). 
However, contrary to the reported data, E2 was abundantly found in nucleolus in this study, 
whereas, in presence of L1, it has become less associated with the nucleolus and more 
nuclear. The same results were obtained using two different E2-specific antibodies 
(TVG261 and sheep anti-E2). The nucleolus is widely considered as an organelle for 
ribosome synthesis (Pederson, 2011). Cell cycle progression depends on stable nucleolar 
functions. Deficiencies in ribosome synthesis due to nucleolar proteins dysfunctioning 
results in nucleolar stress which leads to cell cycle arrest in p53-dependent manner (Pestov 
et al., 2001; Strezoska et al., 2002; Rubbi and Milner, 2003).    
The nucleolar role of E2 and why L1 is changing the nucleolar distribution cannot be 
answered yet. Nonetheless, these findings raise the potential of a new intriguing role of the 
two proteins in virus life cycle. One of the possibilities is that by inhibiting E2’s 
localisation to the nucleolus, L1 is favoring the transcription and replication function of 
E2.  
To ensure that these observations are not an artefact of the C33a cells used, primary 
foreskin keratinocytes were transfected with expression plasmids for E2 and L1. However, 
several attempts to express E2 in these cells were made and the cells that appeared positive 
for E2 were always dead. Despite a lot of optimisation, the co-localisation of E2 and L1 
was observed only in few cells, which did not look healthy. Therefore, robust conclusions 
could not be made about the co-localisation of L1 and E2 in these cells. To determine 
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whether the lack of L1 and E2 expression in these cells was due to low transfection 
efficiency, the primary cells were transfected with plasmid expressing green fluorescence 
protein (GFP) and observed under the microscope. The transfection efficiency was good, 
which further suggested that the cells transfected with E2 and L1 had died by E2-mediated 
apoptosis as proposed by previous reports (Webster et al., 2000; Brown et al., 2008; Parish 
et al., 2006b). 
In order to further investigate E2’s sub-cellular localization in presence of L1 sub-cellular 
fractionation in the absence or presence of L1 protein was carried out. The different cellular 
fractions were retrieved to detect E2 protein as well as cellular markers. Orc2 is the cellular 
protein complex that plays role in replication initiation and localises to the nucleus 
(Prasanth et al., 2004). Vimentin belongs to class-III intermediate filaments and widely 
used as cytoskeletal marker (Xin et al., 2014). Grb2 plays an important role in intracellular 
signal transduction and localises to the cytoplasm (Tanase, 2010) whereas, histone 3 is 
associated with chromatin packaging and therefore is an important marker of chromatin 
bound extracts (Fischle et al., 2005). Interestingly, a decrease in nuclear distribution (NE 
fraction; p value = 0.02) and an increase in cytoskeletal distribution (PE fraction, p 
value=0.04) of E2 was observed in the presence of L1. Rest of the fractions have either 
shown no or subtle change in distribution of E2 protein. This supports the observation made 
in cell imaging experiments that L1 changes the sub-cellular localization of E2 protein.  
When expressed together E1 and E2 proteins form distinct nuclear foci, which are 
considered to be replication factories (Fradet-Turcotte et al., 2011; Reinson et al., 2013; 
Sakakibara et al., 2011; Swindle et al., 1999). Considering that L1 expression enhanced 
E2-dependent transient replication, the recruitment of L1 to replication foci was studied. 
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However, L1 protein was not localised to replication foci. In the presence of HPV 16 E1, 
a reduction in E2-mediated late gene expression has been reported which implies that, 
during viral infection, higher expression of E1 will favor E1-E2 dependent genome 
replication rather than late gene induction by E2 (Johansson et al.,  2012). The absence of 
L1 in the nuclear foci would suggest that L1 assists E2 relocalisation to nucleus where 
replication takes place. These data also suggest that E1 does not favor L1 localisation to 
the foci.  
In this study, E2 and L1 co-localisation is reported for the first time in HPV 16 organotypic 
raft cultures derived from primary tonsil keratinocytes. The E2 protein was observed in 
nucleus of the intermediate and upper layers. In addition, cytoplamic E2 was also seen in 
the upper layers. The L1 protein was also observed in the nucleus of intermediate layers. 
Further examination showed that E2 and L1 co-localised in a sub-set of cells within the 
intermediate layers. This fact is very interesting because of the consideration that 
vegetative virus replication also takes place in the intermediate layers. As expected, L1 was 
not found in the basal layer. The reason for not seeing E2 in basal layer is unclear but could 
be due to the low expression level of E2 that is below the level of sensitivity in this assay. 
Transcripts that could code for the L1 protein have been found in the lower, less 
differentiated, layers of infected epithelium where early proteins including E2 are 
expressed but the capsid proteins are not expressed. This indicates the late transcripts must 
undergo post-transcriptional modification to promote differentiation-dependent expression 
of the late proteins (Stoler et al., 1989; Crum et al., 1990).   
Studies have been reported for E2 expression in tissue. For instance, in BPV 1, E2 has been 
detected in wart tissues, at low levels along basal cells and high levels in the upper layers 
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(Burnett et al., 1990; Penrose and McBride, 2000). These cells were also detected for 
presence of HPV DNA amplifications, which were found positive, indicating the role of 
E2 at that stage (Burnett et al., 1990; Penrose and McBride, 2000). HPV 16 E2 protein 
expression has also been detected in human clinical samples (Maitland et al., 1998; Xue et 
al., 2010). In these studies, E2 expression was found in the intermediate and upper layers 
of cervical intraepithelial lesions (CIN; Xue et al., 2010), which is in accordance to the 
observations made in this study. Xue et al. (2010) also reported that E2 expression was 
high during viral DNA amplification. Similarly BPV 1 E2 was shown to be highly 
expressed in the intermediate layers of differentiated epithelium, also where viral 
amplification replication takes place (Penrose and McBride, 2000; Burnett et al., 1990).  
Taking all the findings regarding the co-localisation of L1 and E2 together, it suggests that 
L1 might be playing an important role in the virus life cycle other than capsid assembly. 
However, the exact mechanism by which the E2-L1 interaction could potentially evoke 
viral processes needs further investigation.
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OVERALL DISCUSSION AND FUTURE DIRECTIONS 
The work within this thesis has sought to address three different aspects regarding high risk 
human papillomavirus. Having very limited information about the HPV prevalence and 
genotyping in Pakistan, the first aspect considered was to relate the etiological agent with 
cervical lesions. The HPV 16 and 18 were detected in cervical samples which is in 
accordance with worldwide reported data. Interestingly, HPV 18 genotype and the rate of 
co-infection of type 16 and 18 were higher than reported from other parts of world. The 
future studies could be designed to study the prevalence and genotyping in larger cervical 
lesion cohort’s, which will help to further establish the primary set of information.  The 
surveillance of HPV infections and the impact of vaccination is a critical element in the 
process of HPV vaccine introduction. This study confirms that Gardasil and Ceravix are 
the right choice for prophylactic vaccination. The treatment and disease management 
strategies involves the accurate and in time detection of disease. The current approaches 
used to detect the cervical lesions involve assessment of Pap smears and HPV DNA 
detection tests. The commercially available HPV DNA tests are expensive and used in 
specific settings. To deal with the situation, it is important to establish a local setting for 
determining the presence of HPV DNA from suspected lesions or cells. Based on this need, 
HPV detection and genotyping test is made commercial in the Atta-ur-Rahman School of 
Applied Biosciences, National University of Sciences and Technology (ASAB, NUST) 
diagnostic laboratory with a view to provide facility to risk prone women (diagnosed with 
abnormal Pap smears) so HPV infection status could be confirmed. 
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It is important to mention that, other than DNA based detection, the understanding of viral 
gene expression pattern during different stages of disease can help in developing novel 
molecular markers. Therefore, future work could be designed to detect biologically 
important regimes in terms of diagnosis in patient samples. Identification of biomarkers 
based on virus progression in low and high grade cervical lesions can promise a potential 
future. 
After establishing the prevalence and genotyping in cervical specimens, the second aspect 
considered was to characterise the HPV 16 virus from Pakistan. This study is the first report 
of HPV 16 genome sequence from this region. The nucleotide sequence of all 8 genes and 
LCR were reported on NCBI, which has been assigned an accession number. The genome 
sequence was then studied for mutational analysis, using multiple sequence alignment 
program which revealed point and silent mutations in amino acids and nucleotides 
sequence. The evolutionary relationship was sought on the basis of L1 sequences, which 
had revealed linkage of Pakistani taxa with European taxa. The future studies could 
involve, the mutational analysis on more samples, which will help to draw more precise 
evolutionary relationship. The novel mutation found, were in the regions important for 
raising immunity. The detailed analysis could give functional insight, which can help in 
answering the potential immunological significance. For instance, the HPV 16 E2 protein 
could be analysed in the laboratory, for its transcription and replication role in the presence 
of I238M and P219S mutations. Similarly, the S46C mutation in the E4 protein can be 
tested for its role in phosphorylation by SPRK1 protein. 
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Viral proteins are known to establish protein-protein interactions, orchestrate protein 
degradation, alters protein localization, modulate their expression level and aids signal 
transduction in the cell. The association of HPV with cervical cancer has been recognised 
for more than two decades. Despite this establishment, the role of viral proteins in causing 
infection has not been completely understood. Therefore, the third aspect of this thesis was 
to address the hypothesis that HPV 16 E2 and L1 proteins interact and undergoes functional 
modifications. All the experiments were performed in C33a cells if stated otherwise. This 
is human epithelial cell line derived from cervical cancer biopsy, negative for HPV. The 
characteristic and origin of this cell line makes it a good choice for evaluation of functional 
characterisation of HPV proteins.  
The study has revealed for the first time that HPV 16 E2 and L1 proteins binds with each 
other. The finding was supported by in silico, in vivo and in vitro studies. The future work 
on E2 and L1 protein interaction in other PVs can provide support to the current study. In 
the light of three dimensional E2-L1 complex, the domain mapping of L1 could bring good 
therapeutic prospective.  
Through usage of more developed computational methods, viral protein interactome could 
be made in order to decipher virus-virus and virus-host relationship. Furthermore 
comparative interactomic methods could be developed in order to improve the 
understanding of virus survival strategies across different pathogenic viruses. Such studies 
are also important to study diversity among viral proteins to use hosts cellular machinery 
as well. For instance, study of E2-L1interaction among other PV types would help to 
observe coherence or variation across different papillomaviruses. Undoubtedly, large scale 
studies, could help in better comprehension of HPV pathogenesis.  
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The functional characterisation of E2 in the presence of L1 has opened various exciting 
avenues. The L1 found to modulate E2 dependent transcription and replication, whereas 
both proteins were not affecting the half-life of proteins. The future work could be carried 
by finding L1 mutant, lacking in interaction with E2. The transcription and replication 
studies with such mutant could further support if L1 plays any role in virus life cycle.  
The E2 and L1 co-localisation studies confirms their presence in nucleus. The 
redistribution of E2 from nucleolus into nucleus in the presence of L1 is likely to represent 
an important feature that might have significant role in HPV’s progression. The complete 
understanding of this novel finding had not made yet. Therefore, future work on role of 
nucleolus E2 could predict its novel and exciting role, as well as the answer that why L1 is 
pulling E2 out of nucleolus. The absence of L1 in nuclear foci is contrary to its role in 
mediating E1-E2 replication. This could be taken into account to design further studies in 
order to determine the exact mechanism of virus replication.    
The significant part of the thesis was detection of E2 and L1 localisation in raft cultures 
which reflects the physiological relevance of cell based detection of E2 and L1 interaction. 
Both of these proteins have been detected first time in the raft cultures and found co-
localised in intermediate sections. This raft culture staining is particularly intriguing and it 
is important to check whether the viral DNA replication could be detected in cells which 
have shown HPV 16 E2 and L1 co-localisation. The detection of replication could further 
shed light on the combined role of E2 and L1.  
The findings of current study are important and indicates to the unknown molecular 
functions that L1 might be performing apart from encapsidation. The improved 
understanding of regulation and expression of L1 could provide antiviral therapies 
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including the inhibition of capsid protein expression as well as its interacting partner for 
example, E2 protein. Therefore, some work is needed to determine if L1 plays a role in 
propagation of infection with the help of other viral and cellular proteins. Moreover, the 
virus-host and virus-virus protein interaction studies have become important to develop 
antiviral strategies based on targeting protein-protein interaction. Hence, the further 
functional characterisation of HPV E2-L1 interaction could be followed by peptide 
designing to target this interaction. 
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APPENDICES 
APPENDIX-I 
 
Table A 1.1: Patient’s information with relation to HPV detection in cervical lesions and 
carcinomas. 
 Sample 
Number 
Location Stage and type of cancer Age of 
patient 
GP5+/6
+ 
HPV 16 HPV 18 
TS CS TS CS 
1.  S4 Rawalpindi Squamous cell carcinoma Stage I 55 + + - - - 
2.  796-09 Multan Chronic cervicitis 50 + + - - - 
3.  791 Multan Squamous cell carcinoma   58 - + + - - 
4.  8671 Multan Well differentiated keratinizing 
squamous cell carcinoma 
38 + - - + + 
5.  1175 Multan Well differentiated keratinizing 
squamous cell carcinoma 
unknown + + + + - 
6.  8151 Multan Large cell non keratinizing squamous 
cell carcinoma 
unknown + - - + + 
7.  7904 Multan Large cell non keratinizing squamous 
cell carcinoma 
65 + - - + + 
8.  1990 Multan Squamous cell carcinoma unknown + - - - + 
9.  4858 Multan Squamous cell carcinoma unknown - + - - - 
10.  MH1 Lahore Well differentiated keratinizing 
squamous cell carcinoma 
unknown  - + - - + 
11.  1996 Lahore Well differentiated keratinizing 
squamous cell carcinoma 
unknown - + - + - 
12.  3381A1 Lahore Well differentiated keratinizing 
squamous cell carcinoma 
unknown + - - + - 
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13.  5269 Lahore Well differentiated keratinizing 
squamous cell carcinoma 
45 + - - + + 
14.  6296 Lahore Well differentiated keratinizing 
squamous cell carcinoma 
unknown - + - - + 
15.  318/09 Lahore Well differentiated keratinizing 
squamous cell carcinoma 
unknown + + + - + 
16.  4974 Lahore Well differentiated keratinizing 
squamous cell carcinoma 
60 + + + - - 
17.  4417 Lahore Adeno carcinoma unknown + + + + - 
18.  2714 Lahore Adenosqouamous carcinoma 64 + + + - - 
19.  2636 Lahore CIN III unknown - - - + - 
20.  6884 Lahore CIN III unknown - - - + + 
21.  574 Lahore CIN III unknown - - - + - 
22.  3391 Lahore CIN III 53 - - + - - 
23.  1885 Lahore CIN III 68 - - + - - 
24.  MH2 Lahore CIN I unknown - + - - + 
25.  MH3 Lahore CIN I unknown - + - - + 
26.  MH4 Lahore CIN I unknown + - - - - 
27.  4558 Lahore CINIII unknown - + - + - 
28.  563 Lahore CINIII unknown - - - - - 
29.  5268 Lahore Chronic metaplasia unknown - - - - - 
30. 8
0 
3791 Lahore Chronic cervicitic with squamous 
metaplasia 
unknown - - - - - 
31.  07-S-1598 Islamabad Chronic cervicitis with squamous  
 
metaplasia 
25   - +  
32.  06-S-3525 Islamabad  Squamous cell carcinoma  
 
(Keratinizing) 
32   - +  
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33.  06-S-3526 Islamabad Squamous cell carcinoma  
 
(Keratinizing) 
55   - +  
34.  05-S-1198 Islamabad Chronic cervicitis with hyperplastic  
 
epithellium 
38   - -  
35.  05-S-0717 Islamabad Squamous metaplasia cervix 40   - -  
36.  05-S-1287 Islamabad Hyperplastic ectocervix 50   - -  
37.  06-S-5044 Islamabad Chronic cervicitis simple cystic  
 
Hyperplasia keratinizeing 
60   + -  
38.  06-S-733 Islamabad Mild atypia 56   - +  
39.  05-S-8450 Islamabad Inflammatory cervical polyp with  
 
squamous metaplasia 
55   + -  
40.  05-S-1279 Islamabad Squamous metaplasia 40   + +  
41.  05-S-0491 Islamabad Squamous metaplasia and chronic  
 
cervicitis 
50   + +  
42.  94-05-20 Islamabad Invasive squamous cell carcinoma 54   - +  
43.  94-07-96 Islamabad CIN III 42   + +  
44.  2328-2329 Rawalpindi Squamous cell carcinoma  
 
(Keratinizing large cell type) 
64  
 
 + -  
45.  1910 Rawalpindi Squamous cell carcinoma  
 
(Keratinizing large cell type) 
40   + -  
46.  1572 Rawalpindi Squamous cell carcinoma - large  
 
cell keratinizing - cervix 
37   + -  
47.  3155 Rawalpindi Squamous hyperplasia (keratosis) 45   - -  
48.  4313 Rawalpindi Squamous cell carcinoma  
 
(keratinizing large cell type) 
unknown    + +  
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49.  4404 Rawalpindi Chronic nonspecific cervicitis with  
 
squamous metaplasia 
40    + +  
50.  4445 Rawalpindi Chronic non-specific cervicitis with  
 
squamous metaplasia 
42   + -  
51.  4479 Rawalpindi CIN III with microinvasion 45    + -  
52.  341 Rawalpindi 1.Cervical intraepithelial neoplasia  
 
CIN III and adenomyosis 
45    + +  
53.  504-506 Rawalpindi Squamous cell carcinoma – basaloid  
 
type 
35   - -  
54.  1609 Rawalpindi CIN III  65    - +  
55.  2144-2146 Rawalpindi Somatic type of squamous cell  
 
carcinoma developing in dermoid  
 
cyst 
42   - -  
56.  1341 Rawalpindi Endometrioid adenocarcinoma – (well  
 
differentiated) 
43   + +  
57.  H-1701-09 Rawalpindi CIN I unknown   + -  
58.  S1 Rawalpindi Squamous cell carcinoma stage IV 65   - -  
59.  S2 Rawalpindi Squamous cell carcinoma stage I 50   + -  
60.  S3 Rawalpindi Squamous cell carcinoma of vulva 55   - -  
61.  J-321 Faisalabad Squamous cell carcinoma 50   - -  
62.  G-234 Faisalabad Moderately differentiated squamous  
 
cell carcinoma (cervix) 
50  
 
 - +  
63.  N-1413 Faisalabad Moderately differentiated  
 
adenosquamous carcinoma (cervix) 
35  
 
 - -  
64.  3338 Faisalabad Well differentiated squamous cell  
 
carcinoma of the cervix 
unknown   + +  
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65.  17755 Faisalabad Moderately differentiated keratinizing  
 
squamous cell carcinoma  
unknown  
 
 + +  
66.  1220 Faisalabad Moderately differentiated squamous  
 
cell carcinoma (cervix) 
50  
 
 + -  
67.  4317 Faisalabad Mod. differentiated keratinizing  
 
squamous cell carcinoma (cervix) 
55  
 
 - -  
68.  534 Faisalabad Undifferentiated squamous cell  
 
carcinoma (cervix) and serious cyst  
 
ovary 
40   + -  
69.  4168 Faisalabad Moderately differentiated squamous  
 
cell carcinoma 
35  
 
 - +  
70.  958 Faisalabad Well differentiated squamous cell  
 
carcinoma 
80  
 
 - -  
71.  1716 Faisalabad Well differentiated squamous cell  
 
carcinoma 
70  
 
 - +  
72.  4191 Multan Moderately differentiated  
 
adenosquamous carcinoma  
65   + -  
73.  N970 Multan Atrophic endometrium 47   - -  
74.  69-9 Multan Squamous cell carcinoma non  
 
keratinizing 
70   - -  
75.  147-9 Multan squamous cell carcinoma non  
 
keratinizing 
25   + -  
76.  173-09 Multan Squamous cell carcinoma 60   - +  
77.  385-09 Multan Squamous cell carcinoma large cell  
 
non keratinizing 
70   - +  
78.  542-09 Multan Squamous cell carcinoma large cell  
 
non keratinizing 
55   - +  
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APPENDIX-II 
 
Table A 1.2: The Pakistani strain is aligned with the reference sequence and amino acid 
mutations are shown. * Indicates the match. The mismatch is shown with the mutation 
found.  
 
 
 
 
 
 
 
79.  455-09 Multan Squamous cell carcinoma 48   - -  
80.  947-09 Multan Squamous cell carcinoma non  
 
keratinizing 
65   - -  
E2 
Codons   219                   238                                                                     
Ref. Sequence 
 
Pakistani strain 
NHIAATHTKAVALGTEETQTTPQRPRSE 
  
**S******************M****** 
 
E6 
Codons       90 
Ref. Sequence 
 
Pakistani strain 
RHYCYSVYGTTLEQQYNKPLCDLLIR  
 
******L******************* 
 
E5 
Codons       44 
Ref. Sequence 
 
Pakistani strain 
YTSLILLVLLLWITAASAFRCFIVYI 
 
*****I******************** 
 
E4 
Codons      46 
Ref. Sequence 
 
Pakistani strain 
KHRRLSSDQDQSQTPETPATPLSCCT  
 
*****C******************** 
E1 
Codons      186 
Ref. Sequence 
 
Pakistani strain 
SERHTICQTPLTNILNVLKTSNAKAA  
 
*****T******************** 
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APPENDIX-III 
 
Table A 1.3: The Pakistani strain is aligned with the reference sequence and nucleotide 
mutations are shown. * Indicates the match. The mismatch is shown with the mutation 
found.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E4 
Nucleotides         32  
Ref. 
Sequence 
 
Pakistani 
strain 
TAGCAGCAACGAAGTATCCTCTCCTG  
 
*******G****************** 
 
E1 
Nucleotides           557      1731 
Ref. 
Sequence 
 
Pakistani 
strain 
AGACACACTATATGCCAAACACCACT  
 
**********C*************** 
 
TGGCCTTATTTACATAATAGATTGGT  
 
*****G******************** 
LCR 
Nucleotides         201       647 
Ref. 
Sequence 
 
Pakistani 
strain 
CAACACCTACTAATTGTGTTGTGGT           
                
********C**************** 
 
CCTAGTCCATACATGAACTGTGTAAA  
          
******G******************* 
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APPENDIX-IV 
 
Figure A 1.1: Schematic representation of In silico protein interaction. Targeted proteins 
are retrieved from RCSB and proceeded for protein docking using different programes like 
ZDOCK, ROSETTA and CLUSPRO. Low energy models were selected and analysed to 
find potential binding sites.   
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APPENDIX-V 
 
 
 
Figure A 1.2: Schematic representation of a standard co-immunoprecipitation assay. Cell 
lysate was treated with an antibody against targeted protein. The antibody-protein complex 
immobilises on a bead and is precipitated followed by washing of unbound protein. The 
target proteins were analysed on Western blot. 
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APPENDIX-VI 
 
 
 
Figure A 1.3: Schematic representation of a standard GST pull down assay. GST tagged 
protein was over expressed and lysate was immobilised on a beads. Resin bound protein 
was incubated with mammalian expressed protein followed by washing of unbound 
protein. The target proteins were analysed on Western blot. 
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APPENDIX-VII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 1.4: Transcription assay. A) Schematic representation of the plasmids used in 
transcription assay as described in material and methods. Firefly and Renilla luciferase were 
encoded by TK and CMV promoters respectively. E2 binding sites are also indicated. B) Steps 
involved in the transcription assay are represented.   
 
 
 
 
 
 
A B 
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APPENDIX-VIII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 1.5: Replication assay. A) Schematic representation of the plasmids used in 
luciferase based replication assay. Firefly and Renilla luciferase genes used were under the 
control of CMV promoter. Virus origin of replication is also indicated. B) Steps involved in 
the replication assay are represented.   
 
 
 
B 
A 
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APPENDIX-IX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 1.6: Principle of the HPV DNA real time PCR based replication assay. A) 
Schematic representation of plasmid encoding HPV 16 origin of replication (adapted from 
Taylor and Morgan, 2003). E1 binding site is represented with black box whereas E2 
binding sites are represented as blue box. Primer binding and DpnI digestion sites are also 
indicated. B) Steps involved in the assay are mentioned schematically.   
 
 
A 
B 
                                     Appendices 
 
207 
 
APPENDIX-X 
 
 
Figure A 1.7: Schematic representation of subcellular fractionation of cells. Cell pellet is 
treated with buffers (CEB, MEB, NEB, PEB) to obtain cellular extracts (cytoplasmic, 
membrane bound, nuclear, chromatin bound and cytoskeletal) as mentioned in material and 
methods. The extracts were analysed using Western blot.   
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APPENDIX-XI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 1.6: Representation of the steps involved in the production of organotypic 
epithelial raft cultures (obtained from Snoeck et al., 2002). 
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